COPE Advertising options


PBL Assay Science COGITO ERGO COPE ADVERTISING SPACE http://immunospot.com/index.php?id=74

COPE Homepage Bottom of page Previous entry:
Monocyte/neutrophil elastase inhibitor-2
Next entry:
Monocyte suppressor factor
Random entry:
Kaposi sarcoma FGF
Search COPE:

Please donate

If you find COPE helpful,
please show your appreciation
by donating what you can afford.

monocytes

Monocytes are essentially immature macrophages. After their formation and release by the bone marrow, these cells enter the bloodstream and circulate for about 36 hours while they mature into macrophages. Sessile macrophages are the tissue counterparts of monocytes of peripheral blood. Sometimes, the term histiocytes is used for these cells. Monocytes together with polymorphonuclear leukocytes (granulocytes) are being referred to collectively as myelomonocytic cells. The term plasmacytoid monocytes refers to a population of cells known also as T-associated plasma cells, plasmacytoid T-cells, plasmacytoid predendritic cells, plasmacytoid dendritic cells, or natural IFN-producing cells. See also: dendritic cells.


The frequently used terms inflammatory monocytes or pro-inflammatory monocytes refer to one subset of monocytes with high level expression of Ly6C, high levels of the chemokine receptor CCR2, and low levels of CX3CR1. The term inflammatory monocytes reflects the observation that cells belonging to this subset preferentially migrate to sites of inflammation (Geissmann et al, 2003). This monocyte subset corresponds to CD14(++) CD16(-) monocytes in humans and is being referred to also as classical monocytes (Belge et al, 2002) (as opposed to nonclassical monocytes, which, however, may also be inflammatory monocytes) (Strauss-Ayali et al, 2007). Use of these terms is not recommended (Ziegler-Heitbrock et al, 2010), because the label inflammatory has been used for different subpopulations in humans and mice. It has been pointed out also that these terms may prematurely ascribe functional attributes to cells based on ex vivo studies while they largely remain to be functionally characterized in vivo. Burke et al (2008) have reported that murine CD43(+) monocytes exhibit features of pro-inflammatory monocytes and are functionally homologeous to the human CD14(+) CD16(+) monocytes.

Human monocytes can be subdivided into 3 subsets on the basis of the expression of CD14 and CD16 (Strauss-Ayali et al, 2007; Ziegler-Heitbrock et al, 2010). Monocytes with high CD14 expression but no CD16 expression are being referred to as classical monocytes (CD14(high) CD16(-) monocytes). The corresponding subset of mouse monocytes is Ly6C(++) CD43(+) monocytes (Ly6C(high) CD43(+) monocytes).

Intermediate monocytes are those showing a high level of CD14 together with low levels of CD16 (CD14(high) CD16(+) monocytes). The corresponding subset of mouse monocytes is Ly6C(++) CD43(++) monocytes (Ly6C(high) CD43(high) monocytes).

Nonclassical monocytes express a low level of CD14 together with high CD16 (CD14(+) CD16(high) monocytes). Without further characterization, CD16(+) monocytes, therefore may comprise intermediate monocytes and nonclassical monocytes. The corresponding subset of mouse monocytes is Ly6C(+) CD43(++) monocytes (Ly6C(+) CD43(high) monocytes).

Expression data for all three subsets show a close relationship between intermediate monocytes and nonclassic monocytes but also distinct features that separate these two populations from one another (Wong et al, 2011). Expression information about intermediate monocytes has been reported also by Zawada et al (2011).


Venneri et al (2007) have identified a distinct subpopulation of murine monocytes, which they have designated TEM [TIE2-expressing monocytes]. These cells appear to have a non-redundant function in promoting tumor angiogenesis and growth in mouse models (De Palma and Naldini, 2009). These cells are characterized by the expression of the TIE-2 angiopoietin receptor and required for the vascularization and growth of several tumor models. TIE-2 expression in human blood identifies a subset of monocytes distinct from classical inflammatory monocytes and comprised within the less abundant "resident" population. These cells account for 2-7 % of blood mononuclear cells in healthy donors and are distinct from rare circulating endothelial cells and progenitors. In human cancer patients, these cells are found in the blood and also within tumors, where they represent the main monocyte population distinct from tumor-associated macrophages. These cells are hardly detected in non-neoplastic tissues. In vitro, TEMs migrate towards the TIE-2 ligand angiopoietin-2. Release of angiopoietin-2 from activated endothelial cells and angiogenic vessels may thus be responsible for the preferential accumulation of these cells within tumors. Purified human TEMs, but not TEM-depleted monocytes, markedly promote angiogenesis in xenotransplanted human tumors, suggesting a role of these cells in human cancer progression.

Medbury et al (2008) have reported that monocytes can transform into fibrocytes. Thus, monocytes may play a more crucial role in the clinical outcome of atherosclerosis than previously realized as they not only contribute directly to plaque instability (through foam cell formation), but also promote plaque stability by transformation into a fibrocyte.


Monocytes have been shown to possess the capacity to express the proteins listed below. Please note the following general observations, which practically apply to all cell types: expression may be influenced by tissue localization, may occur only in discrete subpopulations of cells, may vary between established cell lines, primary cells, embryonic cells, mature cells, fully differentiated cells, activated cells, non-activated cells or growth conditions (confluent vs. sparse cultures), may be influenced by various disease states (including cancer environment), and may differ between species.
Note also: expression profile information lists entities only for which there is an entry in COPE or one of its subdictionaries.

The meaning of ¥ and ¥¥ is as follows: ¥ factor/protein is expressed; ¥¥ receptor (or, in some instances, binding sites) for this factor/protein is expressed. For further explanations concerning format, "hidden" information, and/or ambiguities see my remarks in the entry cell types.


¥ 4-1BB (CD137, CDw137, Ly63, lymphocyte antigen 63, ILA, induced by lymphocyte activation, TNFRSF9, TNF receptor superfamily member 9) (Kienzle and von Kempis, 2000)
¥ 4-1BB ligand (4-1BBL, TNFSF9, TNF ligand superfamily member 9, CD137L, CD137 ligand, Ly63 ligand) (Langstein et al, 1999)
¥ 14-3-3-zeta (YWHAZ, Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein-zeta, 14-3-3-delta, Exo1, FAS, factor activating ExoS) (Kobayashi et al, 2009)

¥ ABIN-3 (A20-binding inhibitor of NF-kappa-B activation-3, LIND, Listeria induced, TNIP3, TNFAIP3 interacting protein 3) (Verstrepen et al, 2008)
¥ Activin A (EDF, erythroid differentiation factor, FRP, Follicle stimulating hormone releasing protein, Restrictin-P, WEHI-MIF, WEHI mesoderm inducing factor, activin-beta-A, INHA, inhibin-alpha, Inhibin-beta-A, INHBA ) (Abe et al, 2002; Yu et al, 1996; Lange et al, 2007)
¥ ADAM8 (disintegrin and metalloprotease domain 8, MS2, CD156) (Richens et al, 2007; Yoshiyama et al, 1997)
¥ ADAMTS2 (Disintegrin and metalloproteinase with thrombospondin motif-2, ADAMTS4, KIAA0688, EC3.4.24.14, PCINP, PCPNI, Procollagen I N-proteinase, Procollagen N-endopeptidase, Procollagen N-proteinase, Procollagen I/II amino propeptide-processing enzyme) (Hofer et al, 2008)
¥ ADFP (adipose differentiation-related protein) (Lange et al, 2007)
¥ adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) (Tsai JS et al, 2010)
¥¥ adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) receptors (ADIPOR1, adiponectin receptor 1, PAQR1, progestin and adipoQ receptor family member 1, ACDCR1, TESBP1A, CGI-45, AURA43, augmented in rheumatoid arthritis 43) (Palmer et al, 2001; Chinetti et al 2004; Kollias et al, 2011; Weigert et al, 2008; Pang and Narendran, 2008)
¥¥ adiponectin (Adpn, Apn, ACDC, adiponectin, C1q and collagen domain containing, ADIPOQ, apM1, adipose Most abundant gene transcript-1, GBP-28, gelatin-binding protein of 28 kDa, adipocyte complement related protein of 30 kDa, Acrp30, 30 kDa adipocyte complement-related protein, adipocyte-specific secretory protein) receptors (ADIPOR2, adiponectin receptor 2, PAQR2, progestin and adipoQ receptor family member 2, ACDCR2) (Halvatsiotis et al 2010; Chinetti et al 2004; Kollias et al, 2011; Weigert et al, 2008; Pang and Narendran, 2008)
¥ ADNP (activity-dependent neuroprotective protein, activity-dependent neuroprotector; activity-dependent neuroprotector homeobox, ADNP1, activity-dependent neuroprotective protein 1, KIAA0784) (Braitch et al, 2010)
¥ Adrenomedullin (ADM, AM) (Nomura et al, 2005)
¥ Alpha-1-acid glycoprotein 1 (orosomucoid, orosomucoid 1, orosomucoid 2, ORM, ORM1, ORM2, ORM1*F1, ORM1*F2, ORM1*S, alpha-1-AGP, alpha-1-AGP 1, alpha-1-AGP 2, AGP, AGP1, AGP2, Alpha-1-acid glycoprotein, Alpha-1-acid glycoprotein 2, AGP-A, AGP-B, AGP-B-prime) (Gahmberg and Andersson, 1978; Nakamura et al, 1993)
¥¥ Alpha-1-acid glycoprotein 1 (orosomucoid, orosomucoid 1, orosomucoid 2, ORM, ORM1, ORM2, ORM1*F1, ORM1*F2, ORM1*S, alpha-1-AGP, alpha-1-AGP 1, alpha-1-AGP 2, AGP, AGP1, AGP2, Alpha-1-acid glycoprotein, Alpha-1-acid glycoprotein 2, AGP-A, AGP-B, AGP-B-prime) receptors (Su and Yeh, 1996; Lecchi C et al, 2008; Singh and Fudenberg, 1986; Carpentier et al, 1993)
¥¥ alpha-MSH (melanocyte stimulating hormone-alpha, alpha-melanotropin, alpha-melanocortin, melanotropin, POMC, proopiomelanocortin) receptors (Bhardwaj et al, 1997)
¥ Alpha-s1-casein (casein-alpha-s1, CSN1S1, CSN1, CASA) (VordenbŠumen et al, 2011)
¥ amphiregulin (AR, AMR, AREG, CRDGF, colorectum cell-derived growth factor, KAF, keratinocyte-derived autocrine factor, SDGF, schwannoma-derived growth factor, AURA9, augmented in rheumatoid arthritis 9) (Mograbi et al, 1997; Lange et al, 2007)
¥¥ angiocidin (26S proteasome regulatory subunit S5A, PSMD4, proteasome (prosome, macropain) 26S subunit, Mcb1, multiubiquitin-chain-binding protein 1, Rpn10) receptors (Kremlev et al, 2008)
¥ angiomotin (p80-angiomotin, p80-Amot, p130-angiomotin, p130-Amot, CAG-2, CAG trinucleotide repeat sequence 2) (Park et al, 2008)
¥ angiopoietin-1 (Ang-1, ANGPT1, KIAA0003) (Marketou ME et al, 2010)
¥ angiopoietin-2 (Ang-2, ANGPT2) (Marketou ME et al, 2010)
¥¥ angiostatin (Angiostatin K1-4, plasminogen kringles 1-4, PK1-4, PlgK1-4, AST-1, angiostatin-1, AST-2, angiostatin-2) receptors (Perri et al, 2007)
¥¥ angiotensin-1 (angiotensin) receptors (StuhlmŸller et al, 2000)
¥¥ angiotensin-2 receptors (He et al, 2006; Schena et al, 1999; Sardo et al, 2009)
¥ Angiotropin (MAT, Monocyto-Angiotropin, monocyte-derived angiogenic substance) (Hockel et al, 1987, 1988)
¥ Annexin-1 (Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation inhibiting factor, CB9, chromobindin-9, calpactin-2) (Chaitidis et al, 2005; Mikuniya et al, 1998, 2001; Morand et al, 1995; Murphy and Reen, 1996; Perretti and Reen, 1996)
¥¥ Annexin-1 (Annexin A1, ANX1, ANXA1, lipocortin-1, LPC1, LCT1, LC1, Lipo1, macrocortin, renocortin, lipomodulin, GIF, glycosylation inhibiting factor, CB9, chromobindin-9, calpactin-2) receptors (Lange et al, 2007; Strausbaugh and Rosen, 2001)
¥ Annexin-5 (Annexin A5, ANX5, ANXA5, 35 kDa Calelectrin, 35-gamma Calcimedin, Anchorin C2, PAP-1, placental anticoagulant protein-1, CBP-I, Calphobindin-1, CBP, calphobindin, Endonexin-2, ENX2, Lipocortin V, Lipocortin-5, VAC-alpha, vascular anticoagulant-alpha, chromobindin-4, 32 kDa calcimedin, EEP 32-2, PP4, placental protein-4, CaBP33, calcium binding protein 33 kDa, CaBP37, calcium binding protein 37 kDa) (Rothhut et al, 1989)
¥ APRIL (TRDL-1-alpha, TRDL-1-beta, TRDL-1-gamma, TNF-related death ligand-1-alpha, TNFSF13, TNF ligand superfamily member 13, TALL-2, TNF and ApoL related leukocyte expressed ligand-2, CD256) (Moreaux J et al, 2005)
¥ Attractin (ATRN, mahogany, Mgca, Mg, zitter, zi, black tremor, bt, myelin vacuolation, mv, DPPT-L) (Laudes M et al, 2010)
¥¥ Attractin (ATRN, mahogany, Mgca, Mg, zitter, zi, black tremor, bt, myelin vacuolation, mv, DPPT-L) receptors (Duke-Cohan et al, 1998, 2000)

¥ B7-H1 (B7 homolog-1, PDCD1L1, PDCD1 Ligand 1, PDL1, programmed death-1 ligand 1, CD274) (Semnani et al, 2011)
¥ B7-H3 (B7 homolog-3, B7RP-2, B7-related protein 2, B7-H3b, 2IgB7-H3, 4IgB7-H3, CD276) (Chapoval et al, 2001; Zhang et al, 2008)
¥ Bactericidal/permeability-increasing protein (BPI, CAP57, cationic antimicrobial protein 57) (Dentener et al, 1996)
¥¥ Bactericidal/permeability-increasing protein (BPI, CAP57, cationic antimicrobial protein 57) receptors (Heumann D et al, 1993)
¥ basigin (BSG, CD147, EMMPRIN, extracellular matrix metalloproteinase inducer, 5A11, CE-9, Collagenase stimulatory factor, gp42, HT7, M6, neurothelin, Oka blood group antigen, OX47) (Schmidt et al, 2008)
¥ BCL3 (B-cell lymphoma/leukemia-3) (Lange et al, 2007)
¥ BDNF (Brain-derived neurotrophic factor, Abrineurin) (Kerschensteiner et al, 1999; Schulte-Herbruggen et al, 2005; Wang et al, 2000)
¥ Beta-2-Microglobulin (Beta-2-M, B2M, Ly-m11, BDGF-2, bone-derived growth factor-2, CRG-8, cytokine responsive gene-8, Thymotaxin, GIP-2, granulocyte inhibitory protein, AURA54, augmented in rheumatoid arthritis 54) (Suzuki et al, 2000)
¥ beta-Endorphin (POMC, proopiomelanocortin) (Przewlocki et al, 1992; van Woudenberg, 1992)
¥¥ beta-Endorphin (POMC, proopiomelanocortin) receptors (Prieto et al, 1989)
¥ bFGF (basic fibroblast growth factor, FGF basic, FGF-2, Fibroblast growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF-2, heparin binding growth factor-2) (Panutsopulos et al, 2003; Pakala et al, 2002)
¥¥ bFGF (basic fibroblast growth factor, FGF basic, FGF-2, Fibroblast growth factor-2, FGF-beta, Fibroblast growth factor-beta, HBGF-2, heparin binding growth factor-2) receptors (Corseaux et al, 2000; Ohsaka et al, 2001)
¥ Biglycan (BGN, PG-S1, Bone/cartilage proteoglycan 1; bone small proteoglycan 1, small proteoglycan 1, Proteoglycan-1, DSPG1, dermatan sulfate proteoglycan-1, SLRR1A) (Sardo et al, 2009, 2010)
¥¥ BLAME (B-lymphocyte activator macrophage expressed, BCM-like membrane protein, SLAMF8, SLAM family member 8, signaling lymphocyte activation molecule family member 8, CD353) (Kingsbury et al, 2001)
¥ BLyS (B-lymphocyte stimulator, BAFF, B-cell activating factor belonging to the TNF family, TALL-1, TNF and ApoL related leukocyte expressed ligand-1, THANK, TNF homolog activating apoptosis nuclear factor-kappaB c-Jun NH2-terminal kinase, TNFSF13B, TNF ligand superfamily member 13B, TNFSF20, TNF ligand superfamily member 20, CD257) (Lavie et al, 2008; Moreaux J et al, 2005; Kumsiri R et al, 2010; Moore PA et al, 1999)
¥¥ BMP3 (bone morphogenetic protein-2, osteogenin) receptors (Cunningham et al, 1992)
¥¥ BMP4 (bone morphogenetic protein-4, bone morphogenetic protein-2B, BMP2B, DVR-4, decapentaplegic-Vg-related-4, BIP, bone-inducing protein) receptors (Cunningham et al, 1992)
¥ BMP6 (DVR-6, decapentaplegic-Vg-related-6, Vgr-1, vegetal-specific-related-1) (Lange et al, 2007)
¥ BNIP3 (BCL2/adenovirus E1B 19 kDa protein interacting protein-3, NIP-3) (Turpaev et al, 2005)

¥ C1 inhibitor (C1INH, Serpin G1; HAE1, hereditary angioedema type 1, HAE2, hereditary angioedema type 2) (Barbey-Morel et al, 1987; Bensa et al, 1983; Gulati et al, 1993, 1994; Lappin et al, 1990, 1992; Lappin and Whaley, 1991; Lotz and Zuraw, 1987; Reboul et al, 1985)
¥ C1q (complement C1q; complement component 1 q; complement factor C1q, C1QA, complement component 1 q subcomponent A chain, C1QB, complement component 1 q subcomponent B chain, and C1QC, complement component 1 q subcomponent C chain) (Tenner and Volkin, 1986; Fraser et al, 2007; Schwaeble et al, 1995; Moosig et al, 2006)
¥¥ Calcitonin gene-related peptide (CALC1, CALCA, Calcitonin gene-related polypeptide-alpha, alpha-CGRP, CGRP-alpha, beta-CGRP, CGRP-beta, CGRP1, Calcitonin gene-related peptide-1, CGRP2, Calcitonin gene-related peptide-2, CALCB, Calcitonin gene-related polypeptide-beta, CALC2) receptors (He et al, 2002; Monneret et al, 2003)
¥ cancer cachectic factor receptors (Watchorn et al, 2005)
¥ CAMP (cathelicidin antimicrobial peptide, CRAMP, cathelin-related antimicrobial peptide, CAP-18, cationic antimicrobial protein of 18 kDa, LL-37, leucine-leucine-37, FA-LL-37, FALL39, PR-39, ALL-38) (Rivas-Santiago et al, 2008)
¥ CAP-37 (Cationic antimicrobial protein-37, Neutrophil-derived Heparin binding protein, HBP, heparin binding protein, Azurocidin, AZU1, azurocidin 1, NAZC, neutrophil azurocidin) (Schou et al, 2011)
¥ CARD8 (caspase recruitment domain-containing protein-8, TUCAN, tumor upregulated CARD containing antagonist of caspase nine, NDPP-1, CARDINAL, CARD-inhibitor of NF-kappa-B-activating ligands, Dacar, KIAA0955) (Razmara et al, 2002)
¥ Cartducin (CTRP3, C1q/TNF-related protein 3, C1ATNF3, Complement C1q tumor necrosis factor-related protein 3, C1QTNF3, C1q and tumor necrosis factor related protein 3, CORS26, collagenous repeat-containing sequence of 26-kDa protein, cartonectin) (Weigert et al, 2005; Kopp et al, 2010)
¥¥ Cartducin (CTRP3, C1q/TNF-related protein 3, C1ATNF3, Complement C1q tumor necrosis factor-related protein 3, C1QTNF3, C1q and tumor necrosis factor related protein 3, CORS26, collagenous repeat-containing sequence of 26-kDa protein, cartonectin) receptors (Weigert et al, 2005)
¥¥ casein-beta(1-28) (beta-casein(1-28)) receptors (Kawahara et al, 2004)
¥ cathepsin L (CTSL, CAL, CATL, CTSL1, cathepsin L1, MEP, major excreted protein, IL8 converting enzyme, CP-2, cycling protein-2) (Schmid et al, 2002)
¥ CCL1 (CC chemokine ligand 1, chemokine (C-C motif) ligand 1, SCYA1, I-309, TCA-3, T-cell activation-3, P500, SIS-epsilon) (Selvan et al, 1997)
¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) (Asano et al, 1994; Badolato et al, 1997; Locati et al, 2002; Beaudeux et al, 2004; Bliss et al, 1998; Burysek et al, 2002; Bussfeld et al, 2000; Caux et al, 1994; Chaitidis et al, 2005; Comabella et al, 2002; Fantuzzi et al, 2001; Kessel et al, 1998; Moller et al, 2004; Musso et al, 1995, 2005; Wang et al, 2000; Kaminsky and Rogers, 2008; Merck et al, 2006; Lehmann et al, 2009; Olsnes et al, 2009; Kim et al, 2005; Popovic et al, 2008; Yano et al, 2007; Ancuta et al, 2006; Song et al, 2009; Conroy et al, 2009; Perelman N et al, 2003; Selvaraj SK, et al, 2003; Schwartzkopff F et al, 2012; Schraufstatter et al, 2012)
¥¥ CCL2 (CC chemokine ligand 2, chemokine (C-C motif) ligand 2, GDCF, Glioma-derived monocyte chemotactic factor-2, GDCF-2, HC11, JE, LDCF, MCAF, MCP, monocyte chemoattractant protein, MCP-1, monocyte chemoattractant protein-1, SMC-CF, smooth muscle cell chemotactic factor, TDCF, tumor-derived chemotactic factors, TSG-8, tumor necrosis factor-stimulated gene sequence-8, SCYA2) receptors (Azuma et al, 1997, 1996; Ernofsson and Siegbahn, 1996; Ernofsson et al, 1996; Klier et al, 2001; Uguccioni et al, 1995; Royaee et al, 2006; Dijkstra et al, 2007)
¥ CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) (Andersson et al, 2000; Berkman et al, 1996; Comabella et al, 2002; de Waal Malefyt et al, 1993; Fantuzzi et al, 2001; Kessel et al, 1998; Moller et al, 2004; Suzuki et al, 2000; Wang et al, 2000; Lehmann et al, 2009; Lange et al, 2007; Kim et al, 2005; Song et al, 2009; Conroy et al, 2009; Schwartzkopff F et al, 2012; Schraufstatter et al, 2012)
¥ CCL3 / CCL4 heterodimers (Guan et al, 2001; Olsnes et al, 2009)
¥¥ CCL3 (CC chemokine ligand 3, chemokine (C-C motif) ligand 3, MIP-1-alpha, macrophage inflammatory protein-1-alpha, 464.1, GOS-19-1, L2G25B, LD78, LD78-alpha, SCI, stem cell inhibition factor, stem cell inhibitor, TY5, SCYA3, SCYA3L1) receptors (Drake et al, 2001; Uguccioni et al, 1995)
¥ CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) (Andersson et al, 2000; Fantuzzi et al, 2001; Lange et al, 2007; Lu et al, 2004; Wang et al, 2000; Lehmann et al, 2009; Olsnes et al, 2009; Conroy et al, 2009; Monnier J et al, 2008; Selvaraj SK, et al, 2003; Schwartzkopff F et al, 2012)
¥¥ CCL4 (CC chemokine ligand 4, chemokine (C-C motif) ligand 4, SCYA4, ACT-2, Immune activation gene-2, 744.1, G26, H400, HC21, Cytokine 21, human, LAG-1, lymphocyte activation gene-1, MIP-1-beta, macrophage inflammatory protein-1-beta, SIS-gamma) receptors (Uguccioni et al, 1995)
¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) (Lane et al, 1999; Kaminsky and Rogers, 2008)
¥¥ CCL5 (CC chemokine ligand 5, chemokine (C-C motif) ligand 5, RANTES, EoCP-1, Eosinophil chemotactic polypeptide-1, SIS-delta, TCP228, T-cell-specific protein p228, SCYA5) receptors (Schall et al, 1990; Uguccioni et al, 1995)
¥ CCL7 (CC chemokine ligand 7, chemokine (C-C motif) ligand 7, SCYA7, MCP-3, monocyte chemoattractant protein-3, FIC, Fibroblast-inducible cytokine, NC28, MARC, mast cell activation-related chemokine) (Comabella et al, 2002; Kondo et al, 2000; Polentarutti et al, 1997; Vouret-Craviari et al, 1997; Ancuta et al, 2009)
¥¥ CCL7 (CC chemokine ligand 7, chemokine (C-C motif) ligand 7, SCYA7, MCP-3, monocyte chemoattractant protein-3, FIC, Fibroblast-inducible cytokine, NC28, MARC, mast cell activation-related chemokine) receptors (Uguccioni et al, 1995)
¥¥ CCL8 (CC chemokine ligand 8, chemokine (C-C motif) ligand 8, SCYA8, MCP-2, monocyte monocyte chemoattractant protein-2, HC14, Cytokine 14, human) receptors (Uguccioni et al, 1995; Bosco et al, 2003, 2006)
¥ CCL13 (CC chemokine ligand 13, chemokine (C-C motif) ligand 13, MCP-4, Monocyte chemotactic protein-4, NCC1, new CC chemokine-1, Ck-beta-10, Chemokine-beta-10, SCYL1, SCYA13) (Semnani et al, 2011)
¥ CCL15 (CC chemokine ligand 15, chemokine (C-C motif) ligand 15, HCC2, hemofiltrate CC-Chemokine-2, NCC3, new CC chemokine-3, MIP-5, macrophage inflammatory protein-5, Lkn-1, leukotactin-1, MIP-1-delta, macrophage inflammatory protein-1-delta, HMRP-2B, human MIP-related protein 2B, SCYL3, SCYA15) (Wang et al, 1998; Bosco et al, 2006; Semnani et al, 2011)
¥¥ CCL15 (CC chemokine ligand 15, chemokine (C-C motif) ligand 15, HCC2, hemofiltrate CC-Chemokine-2, NCC3, new CC chemokine-3, MIP-5, macrophage inflammatory protein-5, Lkn-1, leukotactin-1, MIP-1-delta, macrophage inflammatory protein-1-delta, HMRP-2B, human MIP-related protein 2B, SCYL3, SCYA15) receptors (Youn et al, 1997)
¥¥ CCL16 (CC chemokine ligand 16, chemokine (C-C motif) ligand 16, SCYA16, NCC4, new CC chemokine-4, LEC, liver-expressed chemokine, LCC-1, liver CC chemokine-1, HCC4, hemofiltrate CC-Chemokine-4, LMC, Lymphocyte and Monocyte Chemoattractant, Ck-beta-12, Chemokine-beta-12, Monotactin-1) receptors (Musso et al, 2005)
¥ CCL17 (CC chemokine ligand 17, chemokine (C-C motif) ligand 17, SCYA17, TARC, Thymus and Activation Regulated Chemokine, ABCD-2) (Semnani et al, 2011)
¥ CCL18 (CC chemokine ligand 18, chemokine (C-C motif) ligand 18, AMAC-1, alternative activated macrophage associated CC-Chemokine, PARC, pulmonary and activation-regulated chemokine, MIP-4, macrophage inflammatory protein-4, DC-CK1, dendritic cell-derived chemokine-1, Ck-beta-7, Met-chemokine-beta-7, Met-Ck-beta-7, SCYA18) (Schraufstatter et al, 2003, 2004; Kim et al, 2005; Semnani et al, 2011)
¥¥ CCL18 (CC chemokine ligand 18, chemokine (C-C motif) ligand 18, AMAC-1, alternative activated macrophage associated CC-Chemokine, PARC, pulmonary and activation-regulated chemokine, MIP-4, macrophage inflammatory protein-4, DC-CK1, dendritic cell-derived chemokine-1, Ck-beta-7, Met-chemokine-beta-7, Met-Ck-beta-7, SCYA18) receptors (Schraufstatter et al, 2012)
¥ CCL20 (CC chemokine ligand 20, chemokine (C-C motif) ligand 20, SCYA20, LARC, Liver and Activation Regulated Chemokine, Exodus, Exodus-1, MIP-3-alpha, macrophage inflammatory protein-3-alpha, Ck-beta-4, Chemokine-beta-4, ST38) (Marcet et al, 2007; Bosco et al, 2006; Lange et al, 2007)
¥ CCL22 (CC chemokine ligand 22, chemokine (C-C motif) ligand 22, ABCD-1, DC/B-Ck, dendritic cell/B-cell derived chemokine, MDC, Human macrophage-derived chemokine STCP-1, stimulated T-cell chemotactic protein, SCYA22) (Andrew et al, 1998; Chaitidis et al, 2005; Merck et al, 2006; Yeh CH et al, 2010; Semnani et al, 2011; Schraufstatter et al, 2012)
¥¥ CCL22 (CC chemokine ligand 22, chemokine (C-C motif) ligand 22, ABCD-1, DC/B-Ck, dendritic cell/B-cell derived chemokine, MDC, Human macrophage-derived chemokine STCP-1, stimulated T-cell chemotactic protein, SCYA22) receptors (Godiska et al, 1997)
¥ CCL23 (CC chemokine ligand 23, chemokine (C-C motif) ligand 23, MIP-3, macrophage inflammatory protein-3, MPIF-1, Myeloid progenitor inhibitory factor-1, Ck-beta-8, Chemokine-beta-8, SCYA23) (Bosco et al, 2003, 2006; Kim et al, 2005)
¥¥ CCL23 (CC chemokine ligand 23, chemokine (C-C motif) ligand 23, MIP-3, macrophage inflammatory protein-3, MPIF-1, Myeloid progenitor inhibitory factor-1, Ck-beta-8, Chemokine-beta-8, SCYA23) receptors (Forssmann et al, 1997)
¥ CCR1 (CC-Chemokine receptor 1, RANTES receptor, MIP-1-alpha receptor, LD78 receptor, CC-CKR1, HM145, YT4, CD191, CMKBR1, chemokine-beta receptor 1) (Kaufmann et al, 2001; Klier et al, 2001; Locati et al, 2002; Nardelli et al, 1999; Nibbs RJ et al, 1997; Salentin et al, 2003; Morrison et al, 2007; Bosco et al, 2003, 2006; Kim et al, 2005; Heo et al, 2008; Schwartzkopff F et al, 2012)
¥ CCR2 (CC-Chemokine receptor 2, CC-CKR2A, CCR2A, CC-CKR2B, CCR2B, MCP-1 receptor A, MCP-1 receptor B, CMKBR2, chemokine-beta receptor 2, CD192) (Fantuzzi et al, 1999; Garcia-Zepeda et al, 1996; Han et al, 2004; Ishibashi et al, 2004; Janis et al, 2004; Lange et al, 2007; Maus et al, 2005; Moller et al, 2004; Ogilvie et al, 2003; Penton-Rol et al, 1998; Salentin et al, 2003; Tanaka et al, 2002; Wang and O, 2001; Okutsu et al, 2008; Bosco et al, 2003, 2006; Grip et al, 1007, 2008; Green et al, 2006; Tacke et al, 2007; Okumoto et al, 2009; Heo et al, 2008; Schwartzkopff F et al, 2012; Nieto et al, 2012)
¥ CCR3 (CC-Chemokine receptor 3, CC-CKR3, Eotaxin receptor, CMKBR3, chemokine-beta receptor 3, MIP-1-alpha RL2, MIP-1-alpha receptor-like-2, CD193) (Garcia-Zepeda et al, 1996; Nibbs RJ et al, 1997)
¥ CCR4 (CC-Chemokine receptor 4, CC-CKR4, CKR4, CMKBR4, chemokine-beta receptor 4, K5-5, CD194) (Power et al, 1995; Nieto et al, 2012)
¥ CCR5 (CC-Chemokine receptor 5, CC-CKR5, CMKBR5, ChemR13, CD195) (Deng et al, 1999; Giri et al, 2005; Houle et al, 1999; Juffermans et al, 2002; Kaufmann et al, 2001; Lane et al, 1999; Lehoux et al, 2003; Naif et al, 1998; Nibbs RJ et al, 1997; Salentin et al, 2003; Ubogu et al, 2006; Chernova et al, 2009; Kim et al, 2005; Tacke et al, 2007; Schwartzkopff F et al, 2012; Nieto et al, 2012)
¥ CCR6 (CC-Chemokine receptor 6, GPRCY4, STRL22, DRY6, CKR-L3, CMKBR6, chemokine-beta receptor 6, GPR29, CD196) (Nieto et al, 2012)
¥ CCR7 (CC-Chemokine receptor 7, EBI-1, EBV induced gene-1, blr-2, CMKBR7, Burkitt lymphoma receptor-2, CD197) (Bouma et al, 2005; Kim et al, 2005)
¥ CCRL2 (Chemokine CC Receptor-like-2, HCR, Human chemokine receptor, CCRL2A, Chemokine CC Receptor-like-2A, CCRL2B, Chemokine CC Receptor-like-2B, CRAM-A, chemokine receptor expressed in activated monocytes A, CRAM-B, chemokine receptor expressed in activated monocytes B, CRAM, chemokine receptor expressed in activated monocytes) (Migeotte et al, 2002; Patel et al, 2001)
¥ CD1 (CD1a, T6, Leu6, R4, HTA1, human thymocyte antigen-1, NA1/34) (Kasinrerk et al, 1993; Sloma et al, 2004; Thomssen et al, 1996; Athanasas-Platsis et al, 1995; Gregory et al, 2000; Gregory et al, 2000; Liu et al, 2001; Winning et al, 1996)
¥ CD1b (Kasinrerk et al, 1993; Giuliani et al, 1997; Prete et al, 2001; Tentori et al, 1998)
¥ CD1c (BDCA1, blood dendritic cell antigen 1) (Kasinrerk et al, 1993; Chaitidis et al, 2005; Karlsson KR et al, 2008)
¥ CD1d (R3, R3G1, Ly38, CD1d1, CD1.1, CD1d2, CD1.2) (Balreira et al, 2005; Exley et al, 2000; Yue et al, 2005; Ancuta et al, 2009)
¥ CD2 (T11, 35.1, M-T910, 9.6, OX34, Tp50, LFA-2, lymphocyte function-associated antigen-2, Leu5, Leu5b, Ly37, OKT11, SRBC receptor, sheep red blood cell receptor, sheep erythrocyte receptor, erythrocyte receptor, E-rosette receptor, Rosette receptor, HuLy-m1) (Di Pucchio et al, 2003)
¥ CD4 (T4, Leu3, OKT4, L3T4, Ly4, W3/25, OX38, OX35) (Faltynek et al, 1989; Filion et al, 1990; Graziani-Bowering and Filion, 2000; Kampalath et al, 1998; Pietrella et al, 1998; Sorg et al, 2001; Tanaka et al, 1999; Karlsson KR et al, 2008)
¥ CD10 (CALLA, common acute lymphocytic leukemia antigen; common ALL antigen, endopeptidase 24.11, enkephalinase, gp100, enkephalinase A, enkephalin-dipeptidyl-carboxypeptidase, kidney enkephalinase, renal brush-border neutral proteinase, kidney brush-border neutral proteinase, J5, atriopeptidase, MME, membrane metalloendopeptidase, NEP, neutral endopeptidase, EC3.4.24.11, neprilysin, neutral endopeptidase, neutral endopeptidase 24.11) (Casale et al, 1994)
¥ CD11a (ITGAL, integrin-alpha-L, LFA-1, Ly15, Ly21, LFA-1, lymphocyte function-associated antigen-1, LFA-1-alpha, lymphocyte function-associated antigen-1-alpha, neutrophil adherence receptor alpha-M subunit, OND(a), OND) (Chiricolo et al, 1995; Couturier et al, 1990; Prieto et al, 1994; Sorg et al, 2001; Tanaka et al, 1999; Ancuta et al, 2009)
¥ CD11b (CR3, CR3a, complement receptor-3, C3bi receptor, ITGAM, integrin-alpha-M, HNA4a, human neutrophil antigen 4a, MART, MART(a), Mo1, Ly40, Mac-1, OKM1, OX42, VIM12) (Aubry et al, 1997; Becker and Soukup, 1998; Boschmann et al, 2005; Couturier et al, 1990; de Waal Malefyt et al, 1993; Finnin et al, 1999; Lundahl et al, 1995; Ohsaka et al, 2001; Prieto et al, 1994; Sorg et al, 2001; Tanaka et al, 1999; Prieto et al, 1989; Ancuta et al, 2009)
¥ CD11c (CR4, complement receptor-4, iC3b receptor, ITGAX, integrin-alpha-X, Leu M5, myeloid membrane antigen, OX42, p150,95) (Aubry et al, 1997; de Waal Malefyt et al, 1993; Finnin et al, 1999; Prieto et al, 1994; Schwarzer et al, 1998; Sorg et al, 2001; Tanaka et al, 1999; Rosas-Taraco et al, 2009)
¥ CD13 (alanyl aminopeptidase, AAP, ANPEP, alpha-aminoacyl-peptide hydrolase (microsomal), aminopeptidase N, PEPN, APN, APM, aminopeptidase M, EC3.4.11.2, LAP1, microsomal aminopeptidase, MY7, MCS-2, gp150) (de Waal Malefyt et al, 1993; Finnin et al, 1999; Griffin et al, 1981; Kehlen et al, 2004; Mina-Osorio and Ortega, 2005; Navarrete Santos et al, 2000; Hoogsteden et al, 1989; Prieto et al, 1989)
¥ CD14 (endotoxin receptor, Leu M3, LPS-R, Mo2, MY4, myeloid cell-specific leucine-rich glycoprotein, hdl, heedless) (Antal-Szalmas et al, 1997, 2000; Babatz et al, 2003; Bazil and Strominger, 1991; Beekhuizen et al, 1991; Bliss et al, 1998; Cosentino et al, 1995; Crawford et al, 2003; de Waal Malefyt et al, 1993; Di Pucchio et al, 2003; Durieux et al, 1994; Finnin et al, 1999; Griffin et al, 1981; Liu et al, 2001; Nagasawa et al, 2004; Tanaka et al, 1999; Tobias and Ulevitch, 1993; Sandanger et al, 2009; Uehara et al, 2007; Kim et al, 2005; Grip et al, 2007; Hoogsteden et al, 1989; Ancuta et al, 2009; Schraufstatter et al, 2012)
¥ CD15 (3-FAL, 3-Fucosyl-N-Acetyllactosamine, 3-FL, 3-Fucosyl-lactosamine, 80H.5, AGF 4.48, C3D-1, DAKO-M1, ELFT, ELAM-1 ligand fucosyltransferase, FAL, Fucosyl-N-Acetyllactosamine, 3-alpha-fucosyl-N-acetyl-lactosamine, FCT3A, alpha-3-fucosyltransferase, FUC-T-IV, fucosyltransferase 4, FUT-4, fucosyltransferase 4, LeuM1, LeX, Lewis X, X-hapten, hapten X, X-determinant, LNF-3, lacto-N-fucopentaose 3, LNFP-3, Lacto-N-Fucopentose 3 ceramide, MMA, My-1, myeloid-associated surface antigen, PMN7, polymorphonuclear leukocyte antigen 7, SSEA-1, stage-specific embryonic antigen-1) (Nakayama et al, 2001; Prieto et al, 1994; Tanaka et al, 1999)
¥ CD15s (CD15, 3-FAL, 3-Fucosyl-N-Acetyllactosamine, 3-FL, 3-Fucosyl-lactosamine, 80H.5, AGF 4.48, C3D-1, DAKO-M1, ELFT, ELAM-1 ligand fucosyltransferase, FAL, Fucosyl-N-Acetyllactosamine, 3-alpha-fucosyl-N-acetyl-lactosamine, FCT3A, alpha-3-fucosyltransferase, FUC-T-IV, fucosyltransferase 4, FUT-4, fucosyltransferase 4, LeuM1, LeX, Lewis X, X-hapten, hapten X, X-determinant, LNF-3, lacto-N-fucopentaose 3, LNFP-3, Lacto-N-Fucopentose 3 ceramide, MMA, My-1, myeloid-associated surface antigen, PMN7, polymorphonuclear leukocyte antigen 7, SSEA-1, stage-specific embryonic antigen-1) (Prieto et al, 1994)
¥ CD16 (hFcRIII, Fc-gamma R3, FCGR3A, FCGR3, Neutrophil antigen NA, HNA1, human neutrophil antigen 1, Leu11, VEP13, B73.1, 31D8, N901) (Abrahams et al, 2000; Allen et al, 1991; Baumgartner et al, 1988; Clarkson and Ory, 1988; de Waal Malefyt et al, 1993; Kruger et al, 1996; Masuda and Roos, 1993; Mytar et al, 2002; Nagasawa et al, 2004; Sorg et al, 2001; Tanaka et al, 1999; Heron et al, 2008; Todd et al, 2007; Ancuta et al, 2006; Grip et al, 2007; Ancuta et al, 2009)
¥ CD18 (ITGB2, integrin-beta-2, 2E6, AURA46, augmented in rheumatoid arthritis 46) (Chiricolo et al, 1995; Couturier et al, 1990; de Waal Malefyt et al, 1993; Lundahl et al, 1995; Prieto et al, 1994; Sorg et al, 2001; Olsnes et al, 2009; Karlsson KR et al, 2008)
¥ CD20L (CD20-like, MS4A3, Membrane-spanning 4-domains subfamily A member 3, HTm4, Hematopoietic-specific transmembrane protein 4) (Kutok et al, 2011)
¥ CD23 (CD23a, CD23b, FCER2, Fc-epsilon R2, Leu20, B6, Blast-2, 18.6 antigen, Ly42, CLEC4J, C-type lectin domain family 4 member J, EBVCS, EBV cell surface antigen, EBVCS1, EBVCS2, EBVCS3, EBVCS4, EBVCS5, MHM6) (Aiba et al, 2003; Alderson et al, 1994; Becker et al, 1991; Buckley et al, 1995; de Waal Malefyt et al, 1993; Fargeas et al, 1990; Fremeaux-Bacchi et al, 1998; Marshall et al, 1998; Morinobu et al, 1996; Paul-Eugene et al, 1992; Spittler et al, 1995; Ten et al, 1999; Vercelli et al, 1988; Chaitidis et al, 2005)
¥¥ CD23 (CD23a, CD23b, FCER2, Fc-epsilon R2, Leu20, B6, Blast-2, 18.6 antigen, Ly42, CLEC4J, C-type lectin domain family 4 member J, EBVCS, EBV cell surface antigen, EBVCS1, EBVCS2, EBVCS3, EBVCS4, EBVCS5, MHM6) receptors (Hashimoto et al, 1997)
¥ CD26 (1F7, 2B9, 5F8, ACT-3, ADABP, ADA binding protein, ADCP2, adenosine deaminase complexing protein 2, BT5/9, DPCR1, DPP4, dipeptidyl peptidase 4, HAM.4, intestinal dipeptidyl peptidase, EC3.4.14.5, OX61, TA1, TA5/9, THAM, thymocyte-activating molecule, TP103, WC10 antigen, FAP-beta, Fibroblast activation protein-beta) (Laudes M et al, 2010)
¥ CD29 (FNRB, fibronectin receptor beta chain, ITGB1, integrin-beta-1, platelet protein GPIIa, VLA-beta, very late activation antigen-beta, VLA-beta-1, VLA-4 beta subunit) (de Waal Malefyt et al, 1993; Gebel et al, 1995; Prieto et al, 1994; Suzuki et al, 2007; Varis et al, 2001)
¥ CD30 (Ki-1, Ki-2, R4-4, Ber H2 antigen, TNFRSF8, TNF receptor superfamily member 8) (Epstein et al, 1992; Ancuta et al, 2009)
¥ CD31 (EndoCAM, endothelial cellular adhesion molecule, ER-MP12, PECAM-1, platelet-endothelial cell adhesion molecule 1) (Berman and Muller, 1995; Chen et al, 1994; Elias et al, 1998; Kim et al, 2009; Ancuta et al, 2009)
¥ CD32 (hFcRII, Fc-gamma R2, FCG2, FCGR2, CD32a, CD32b, FCGR2A, Fc-gamma R2a, FCGR2B, Fc-gamma R2b, IGFR2, immunoglobulin G Fc receptor 2) (Abrahams et al, 2000; Alevy et al, 1992; Chang, 1995; Chen et al, 1994; de Waal Malefyt et al, 1993; Debets et al, 1990; Masuda and Roos, 1993; Reterink et al, 1996; Sorg et al, 2001; Bosco et al, 2003, 2006; Karlsson KR et al, 2008)
¥ CD33 (CD33M, CD33m, MY9, SIGLEC-3, sialic acid binding immunoglobulin-like lectin 3) (Finnin et al, 1999; Griffin et al, 1984; Lajaunias et al, 2005; Sorg et al, 2001; Tanaka et al, 1999; Jaroenpool et al, 2007; Karlsson KR et al, 2008)
¥ CD35 (C3 binding protein, C3b receptor, C3bR, C3b/C4b receptor, C4b receptor, complement 3b/4b receptor, CR1, complement receptor-1, Knops blood group antigen, Kn(a), Kn(b), McCoy blood group antigen, McC, Swain-Langley blood group antigen, Sl, Yk(a), York blood group antigen) (Bacle et al, 1990; Thieblemont et al, 1995; Amara et al, 2010)
¥ CD36 (collagen type 1 receptor, FAT, fatty acid translocase, glycoprotein 3b, GP4, platelet glycoprotein 4, GPIIIb, Naka blood group antigen, OKM5, PAS-4 protein, periodic acid/Schiff-positive protein 4, PASIV, periodic acid/Schiff-positive band 4, platelet collagen receptor, thrombospondin receptor, UA009, obl, oblivious) (Berry et al, 2005, 2007; Fimiani et al, 1997; Huh et al, 1995; Janciauskiene et al, 2001; Meroni et al, 2005; Prieto et al, 1994; Ruiz-Velasco et al, 2004; Sampson et al, 2003; Cserti-Gazdewich et al, 2009; Olsnes et al, 2009; Xanthis et al, 2010; Niebuhr et al, 2010; Ancuta et al, 2009; Jiang Y et al, 2011)
¥ CD38 (ADP-ribosyl cyclase, ADP-ribosyl cyclase-1, cyclic ADP-ribose hydrolase, ecto-NAD+ glycohydrolase, Ecto-nicotinamide adenine dinucleotide glycohydrolase, EC3.2.2.5, Leu17, OKT10, T10) (Farina et al, 2004; Lande et al, 2002; Musso et al, 2001; Pfister et al, 2001; Tanaka et al, 1999)
¥ CD39 (apyrase, ATPDase, ATP diphosphohydrolase, EC3.6.1.5, Ecto-Apyrase, Ecto-ATPase, ENTPD1, ectonucleoside triphosphate diphosphohydrolase 1, NTPDase-1, vascular ATP diphosphohydrolase, G28-8, Bgp95) (Koziak et al, 1999)
¥ CD40 (Bp50, TNFRSF5, TNF receptor superfamily member 5) (Alderson et al, 1993; Browatzki et al, 2005; Burysek et al, 2002; Kiener et al, 1995; la Sala et al, 2000; Marckmann et al, 2004; Melter et al, 2000; Sorg et al, 2001; Takahashi et al, 2005; Moschen AR et al, 2007)
¥ CD40 ligand (CD40L, CD40LG, TRAP, TNF-related activation protein, CD154, 5c8, gp39, Ly62, T-BAM, IMD3, TNFSF5, TNF ligand superfamily member 5) (Katsiari et al, 2002)
¥ CD41b CD41, Bak, Bak(a), Bak(b), GPIIb, platelet glycoprotein IIb, HPA-3, human platelet antigen-3, ITGAB, integrin-alpha-2b, Lek(a)) (Prieto et al, 1994)
¥ CD43 (3E8 antigen, GALGP, galactoglycoprotein, gpL115, L60, Leu22, Lp-3, LSN, leukosialin, Ly48, MT1, OX75, S7 antigen, SPN, sialophorin, W3/13) (Ahuja et al, 1995; Kyriakou et al, 2000; Scriba et al, 1998; Burke et al, 2008; Ancuta et al, 2009)
¥ CD44 (CDw44, CD44H, CD44A, CD44s, CD44st, CD44std, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, class 3 ECMR, gp85, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Cairns et al, 2001; Culty et al, 1994; del Fresno et al, 2005; Gruber et al, 1992; Levesque and Haynes, 1996; Locati et al, 2002; Prabhakar et al, 1993; Prieto et al, 1994; Shi et al, 2001; Tjew et al, 2005; Varis et al, 2001; Webb et al, 1990; Zembala et al, 1994)
¥ CD44v (CD44, CD44H, CD44A, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Khaldoyanidi S et al, 1996)
¥ CD44v3 (CD44, CD44v, CD44H, CD44A, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Legras et al, 1998; Madden et al, 2009)
¥ CD44v6 (CD44, CD44v, CD44H, CD44A, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Mytar et al, 2002; Buckner et al, 2011; Legras et al, 1998; Marcondes et al, 2008)
¥ CD44v7 (CD44, CD44v, CD44H, CD44A, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Seiter et al, 2000)
¥ CD44v7/8 (CD44, CD44v, CD44H, CD44A, AnWj blood group antigen, ECMR-3, extracellular matrix receptor-3, HCAM, homing-associated cell adhesion molecule, Hermes-1, Hermes antigen, HUTCH-1, Indian blood group antigen, In blood group antigen, Ly24, MC56, MDU2, MDU3, MIC4, MUC 2-63, OX49, PGP1, PGP1.1, phagocytic glycoprotein-1, GM35 antigen) (Mytar et al, 2002)
¥ CD45 (B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (Gabriel et al, 1997; Gruber et al, 1992; Webb et al, 1990; Prabhakar et al, 1993; Virts et al, 1997)
¥ CD45R0 (UCHL-1, B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (Sorg et al, 2001)
¥ CD45RA (OX33, B220, HuLy-m4, LCA, leukocyte common antigen, Ly5, OX1, OX22, OX30, PTPRC, protein tyrosine phosphatase receptor type C, EC3.1.3.4, T200) (Brohee and Higuet, 1992; Nagasawa et al, 2004; Sorg et al, 2001)
¥ CD46 (gp45-70, HuLy-m5, MCP, membrane cofactor protein, measles virus receptor, MIC10, TLX, TRA-2-10, trophoblast-leukocyte common antigen, trophoblast-lymphocyte cross-reactive antigen) (Guc et al, 1993)
¥ CD47 (1D8, B6H12, BRIC 126, IAP, integrin-associated protein, integrin-associated signal transducer, MER6, OA3, ovarian carcinoma antigen 3, OVTL3) (Hermann et al, 1999; Johansson et al, 2004)
¥ CD48 (17D6, 5-8A10, 6.28, BCM1, B-cell activation marker 1, BLAST, B-LAST 1, Blast-1, HM48-1, Ly-m3, HuLy-m3, MEM-102, OX45, OX46, OX78, sgp-60, SLAMF2, signaling lymphocyte activation molecule family member 2, SLAM family member 2, TCT.1, T-cell target 1) (Sorg et al, 2001; Lange et al, 2007)
¥ CD49a (ITGA1, integrin-alpha-1, VLA-1, very late activation antigen 1, VLA-alpha 1, very late activation antigen alpha-1) (Suzuki et al, 2007; Heron et al, 2008)
¥ CD49d (ITGA4, integrin-alpha-4, VLA-4, very late activation antigen 4, VLAA4, VLA4 receptor alpha 4 subunit, VLA-alpha 4, very late activation antigen alpha-4) (Prieto et al, 1994)
¥ CD49e (fibronectin receptor alpha chain, FNRA, ITGA5, integrin-alpha-5, ECMR-6, Extracellular matrix receptor-6, class 6 ECMR, GPIc, platelet glycoprotein Ic, VLA-alpha 5, very late activation antigen alpha-5, VLA-5, very late activation antigen 5, VLA-5-alpha) (de Waal Malefyt et al, 1993; Prieto et al, 1994)
¥ CD49f (ITGA6, integrin-alpha-6, platelet gpI, VLA-6, very late activation antigen 6, VLA-6 alpha chain, VLA-alpha 6, very late activation antigen alpha-6, GPIc*, platelet glycoprotein Ic*) (Prieto et al, 1994)
¥ CD50 (ICAM-3, intercellular adhesion molecule 3, ICAM-R, ICAM receptor) (Kessel et al, 1998; Sorg et al, 2001)
¥ CD54 (7F7, BB2, human rhinovirus receptor, ICAM-1, intercellular adhesion molecule 1, IFN-gamma regulated human melanoma-associated antigen, Ly47, MALA-2, Me14-D12, P3.58) (Buchwald et al, 1999; Kiener et al, 1995; la Sala et al, 2000; Prieto et al, 1994; Salek-Ardakani et al, 2002; Schwarzer et al, 1998; Song et al, 1997; Sorg et al, 2001; Stuyt et al, 2003; Willems et al, 1994; Wang et al, 2000; Domeij et al, 2005; Xie and Gu, 2008; Mytar et al, 2002; Rich et al, 1993; Schmittel et al, 1995; Varis et al, 2001; Moschen AR et al, 2007)
¥ CD55 (CD55a, CD55b, complement decay-accelerating factor, decay-accelerating factor, DAF, DAF-GPI, DAF-TM, GPI-DAF, TM-DAF, DAF1, decay-accelerating factor 1, DAF2, decay-accelerating factor 2, Cromer blood group antigen) (Guc et al, 1993; Lange et al, 2007; Amara et al, 2010; Abbott RJ et al, 2007)
¥ CD56 (5.1.H11, BASCA, brain-associated small cell lung cancer antigen, Leu19, MSK39, NCAM, neural cell adhesion molecule, NCAM1, neural cell adhesion molecule-1, NCAM-120, neural cell adhesion molecule-120, NCAM-140, neural cell adhesion molecule-140, NCAM-180, neural cell adhesion molecule-180, NKH-1, PSA-NCAM, polysialylated NCAM, E-NCAM, embryonic NCAM, embryonic neural cell adhesion molecule) (Carter et al, 1999)
¥ CD58 (LFA-3, lymphocyte function-associated antigen-3, T11TS, T11 target structure) (Gruber et al, 1992; Rich et al, 1993; Schmittel et al, 1995; Varis et al, 2001; Webb et al, 1990; Lopez et al, 2001; Prabhakar et al, 1993; Prieto et al, 1994; Sorg et al, 2001)
¥ CD59 (CD59a, protectin, MIC11, MIN2, MIN3, MSK21, HRF20, homologous restriction factor-20 kDa, MACIF, membrane attack complex inhibitory factor, MAC-IP, MAC-inhibitory protein, H19, MIRL, membrane inhibitor of reactive lysis, P18, 1F5, 16.3A5, BRIC 229, YTH 53.1) (Amara et al, 2010)
¥ CD61 (CD61A, F4, F11, GPIIb/IIIa, HPA-1, human platelet antigen-1, HPA-4, human platelet antigen-4, ITGB3, integrin-beta-3, Pen alloantigen, Pen(a), Pen(b), PL(A1), platelet fibrinogen receptor beta subunit, platelet glycoprotein IIIa, GP3A, Yuk alloantigen, Yuk(a), Yuk(b), Zw alloantigen, Zw(a), Zw(b)) (Prieto et al, 1994)
¥ CD62L (gp90-MEL, LAM-1, leukocyte adhesion molecule 1, LECAM-1, leukocyte adhesion molecule 1, Leu8, LSEL, L-selectin, selectin-L, SELL, LYAM1, MEL-14, OX85, PLNHR, TQ-1) (Griffin et al, 1990; Lundahl et al, 1995; Prieto et al, 1994; Spertini et al, 1996; Wikman et al, 2003; Varga et al, 2008; Ancuta et al, 2009)
¥ CD64 (hFcRI, FCGR1, Fc-gamma R1, FCGR1A, Fc-gamma R1A, FCGR1B, Fc-gamma R1B, FCGR1C, Fc-gamma R1C) (Abrahams et al, 2000; Beigier-Bompadre et al, 2001; Benichou et al, 1987; Bovolenta et al, 1998; de Waal Malefyt et al, 1993; Debets et al, 1990; Chang, 1995; Feldman et al, 1995; Frasnelli et al, 2005; Gabriel et al, 1997; Masuda and Roos, 1993; Sorg et al, 2001; Bosco et al, 2003, 2006; Li et al, 2009)
¥ CD66f (B1G1, FL-NCA-1/2, fetal liver nonspecific crossreactive antigen 1/2, PBG1, pregnancy-specific b1 glycoprotein, pregnancy-specific beta-1 glycoprotein C/D, PSBG1, PSG1, pregnancy-specific beta-1 glycoprotein 1, PSG, pregnancy-specific glycoprotein, PSG95, pregnancy-specific glycoprotein 95, PSGGA, pregnancy-specific glycoprotein gene A, SP-1, Schwangerschaftsprotein 1) (Heikinheimo et al, 1987)
¥¥ CD66f (B1G1, FL-NCA-1/2, fetal liver nonspecific crossreactive antigen 1/2, PBG1, pregnancy-specific b1 glycoprotein, pregnancy-specific beta-1 glycoprotein C/D, PSBG1, PSG1, pregnancy-specific beta-1 glycoprotein 1, PSG, pregnancy-specific glycoprotein, PSG95, pregnancy-specific glycoprotein 95, PSGGA, pregnancy-specific glycoprotein gene A, SP-1, Schwangerschaftsprotein 1) receptors (Snyder et al, 2001)
¥ CD68 (EBM11, gp110, Ki-M6, Ki-M7, KP-1, macrosialin, microsialin, PG-M1, PM-1k, SCARD1, scavenger receptor class D member 1, Y1/82A, Y2/131) (Strobl et al, 1995; Pulford et al, 1990; Mytar et al, 2002; Karlsson KR et al, 2008)
¥ CD69 (AIM, activation inducer molecule, BL-AC/P26, CLEC2C, C-type lectin domain family 2 member C, EA1, early antigen 1, early T-cell activation antigen p60, gp34/28, Leu23, MLR3, VEA) (Farina et al, 2004; Bosco et al, 2003, 2006; Heron et al, 2008)
¥ CD73 (5'-ribonucleotide phosphohydrolase, EC3.1.3.5, L-VAP-2, Lymphocyte-vascular adhesion protein-2, NT5E, E5NT, E-5'Nu, NTE, ecto-5'-nucleotidase, 5'-nucleotidase, SH-3, SH-4) (Lange et al, 2007)
¥ CD74 (HLA-DR-gamma, HLADG, HLA class 2 histocompatibility antigen gamma chain, HLA-DR associated invariant chain, Ia-gamma, LN2, MHC class 2 invariant chain) (Suzuki et al, 2000)
¥ CD80 (B7, B7-1, BB1, B-lymphoblast antigen-1, Ly53) (Boylan et al, 1999; Creery et al, 1996; Farina et al, 2004; Fleischer et al, 1996; Freedman et al, 1991; Fujihara et al, 1996; la Sala et al, 2000; Lahat et al, 2003; Liu et al, 1999; Marckmann et al, 2004; Moschen AR et al, 2007; Raymond and Wilkie, 2005; Salek-Ardakani et al, 2002; Schmittel et al, 1995; Shinohara et al, 2004; Sorg et al, 2001; Varis et al, 2001; Vecchiarelli et al, 1998; Willems et al, 1994)
¥ CD83 (BL11, HB15) (Aiba et al, 2003; Cao et al, 2005; Farina et al, 2004)
¥ CD84 (CDw84, Ly9b, lymphocyte antigen 9b, lymphocyte antigen 9-beta, Ly9-beta, MAX.3 antigen, SLAMF5, signaling lymphocyte activation molecule family member 5, SLAM family member 5) (de la Fuente et al, 1997; Zaiss et al, 2003; Sintes et al, 2010)
¥ CD84-H1 (CD84 homolog 1, CD2F-10, CD2 family member 10, SLAMF9, SLAM family member 9, SF2001, SLAM family 2001) (Zhang W et al, 2001)
¥ CD85d (LILRB2, leukocyte immunoglobulin-like receptor subfamily B member 2, ILT4, immunoglobulin-like transcript 4, LIR2, leukocyte immunoglobulin-like receptor 2, MIR10, monocyte/macrophage immunoglobulin-like receptor 10) (Colonna et al, 1997; Chang et al, 2002; Fanger et al, 1998)
¥ CD85e (LILRA3, leukocyte immunoglobulin-like receptor subfamily A member 3, ILT6, immunoglobulin-like transcript 6, LIR4, leukocyte immunoglobulin-like receptor 4, HM43/HM31, Monocyte inhibitory receptor HM43/HM31, HM43, HM31) (An et al, 2010)
¥ CD85f (LILRA5, leukocyte immunoglobulin-like receptor subfamily A member 5], LILRB7, leukocyte immunoglobulin-like receptor subfamily B member 7, ILT11, immunoglobulin-like transcript 11, LIR9, leukocyte immunoglobulin-like receptor 9) (Bosco et al, 2006)
¥ CD85g (LILRA4, leukocyte immunoglobulin-like receptor subfamily A member 4, ILT7, immunoglobulin-like transcript 7) (Rissoan et al, 2002)
¥ CD85h (LILRA2, leukocyte immunoglobulin-like receptor subfamily A member 2, ILT1, immunoglobulin-like transcript 1, LIR7, leukocyte immunoglobulin-like receptor 7) (Bleharski et al, 2003)
¥ CD85i (LIR6, leukocyte immunoglobulin-like receptor 6, LILRA1, leukocyte immunoglobulin-like receptor subfamily A member 1) (Borges et al, 1997)
¥ CD85j (ILT2, immunoglobulin-like transcript 2, LIR1, leukocyte immunoglobulin-like receptor 1, MIR7, monocyte/macrophage immunoglobulin-like receptor 7, LILRB1, leukocyte immunoglobulin-like receptor subfamily B member 1) (Vlad et al, 2003; Banham et al, 1999; Samaridis and Colonna, 1997; Cosman et al, 1997; Colonna et al, 1997; Tenca et al, 2005; Fanger et al, 1998; Ancuta et al, 2009)
¥ CD85k (LILRB4, leukocyte immunoglobulin-like receptor subfamily B member 4, ILT3, immunoglobulin-like transcript 3, LIR5, leukocyte immunoglobulin-like receptor 5, HM18, Monocyte inhibitory receptor HM18, gp49B, gp49B1, gp49B2) (Cella et al, 1997; Arm et al, 1997; Borges et al, 1997; Chang et al, 2002)
¥ CD86 (B70, B72, B7-2, BU-63, CD28 ligand-2, CD28LG2, CLS1, FUN-1, GR65, LAB7-2, Ly58, MB7) (Aiba et al, 2003; Boylan et al, 1999; Creery et al, 1996; Engel et al, 1994; Engel et al, 1994; Farina et al, 2004; Fleischer et al, 1996; Fujihara et al, 1996; Girndt et al, 2001; Kiener et al, 1995; Kumar et al, 1999; la Sala et al, 2000; Liu et al, 1999; Marckmann et al, 2004; Smyth et al, 1998; Sorg et al, 2001; Vecchiarelli et al, 1998; Mytar et al, 2002; Varis et al, 2001
¥ CD87 (MO3, PLAUR, plasminogen activator urokinase receptor, UPA-R, urokinase plasminogen activator receptor, URKR, urokinase receptor) (Finnin et al, 1999; Kirchheimer et al, 1988; Locati et al, 2002; Paysant et al, 1998)
¥ CD88 (C5aR, C5a receptor, C5R1, complement component 5 receptor 1) (Ember et al, 1994; Furebring et al, 2002; Geiger et al, 1992; Conroy et al, 2009; Karp et al, 2000; Ohura et al, 1987; Oppermann et al, 1993; Thivierge et al, 1999; Wittmann et al, 1999l Zahn et al, 1997; Zwirner et al, 1999)
¥ CD89 (FCAR, Fc fragment of IgA receptor, IgA receptor, immunoglobulin A Fc receptor, Fc-alpha R, Fc-alpha RI) (Bosco et al, 2003; Chiamolera et al, 2001; Hamre et al, 2003; Patry et al, 1996; Pilette et al, 2010; Pleass et al, 1997; Patry et al, 1996; Reterink et al, 1996; Toyabe et al, 1997; van der Heul-Nieuwenhuijsen L et al, 2010; Wolf et al, 1996; Stockmeyer et al, 2000)
¥ CD91 (A2MR, Alpha-2-Macroglobulin receptor, APOER, apolipoprotein E receptor, APR [apolipoprotein receptor, CED1, LRP, Low density lipoprotein receptor-related protein, LRP1, lipoprotein receptor-related protein, TGFBR5, TGF-beta receptor 5; transforming growth factor-beta receptor 5; TGF-beta receptor type 5; type 5 TGF-beta receptor, IGFBP3R, IGFBP3 receptor; Insulin-like growth factor binding protein-3 receptor) (Kebba et al, 2005; Stebbing et al, 2004)
¥ CD92 (CTL1, CHTL1, choline transporter-like protein 1, GR9, SLC44A1 [solute carrier family 44 member 1) (Wille et al, 2001)
¥ CD93 (AA4, C1q receptor, C1qR1, C1qRp, collectin receptor, GR11, Ly68, MXRA4) (Dean et al, 2000, 2001; Maruyama et al, 2003; Bosco et al, 2006; Moosig et al, 2006; Bohlson et al, 2005; Ancuta et al, 2009)
¥ CD97 (BL-KDD/F12, GR1, TM7LN1, AURA51, augmented in rheumatoid arthritis 51) (Ancuta et al, 2009)
¥ CD98 (CD98LC, 4F2lc, 4F2, 4F2hc, FRP-1, fusion regulatory protein-1, LAT1, system-L amino acid transporter 1, L-type amino acid transporter 1, Ly10, Ly-m10, MDU1, MPE16, membrane protein E16, RL-388, SLC3A2, solute carrier family 3 member 2, SLC7A5, solute carrier family 7 member 5) (Miyamoto et al, 2000; Ohgimoto et al, 1995; Lange et al, 2007)
¥ CD99 (12E7, MIC2, MIC2X, MIC2Y, E2 antigen, CD99R, O13, hec2, HBA-71) (Bernard et al, 1988; Schenkel et al, 2002; Ancuta et al, 2009)
¥ CD105 (endoglin, ENG, Edg, L-endoglin, S-endoglin, E9 protein, MJ7/18 antigen, HHT1, hereditary hemorrhagic telangiectasia type 1, ORW, Osler-Rendu-Weber syndrome, ORW1, SH-2) (Dharmapatni AA et al, 2001; Jeziorska M, 2004; Sanz-Rodriguez F et al, 2004)
¥ CD112 (HveB, Herpesvirus entry mediator B, Herpes simplex virus entry protein B, nectin-2, Nectin-2-alpha, Nectin-2-delta, PRR2, poliovirus receptor-related-2, PVRL2, Poliovirus receptor-like-2, PRR2-alpha, PRR2-delta) (Rosche et al, 2004)
¥ CD141 (thrombomodulin, TM, THBD, THRM, Alpha-Thrombomodulin, Beta-Thrombomodulin, fetomodulin, FM) (Chen et al, 2009; Grey and Hancock, 1996; Kim HK et al, 2008, 2007; McCachren et al, 1991; Satta et al, 1997; Lange et al, 2007)
¥ CD143 (ACE, angiotensin converting enzyme, angiotensin-1 converting enzyme, dipeptidyl carboxypeptidase, dipeptidyl carboxypeptidase 1, EC3.4.15.1, kininase 2, peptidase P, peptidyl dipeptidase A) (Costerousse et al, 1993; Lazarus et al, 1994; Goto et al, 1990)
¥ CD148 (143-41 antigen, DEP-1, high cell density-enhanced PTP-1, Density enhanced phosphatase-1, EC3.1.3.48, HPTP-eta, human protein tyrosine phosphatase-eta, protein tyrosine phosphatase-eta, p260, PTPRJ, Protein tyrosine phosphatase receptor type J, SCC1, susceptibility to colon cancer 1, protein tyrosine phosphatase-eta) (de la Fuente-Garc’a et al, 1998)
¥ CD150 (IPO-3, measles virus receptor, SLAM, signaling lymphocyte activation molecule, SLAMF1, signaling lymphocyte activation molecule family member 1, SLAM family member 1) (Farina et al, 2004; Minagawa et al, 2001; Theil et al, 2005)
¥ CD155 (Necl-5, Nectin-like molecule-5, PVR, poliovirus receptor, Tage-4, tumor associated glycoprotein E4, TuAg1) (Rosche et al, 2004)
¥ CD161 (CLEC5B, C-type lectin domain family 5 member B, KLRB1, killer cell lectin-like receptor subfamily B member 1, NKR-P1A, CD161a) (Scriba et al, 1998)
¥ CD162 (PSGL, P-selectin glycoprotein ligand, PSGL-1, P-selectin glycoprotein ligand-1, SELPLG [selectin-P ligand) (Davenpeck et al, 2000)
¥ CD163 (Ber-MAC3, GHI/61, HbSR, hemoglobin scavenger receptor, hemoglobin/haptoglobin scavenger receptor, Ki-M8, M130, p155, Mac 2-48, RM3/1, SM4) (Buechler et al, 2000; Chamorro et al, 2004; Cranny et al, 2002; Frings et al, 2002; Hšgger et al, 1998; Sanchez-Torres et al, 2003; Sulahian et al, 2000; Timmermann and Hogger, 2005; Bosco et al, 2003, 2006; Varga et al, 2008; Philippidis P et al, 2010; Philippidis P et al, 2010; Tippett et al, 2011; Maniecki et al, 2011; Colo Brunialti et al, 2012)
¥ CD164 (endolyn, endolyn-78, MGC-24, multiglycosylated core protein-24, MGC-24v, MUC-24) (Watt et al, 1998)
¥ CD171 (8D9, CAML1, cellular adhesion molecule L1, G4, HSAS, HSAS1, L1, L1CAM, L1 cell adhesion molecule, MASA, MIC5, NCAM L1, neural cell adhesion molecule like-1, NgCAM, neuron-glia cell adhesion molecule, NILE, nerve growth factor-inducible large external, NGF-inducible large external, S10, SPG1, spastic paraplegia 1) (Pancook et al, 1997)
¥ CD172A (BIT, brain Ig-like molecule with tyrosine-based activation motif, MFR, macrophage fusion receptor, MYD1, p84, PTPNS1, protein tyrosine phosphatase nonreceptor type substrate 1, OX41, SHPS1, SHP substrate 1, SIRP-alpha, SIRP-alpha-1, signal regulatory protein-alpha, tyrosine phosphatase SHP substrate 1) (de Vries et al, 2002; Barros et al, 2009)
¥ CD172B (SIRPB1, SIRP-beta, SIRP-beta-1, signal regulatory protein-beta-1) (Barros et al, 2009)
¥ CD180 (BGP95, Ly64, Ly78, RP105, radioprotective protein 105 kDa) (Miura et al, 1996, 1998)
¥ CD204 (Macrophage acetylated LDL receptor, Macrophage acetylated LDL receptor I, Macrophage acetylated LDL receptor II, MSR1, macrophage scavenger receptor, Scvr, Scavenger receptor class A, SRA, scavenger receptor A, SCARA1, scavenger receptor class A member 1, SRA-I, scavenger receptor AI, SRA-II, scavenger receptor AII) (Bosco et al, 2006; Kim JR et al, 2010)
¥ CD206 (CLEC13D, C-type lectin domain family 13 member D, MMR, macrophage mannose receptor, MRC1, mannose receptor C type-1, MR, mannose receptor) (Schraufstatter et al, 2012; Semnani et al, 2011; Colo Brunialti et al, 2012)
¥ CD225 (fragilis2, IFI17, interferon-induced protein 17, IFITM1, interferon-induced transmembrane protein 1, 9-27, Interferon-inducible protein 9-27, Leu13) (Baca et al, 1994; Wildenberg et al, 2008; Ancuta et al, 2009)
¥ CD226 (DNAM-1, DNAX accessory molecule 1, PTA1, platelet and T-cell activation antigen 1, TLiSA1, T lineage-specific activation antigen 1) (Shibuya et al, 1996; Jia et al, 2000; Burns et al, 1985)
¥ CD227 (DF3, carcinoma-associated mucin, EMA, epithelial membrane antigen, episialin, H23, MAM6, MSA, mammary serum antigen, MUC-1, mucin 1, PEM, polymorphic epithelial mucin, PEMT, tumor-associated mucin, PUM, peanut-reactive urinary mucin, cancer antigen 15.3, CA 15.3, carbohydrate antigen 15.3) (Wykes et al, 2002)
¥ CD229 (hly9, HumLy9, Lgp100, Ly9, SLAMF3, signaling lymphocyte activation molecule family member 3, T100 (Sintes et al, 2007)
¥ CD244 (2B4, 2B4-S, 2B4-L, C1.7, C9.1, Ly90, NAIL, NK-cell activation-inducing ligand, NKR2B4, natural killer cell receptor 2B4, NK-cell receptor 2B4, Nmrk, Non-MHC restricted killing associated, p38, SLAMF4, signaling lymphocyte activation molecule family member 4) (Boles et al, 2001; Romero et al, 2004)
¥ CD275 (B7-H2, B7RP-1, B7-related protein 1, GL50, H4, ICOSL, inducible T-cell co-stimulator ligand, ICOS ligand, KIAA0653, LICOS, ligand for ICOS) (Farina et al, 2004)
¥ CD300A (CMRF35H, CMRF35H9, IGSF12, immunoglobulin superfamily member 12, IRC1, IRC2, IRp60, Inhibitory receptor protein 60, MAIR-I, myeloid-associated immunoglobulin-like receptor I, CLM8, CMRF35-like molecule-8, LMIR1, leukocyte mono-Ig-like receptor 1) (Green et al, 1998)
¥ CD300B (CD300LB, CD300 molecule-like family member B, CLM7, CMRF35-like molecule-7, CMRF35-like molecule-7, IREM3, immune receptor expressed by myeloid cells 3, TREM5, triggering receptor expressed on myeloid cells 5, MAIR-VII, myeloid-associated immunoglobulin-like receptor VII, LMIR5, leukocyte mono-Ig-like receptor 5) (Martinez-Barriocanal and Sayos, 2006; Wu Y et al, 2011)
¥ CD300C (CMRF35, CMRF35A, CMRF35A1, IGSF16, immunoglobulin superfamily member 16, LIR, MAIR-III, myeloid-associated immunoglobulin-like receptor III, CLM6, CMRF35-like molecule-6) (Jackson et al, 1992)
¥ CD300D (CD300LD; MAIR-II, myeloid-associated immunoglobulin-like receptor II, CLM4, CMRF35-like molecule-4, LMIR2, leukocyte mono-Ig-like receptor 2, DIgR1, DC-derived Ig-like receptor 1; Dendritic cell-derived Ig-like receptor 1, CMRF35A4, CMRF35-like molecule A4) (Luo K et al, 2001)
¥ CD300E (CD300LE, CD300 molecule-like family member LE, CLM2, CMRF35-like molecule-2, CMRF35-like molecule-2, IREM2, immune receptor expressed by myeloid cells 2, MAIR-VIII, myeloid-associated immunoglobulin-like receptor VIII, LMIR6, leukocyte mono-Ig-like receptor 6) (Aguilar et al, 2004)
¥ CD300F (CD300LF, CD300 molecule-like family member F, CLM1, CMRF35-like molecule-1, IGSF13, immunoglobulin superfamily member 13, IREM1, immune receptor expressed on myeloid cells 1, NKIR, NK inhibitory receptor, MAIR-V, myeloid-associated immunoglobulin-like receptor V, LMIR3, leukocyte mono-Ig-like receptor 3, CLM1, CMRF35-like molecule-1, DIgR2, DC-derived Ig-like receptor 2; Dendritic cell-derived Ig-like receptor 2) (Sui et al, 2004; Alvarez-Errico et al, 2004)
¥ CD301 (CD301a, MGL1 [Macrophage galactose-type C-type lectin-1, CD301b, MGL2, Macrophage galactose-type C-type lectin-2, CLEC10A, C-type lectin domain family 10 member A, CLECSF13, C-type lectin domain superfamily member 13, CLECSF14, C-type lectin domain superfamily member 14, HML, human macrophage lectin, HML2, human macrophage lectin 2, Macrophage lectin 2) (Raes et al, 2005; Semnani et al, 2011)
¥ CD302 (BIMLEC, CLEC13A, C-type lectin domain family 13 member A, DCL-1, DEC-205-associated C-type lectin-1) (Kato et al, 2007)
¥ CD305 (LAIR1, leukocyte-associated Ig-like receptor 1, 9.1C3) (Bosco et al, 2006)
¥ CD312 (EMR2, EGF-like module containing mucin-like hormone receptor-like-2) (Chang et al, 2007; Kwakkenbos et al, 2002; Lin HH et al, 2000; Karlsson KR et al, 2008)
¥ ceruloplasmin (Cp, ferroxidase, Fe(II) - oxygen oxidoreductase, iron (II) - oxygen oxidoreductase, EC1.16.3.1, Ran-2 antigen, rat neural antigen-2, PACAP(1-38) binding factor, pituitary adenylate cyclase-activating polypeptide1-38-binding factor) (Mazumder et al, 1997; Yang et al, 1986; Marques L et al, 2012)
¥ CHI3L1 (chitinase 3-like-1, cartilage glycoprotein 39, gp39; gp39k HC-gp39, chondrocyte protein YKL40, YKL40, Chondrex) (Baeten et al, 2000)
¥ chromogranin A (CGA, CHGA, granin A, Parathyroid secretory protein-1, Parathyroid secretory protein, PSP, PSP1, pituitary secretory protein-1, Secretory protein-1, SG-I, catestatin) (Tasiemski et al, 2002)
¥ chromogranin B (CGB, CHGB, Secretogranin-1, SCG1) (Tasiemski et al, 2002)
¥ CIDE-B (Cell death-inducing DFF45-like effector B) (Turpaev et al, 2005)
¥ CKLF-1 (chemokine-like factor-1, CKLF, chemokine-like factor) (Shao L et al, 2010)
¥ Clusterin (CLU, dimeric acidic glycoprotein, DAG protein, testosterone repressed prostate message-2, TRPM-2, sulfated glycoprotein-2, SGP-2, complement-associated protein SP-40,40, SP-40,40, complement lysis inhibitor, CLI, Apolipoprotein J) (Guc et al, 1993)
¥ common gamma (IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, gammac, gamma common, common cytokine receptor-gamma, cytokine receptor common subunit gamma, CD132, IMD4, immunodeficiency 4, SCIDX, X-linked severe combined immunodeficiency, SCIDX1, X-linked severe combined immunodeficiency, SCIDX1, X-linked severe combined immunodeficiency-1, XSCID, X-linked severe combined immunodeficiency) (Bosco et al, 1994, 1997; Epling-Burnette et al, 1995)
¥ complement factor C3 (ECI, Eosinophil cytotoxicity inhibitor, C3-beta-c, complement factor C3b, ETF-3, embryotrophic factor-3, HSE-MSF, hepatic sinusoidal endothelial cell-derived migration stimulating factor) (Andoh et al, 1993; Drouin et al, 1998; Hogasen et al, 1995)
¥ complement factor H (factor H, CFH, H factor, HF, H factor-1, HF1, beta 1 H globulin, C3b inactivator accelerator, A-C3bINA, AMBP-1, AM34 antigen, Adrenomedullin binding protein-1, AM binding protein-1) (Lappin and Whaley, 1990; Lemercier et al, 1992; Guc et al, 1993)
¥¥ complement factor H (factor H, CFH, H factor, HF, H factor-1, HF1, beta 1 H globulin, C3b inactivator accelerator, A-C3bINA, AMBP-1, AM34 antigen, Adrenomedullin binding protein-1, AM binding protein-1) receptors (Iferroudjene et al, 1991; Guc et al, 1993; Malhotra and Sim, 1985; Schwaeble et al, 1991)
¥¥ Corticotropin releasing hormone (CRH, CRF, Corticotropin releasing factor, Corticoliberin) receptors (Wang et al, 2000)
¥ cortistatin (Cort, CST, CST-14, Cortistatin-14, CST-17, Cortistatin-17) (Dalm et al, 2003)
¥¥ cortistatin (Cort, CST, CST-14, Cortistatin-14, CST-17, Cortistatin-17) receptors (Dalm et al, 2003; Lichtenauer-Kaligis et al, 2004)
¥ CRADD (Caspase and RIP adaptor with death domain, RAIDD, RIP associated Ich-1/CED homologous protein with death domain) (Lange et al, 2007)
¥ CRP (C-reactive protein, PTX1, pentraxin-1, PCBP, phosphorylcholine-binding protein) (Kearney, 1982)
¥¥ CRP (C-reactive protein, PTX1, pentraxin-1, PCBP, phosphorylcholine-binding protein) receptors (Ballou and Cleveland, 1991; Zhang and Wahl, 2006; Cermak et al, 1993; Stein et al, 2000; Ramani et al, 1994; Han et al, 2004; Hanriot et al, 2008; Eisenhardt et al, 2009)
¥¥ CTGF (Connective tissue growth factor, Hcs24, hypertrophic chondrocyte-specific gene product 24, Fisp-12, fibroblast inducible secreted protein-12, IGFBP8, Insulin-like growth factor binding protein-8, IGFBPrP2, Insulin-like growth factor binding protein related protein-2, Ecogenin, endochondral ossification genetic factor, CCN2) receptors (Schober et al, 2002)
¥ C-type natriuretic peptide (CNP, ANP-C, NPPC, natriuretic peptide precursor type C, CNP-22, CNP-53, NPPC) (Kubo et al, 2001)
¥¥ CX3CL1 (fractalkine, FKN, FK, CX3C membrane-anchored chemokine, C3Xkine, neurotactin, NTT, NTN, ABCD-3, SCYD1) receptors (CX3CR1, V28, CMKBRL1, chemokine beta receptor-like-1, GPR13, G-protein-coupled receptor-13) (Ancuta et al, 2003, 2006, 2009; Apostolakis et al, 2007; Grip et al, 2007, 2008; Varga et al, 2008; Landsman et al, 2009; Pachot et al, 2008; Green et al, 2006; Tacke et al, 2007; Apostolakis et al, 2010; Ramos et al, 2010)
¥ CXCL1 (CXC chemokine ligand 1, chemokine (C-X-C motif) ligand 1, SCYB1, CINC-1, Cytokine induced neutrophil chemoattractant-1, fsp, fibroblast secretory protein, GRO1, GRO-alpha, KC, MGSA, melanoma growth stimulatory activity, MGSA-alpha, melanoma growth stimulatory activity-alpha, NAP-3, neutrophil-activating protein-3, N51) (Armstrong et al, 2004; Schroder et al, 1990; Hanriot et al, 2008; StuhlmŸller et al, 2000; Monnier J et al, 2008)
¥ CXCL2 (CXC chemokine ligand 2, chemokine (C-X-C motif) ligand 2, CINC-2-alpha, Cytokine induced neutrophil chemoattractant-2-alpha, GRO2, growth-related oncogene-2, GRO-beta, growth regulated oncogene-beta, MIP-2-alpha, macrophage inflammatory protein-2-alpha, MGSA-beta, melanoma growth stimulatory activity-beta, SCYB2) (Hanriot et al, 2008; StuhlmŸller et al, 2000)
¥ CXCL3 (CXC chemokine ligand 3, chemokine (C-X-C motif) ligand 3, CINC-2-beta, Cytokine induced neutrophil chemoattractant-2-beta, DCIP-1, DC inflammatory protein-1, GRO3, GRO-gamma, growth regulated oncogene-gamma, growth-related oncogene-3, MGSA-gamma, melanoma growth stimulatory activity-gamma, MIP-2-beta, macrophage inflammatory protein-2-beta) (Wang et al, 2000; Subimerb et al, 2010)
¥¥ CXCL4 (CXC chemokine ligand 4, chemokine (C-X-C motif) ligand 4, PF4, platelet factor-4, Endothelial cell growth inhibitor, Heparin neutralizing protein, Megakaryocyte-stimulatory-factor, Oncostatin A, SCYB4) receptors (Engstad et al, 1995; Schwartzkopff F et al, 2012)
¥ CXCL5 (CXC chemokine ligand 5, chemokine (C-X-C motif) ligand 5, ENA-78, Epithelial neutrophil-activating protein 78, epithelial cell-derived neutrophil attractant-78, LIX, LPS induced CXC chemokine, AMCF-2, Alveolar macrophage chemotactic factor-2, SCYB5) (Bliss et al, 1998; Schnyder-Candrian and Walz, 1997; Walz et al, 1997; Wang et al, 2000; Merck et al, 2006; Barksby et al, 2009)
¥ CXCL6 (CXC chemokine ligand 6, chemokine (C-X-C motif) ligand 6, GCP-2, granulocyte chemotactic peptide-2, CKA-3, chemokine alpha 3, SCYB6) (Royaee et al, 2006)
¥ CXCL7 (CXC chemokine ligand 7, chemokine (C-X-C motif) ligand 7, CTAP-3, Connective tissue activating protein-3, LA-PF4, low affinity platelet factor-4, LDGF, Leukocyte-derived growth factor, MDGF, macrophage-derived growth factor, NAP-2, Neutrophil-activating protein-2, PPBP, pro-platelet basic protein, PBP, platelet basic protein, SCYB7) (El-Gedaily A et al, 2006; Schaffner et al, 2004; Pillai et al, 2006; van der Heul-Nieuwenhuijsen L et al, 2010; Fu et al, 2004)
¥ CXCL9 (CXC chemokine ligand 9, chemokine (C-X-C motif) ligand 9, mig, monokine induced by gamma-Interferon, Humig, Mumig, CRG-10, cytokine responsive gene-10, M119, SCYB9) (Comabella et al, 2002; Wang et al, 2000)
¥ CXCL10 (CXC chemokine ligand 10, chemokine (C-X-C motif) ligand 10, IP-10, INP-10, inflammatory protein 10, Interferon-inducible protein-10, IFN-inducible protein 10, immune protein-10; 10 kDa interferon-inducible protein, gamma-IP-10, CRG-2, cytokine responsive gene-2, C7, Ifi10, interferon-inducible-10, mob-1, SCYB10) (Kasama et al, 2002; Bussfeld et al, 2000; Comabella et al, 2002; Finbloom et al, 1993; Mendez Samperio et al, 2004; Wang et al, 2000; Lehmann et al, 2009; Yeh CH et al, 2010)
¥¥ CXCL12 (CXC chemokine ligand 12, chemokine (C-X-C motif) ligand 12, IRH, intercrine reduced in hepatomas, hIRH, intercrine reduced in hepatomas, SDF-1-alpha, CXCL12-alpha, SDF-1-beta, CXCL12-beta, SDF, SDF-1, Stromal cell-derived factor, Stromal cell-derived factor-1-alpha, Stromal cell-derived factor-1-beta, PBSF, pre-B-cell growth stimulating factor, TLSF, Thymic lymphoma cell stimulating factor, Thymic lymphoma cell stimulating factor-alpha, Thymic lymphoma cell stimulating factor-beta, TLSF-alpha, TLSF-beta, TPAR-1, TPA repressed gene-1, SCYB12) receptors (Klier et al, 2001)
¥ CXCL13 (CXC chemokine ligand 13, chemokine (C-X-C motif) ligand 13, BLC, B-lymphocyte chemoattractant, BCA-1, B-cell attracting chemokine 1, blr-1L, blr-1 ligand, Angie-2, SCYB13) (Carlsen et al, 2004)
¥¥ CXCL14 (CXC chemokine ligand 14, chemokine (C-X-C motif) ligand 14, BMAC, B-cell and monocyte-activating chemokine, bolekine, BRAK, breast and kidney cell chemokine, KEC, kidney-expressed chemokine, KS1, MIP-2-gamma, macrophage inflammatory protein-2-gamma, NJAC, SCYB14) receptors (Augsten et al, 2009)
¥ CXCL16 (CXC chemokine ligand 16, chemokine (C-X-C motif) ligand 16, SR-PSOX, scavenger receptor that binds phosphatidylserine and oxidized lipoprotein, SCYB16) (Ancuta et al, 2009; GŸnther et al, 2012)
¥¥ CXCL17 (CXC chemokine ligand 17, chemokine (C-X-C motif) ligand 17, DMC, dendritic cell and monocyte chemokine-like protein, VCC-1, VEGF co-regulated chemokine 1) receptors (Pisabarro et al, 2006)
¥ CXCR3 (CXCR3A, CXC-Chemokine receptor 3, IP-10 receptor, Mig receptor, CKR-L2, GPR9, CD183) (Cella et al, 1999; Janis et al, 2004; Kawamura et al, 2003; Nieto et al, 2012)
¥ CXCR4 (CXC-Chemokine receptor 4, LESTR, leukocyte-derived 7-transmembrane domain receptor, HUMSTR, NPYRL, neuropeptide Y receptor-like, NPY3R, neuropeptide Y receptor Y3, HM89, Fusin, LCR-1, FB22, LAP3, Lipopolysaccharide-associated protein 3, SDF-1 receptor, CD184, AURA86, augmented in rheumatoid arthritis 86) (Caulfield et al, 2002; Deng et al, 1999; Juffermans et al, 2002; Nieto et al, 2012)
¥ CXCR5 (MDR15, monocyte-derived receptor 15, blr-1, Burkitt lymphoma receptor-1, CD185) (Kim et al, 2005)
¥ CXCR6 (CXC-Chemokine receptor 6, TYMSTR, T-lymphocyte-expressed seven-transmembrane domain receptor, Bonzo, STRL33, CD186) (Huang et al, 2008)
¥ CXCR7 (CXC-Chemokine receptor 3, RDC1, CMKOR1, chemokine orphan receptor 1, GPR159, G-protein-coupled receptor-159) (Bosco et al, 2006)
¥¥ cyclophilin A (CYPA, CYPH, Cyclosporin A binding protein, PPIA, peptidyl-prolyl cis-trans isomerase A, peptidylprolyl isomerase A, PPIase A, Rotamase A, sp18, secreted protein 18 kDa) receptors (Wang L et al, 2010; Sherry et al, 2007; Payeli et al, 2008)
¥ Cystatin A (CSTA, Keratolinin, Stefin A, STFA, STF1, ACPI, acid cysteine proteinase inhibitor) (Mlinaric-Rascan et al, 1994)
¥ Cystatin C (CST3, Cystatin-3, Gamma-TRACE, post-gamma globulin) (Suzuki et al, 2000)
¥ Cystatin F (Cystatin-7, CST7, CMAP, cystatin-like metastasis-associated protein, leukocystatin) (Halfon et al, 1998)

¥ D6 (CCBP2, chemokine binding protein-2, CMKBR9, chemokine-beta receptor 9) (Bradford L et al, 2010; McKimmie CS et al, 2008; Nibbs RJ et al, 1997)
¥ Dad-1 (defender against apoptotic death; defender against cell death) (Wang et al, 2000)
¥ DcR-3 (Decoy receptor-3, M68, TR6, TNF receptor-like-6, TNF receptor superfamily member 6b, TNFRSF6b) (Kim et al, 2004)
¥ D-dopachrome tautomerase (DDT, DDCT, Phenylpyruvate tautomerase, D-dopachrome carboxy-lyase, D-dopachrome decarboxylase, Phenylpyruvate tautomerase II, EC4.1.1.84, MIF-2, macrophage migration inhibitory factor-2) (Zeng RZ et al, 2010)
¥ DDR1 (discoidin domain receptor 1, DDR, discoidin domain receptor, CD167, CD167a, Cak, cell adhesion kinase, EDDR1, epithelial discoidin domain receptor 1, EDDR2, epithelial discoidin domain receptor 2, HGK2, MCK10, mammary carcinoma kinase 10 , NEP, neuroepithelial tyrosine kinase, NTRK4, neurotrophic tyrosine kinase receptor 4, PTK3, protein tyrosine kinase 3, RTK6, receptor tyrosine kinase 6, trk6, trkE, tyrosine kinase receptor E) (Kamohara et al, 2001)
¥ Dectin-1 (DC-associated C-type lectin 1, Dendritic cell-associated C-type lectin 1, dectin-1A, dectin-1B, CLEC7A, C-type lectin domain family 7 member A, CLECSF12, C-type lectin domain superfamily member 12, BGR, beta-glucan receptor, BGRA, Beta-glucan receptor A, BGRB, Beta-glucan receptor B) (Elsori et al, 2011; Ferwerda et al, 2008; Taylor et al, 2002; van de Veerdonk et al, 2009; Willment et al, 2001, 2005)
¥ dectin-2 (Dectin-2-alpha, DC-associated C-type lectin 2, Dendritic cell-associated C-type lectin 2, CLEC6A, C-type lectin domain family 6 member A, CLECSF10, C-type lectin domain superfamily member 10, CLEC4N, C-type lectin domain family 4 member N) (Gavino et al, 2005; Taylor et al, 2005)
¥ defensin-beta-1 (beta-Defensin-1, HBD-1, DEFB1, DEFB101) (Duits et al, 2002; Ryan et al, 2003)
¥ defensin-beta-2 (beta-Defensin-2, DEFB4, HBD-2, SAP-1, skin antimicrobial peptide 1) (Duits et al, 2002; Wang TT et al, 2004, 2010)
¥¥ defensin-beta-3 (beta-Defensin-3, HBD-3, DEFB103) receptors (Jin G et al, 2010)
¥ defensin-beta-4 (beta-Defensin-4, DEFB104, HBD-4) (Liu PT et al, 2009; Edfeldt K et al, 2010)

¥ E-cadherin (epithelial cadherin, Arc-1, cadherin-1, CDH1, CAM 120/80, ECAD, L-CAM, liver cell adhesion molecule, Uvomorulin, rrl antigen, CD324) (Lange et al, 2007; Semnani et al, 2011)
¥ ECP (eosinophil cationic protein, ribonuclease A family 3, RNASE3, RNS3, ribonuclease 3, EAR, eosinophil-associated ribonuclease, EAR-1, eosinophil-associated ribonuclease-1) (Bystrom et al, 2001)
¥¥ EGF (epidermal growth factor, EGF-URO, HMGF, human milk growth factor, PGF, prostatic growth factor, beta-Urogastrone, URO, URG, Urogastrone, tooth-lid factor) receptors (EGFR, EGF receptor 1, epidermal growth factor receptor 1, erb, erbB1, HER1, SA-7, species antigen 7) (El Zein N et al, 2010)
¥ egr-3 (Early growth response gene-3, PILOT) (Lange et al, 2007) (Dorsch M et al, 2005)
¥¥ EG-VEGF (Endocrine gland-derived vascular endothelial growth factor, prokineticin-1, PROK1, PK1, PRK1, mambakine, black mamba toxin-related protein, MIT1, mamba intestinal protein 1, Bv8, Bombina variagata peptide 8) receptors (PROKR1, ZAQ, PK-R1, GPR73, GPR73a, GPR73b, G-protein-coupled receptor-73, G-protein-coupled receptor-73a, G-protein-coupled receptor-73b, PROKR2, I5E, PK-R2, GPR73L1, G-protein-coupled receptor-73-like 1 ) (Dorsch M et al, 2005; Monnier J et al, 2008)
¥¥ elastokine receptors (67-kDa elastin-binding protein, EBP, 67 kDa EBP, EBP67), GLB1, Bgl-e, beta-galactosidase-1, GM1 gangliosidase, GM1 ganglioside beta-galactosidase, EC3.2.1.23, Acid beta-galactosidase) (Baranek T et al, 2007; Castiglione Morelli MA et al, 1997; Hance KA et al, 2002; Jacob MP et al, 1987; Robert L et al, 1989; Varga Z et al, 1997)
¥ EMAP-2 (Endothelial-monocyte activating polypeptide-2, p43, AIMP1, ARS-interacting multi-functional protein 1, SCYE1) (Schluesener et al, 1997)
¥ EMP-1 (epithelial membrane protein-1, B4B, TMP, tumor-associated membrane protein, CL-20) (Wilson HL et al, 2002)
¥¥ endothelin-1 (ET-1(1-21), ET-1, EDN1) receptors (Browatzki et al, 2005; Schena et al, 1999; Lange et al, 2007)
¥ ephA1 (Eph receptor A1, EPH, Esk, embryonic stem cell kinase) (Sakamoto et al, 2011)
¥ ephA2 (Eph receptor A2, ECK, epithelial cell kinase) (Sakamoto et al, 2011)
¥ EphA4 (Eph receptor A4, Sek, Sek1, HEK8, human embryo kinase-8, tyro1, tyrosine-protein kinase 1) (Sakamoto et al, 2011; Royaee et al, 2006)

¥ ephA5 (Eph receptor A5, BSK, brain-specific kinase, HEK7, human embryo kinase-7, Rek7) (Sakamoto et al, 2011)
¥ EphA6 (Eph receptor A6, EHK2, EPH homology kinase-2) (Sakamoto et al, 2011)
¥ ephA8 (Eph receptor A8, HEK3, human embryo kinase-3, EEK, EPH and ELK-related kinase) (Sakamoto et al, 2011)
¥ EphB1 (Eph receptor B1, HEK6, human embryo kinase-6, ELK, Eph-like kinase, NET, neuronally expressed EPH-related tyrosine kinase, Cek6, chicken embryonic kinase 6, Xek, Xenopus Elk-like kinase) (Yu et al, 2004; Sakamoto et al, 2011)
¥ EphB2 (Eph receptor B2, ERK, ELK-related tyrosine kinase, HEK5, human embryo kinase-5, Tyro5, tyrosine-protein kinase 5, Sek3, Rek5, DRT, developmentally regulated EPH-related tyrosine kinase, Nuk, Cek5, chicken embryonic kinase 5) (Sakamoto et al, 2011)
¥ EphB3 (Eph receptor B3, HEK2, human embryo kinase-2, Tyro6, MDK5, Mouse Developmental Kinase-5, Sek4, Cek10, chicken embryonic kinase 10) (Yu et al, 2003; Sakamoto et al, 2011)
¥ EphB4 (Eph receptor B4, HTK, hepatoma transmembrane kinase, Myk1, Tyro11, tyrosine-protein kinase 11, MDK2, Mouse Developmental Kinase-2) (Sakamoto et al, 2011)
¥ EphB6 (Eph receptor B6, HEP, human kinase-defective eph-family receptor protein, MEP, murine eph-family protein) (Sakamoto et al, 2011)
¥ ephrin A1 (EFNA1, B61, EPLG1, EPH-related receptor tyrosine kinase ligand-1, Epl1, TNFAIP4, tumor necrosis factor-alpha-induced protein 4, TNF-alpha-induced protein 4, LERK1, Ligand of eph-related kinase-1) (Sakamoto et al, 2011)
¥ Ephrin A3 (EFNA3, LERK3, Ligand of eph-related kinase-3, ELF-2, Eph ligand family-2, EPLG3, EPH-related receptor tyrosine kinase ligand-3) (Sakamoto et al, 2011)
¥ Ephrin A4 (EFNA4, LERK4, Ligand of eph-related kinase-4, EPLG4, EPH-related receptor tyrosine kinase ligand-4) (Sakamoto et al, 2011)
¥ Ephrin A5 (EFNA5, AL-1, RAGS, repulsive axon guidance signal, LERK7, Ligand of eph-related kinase-7, EPLG7, EPH-related receptor tyrosine kinase ligand-7) (Sakamoto et al, 2011)
¥ ephrin B1 (EFNB1, ELK-L, ELK ligand, 25H11 antigen, EPLG2, EPH-related receptor tyrosine kinase ligand-2, LERK2, Ligand of eph-related kinase-2) (Yu et al, 2004; Sakamoto et al, 2011)
¥¥ ephrin B2 (EFNB2, HTK ligand, HTKL, EPLG5, EPH-related receptor tyrosine kinase ligand-5, LERK5, Ligand of eph-related kinase-5, NLERK1) receptors (Braun J et al, 2011; Sakamoto et al, 2011)
¥ Ephrin B3 (EFNB3, Elk-L3, NLERK2, LERK8, Ligand of eph-related kinase-8, EPLG8, EPH-related receptor tyrosine kinase ligand-8) (Yu et al, 2003)
¥ Epiregulin (EREG, EPR) (Thuong et al, 2012; Subimerb et al, 2010)
¥ E-selectin ligand-1 (ESL-1, CFR, cysteine-rich FGF receptor, CFR-1, cysteine-rich FGF receptor-1, MG-160, Selel, GLG1, Golgi complex-localized glycoprotein-1, GLG2) (Li CJ et al, 2009; Ahn et al, 2005)

¥ F4/80 (BM8, Ly71, EMR1, EGF module-containing mucin-like hormone receptor, EGF-like module containing mucin-like hormone receptor-like-1) (Katsura et al, 1992; Karlsson KR et al, 2008)
¥ FABP4 (fatty acid binding protein 4, aP2, adipocyte P2, adipocyte protein 2, ALBP, adipocyte lipid-binding protein, H-ALBP, Human adipocyte lipid-binding protein, A-FABP, Adipocyte-type fatty acid-binding protein, adipocyte fatty acid binding protein, adipose FABP, adipocyte FABP, 422 protein) (Liu QY et al, 2007; Pelton et al, 1999)
¥¥ factor Xa (FX, F10, coagulation factor X) receptors (Worfolk et al, 1992)
¥ ferritin (H-Ferritin, FTH1, FTH, L-Ferritin, FTL, CD-GF, carcinoma-derived growth factor) (Suzuki et al, 2000; StuhlmŸller et al, 2000)
¥ ferroportin (FPN, FPN1, ferroportin-1, SLC40A1, solute carrier family 40 (iron-regulated transporter) member 1, SLC11A3, Solute carrier family 11 member 3, IREG1, iron-regulated transporter-1, MTP1, metal transporting protein 1, weissherbst, flatiron, ffe) (Theurl et al, 2008)
¥¥ FGF-23 (fibroblast growth factor-23, ADHR, autosomal dominant hypophosphatemic rickets, phosphatonin) receptors (Bacchetta et al, 2013)
¥ FGFR1 (fibroblast growth factor receptor-1, BFGFR, basic fibroblast growth factor receptor, FGFBR, FGFB receptor, flt-2, fms-like tyrosine kinase-2, flg, fms-like gene, N-sam, Cek1, chicken embryonic kinase 1, KAL2, Kallmann syndrome 2, CD331) (Bacchetta et al, 2013)
¥ FGFR2 (fibroblast growth factor receptor-2, TK-14, bek, bacterially expressed kinase, Cek3, chicken embryonic kinase 3, K-sam, KATO-III cell-derived stomach cancer amplified gene, KGF receptor, KGFR, CD332) (Bacchetta et al, 2013)
¥ FGFR3 (fibroblast growth factor receptor-3, Cek2, chicken embryonic kinase 2, flg-2, fms-like gene-2, JTK4, CD333) (Bacchetta et al, 2013)

¥ FGFR4 (fibroblast growth factor receptor-4, TKF, tyrosine kinase-related to fibroblast growth factor receptor, FREK, Fibroblast growth factor receptor-like embryonic kinase, JTK2, CD334) (Bacchetta et al, 2013)
¥ fibronectin (FN, fibronectin-1, FN1, LETS, large external transformation-sensitive protein, Fibroblast surface antigen, SF antigen, SFA, CIg, CI globulin, cold-insoluble globulin, CSP, galactoprotein A, MSF, migration stimulating factor, Z protein) (Kitamura et al, 2000; Chaitidis et al, 2005)
¥ Ficolin-1 (FCN1, FCNM, Ficolin-A, Ficolin-alpha, M-ficolin, collagen/fibrinogen domain-containing protein 1, AURA32, augmented in rheumatoid arthritis 32) (Lu et al, 1996; Teh et al, 2000; Liu et al, 2005; Honore et al, 2008; Kjaer et al, 2011)
¥¥ FIZZ-1 (found in inflammatory zone-1, HIMF, Hypoxia-induced mitogenic factor, Resistin-like molecule-alpha, RELM-alpha, Retnla, resistin-like alpha, XCP2, ten-cysteine protein 2) receptors (Yamaji-Kegan K et al, 2006)
¥ flt-3 (fms-like tyrosine kinase-3, flk-2, Fetal liver kinase-2, STK-1, stem cell tyrosine kinase-1, Ly72, CD135) (Wang et al, 2000)
¥ Follicle stimulating hormone receptors (Komorowski and Stepien, 1994)
¥ follistatin-like-1 (FSTL1, FSL1, TSC-36, TGF-beta-stimulated clone-36, follistatin-related protein, FRP, Follistatin-related protein-1, follistatin-like, occ1, Flik, XFRP, Xenopus laevis follistatin-related protein) (Wang et al, 2000)
¥¥ FPR1 (formyl peptide receptor-1, fMLP receptor, FRP, N-formyl peptide receptor, formyl peptide receptor) (El Zein N et al, 2010; Crouser ED et al, 2009; Capra V et al, 2010; Chigaev A et al, 2008; Durstin M et al, 1994; Ancuta P et al, 2009; Beigier-Bompadre et al, 2001; Braun et al, 2001; Soehnlein et al, 2008)
¥¥ FPRL1 (formyl peptide receptor-like-1, FPRH1, formyl peptide receptor homolog-1, FPR2, formyl peptide receptor-2, lipoxin A4 receptor, ALXR, LXA4R, HM63) (De Yang et al, 2000; Durstin M et al, 1994; Deng et al, 1999; Resnati et al, 2002; Soehnlein et al, 2008)
¥ fragilis (IFITM3 [interferon-induced transmembrane protein 3) (Ancuta et al, 2009)
¥ frizzled-2 (frizzled family receptor 2, FzD2, FzE2, Fz2) (Lange et al, 2007)

¥ Galectin-3 (Gal-3, LGALS3, galactose-specific soluble lectin 3, Mac-2, macrophage galactose-specific lectin-2, L-29, CBP-35, carbohydrate binding protein-35, IgE binding factor epsilon, Epsilon BP) (Liu et al, 1995; Greenwald et al, 2009)
¥¥ Galectin-3 (Gal-3, LGALS3, galactose-specific soluble lectin 3, Mac-2, macrophage galactose-specific lectin-2, L-29, CBP-35, carbohydrate binding protein-35, IgE binding factor epsilon, Epsilon BP) receptors (Greenwald et al, 2009)
¥ galectin-3-binding protein (LGALS3BP, Mac2BP, M2BP, Mac-2-binding protein, TAA90K, Tumor-associated antigen 90K, serum protein 90K, L3 antigen, CyCAP, cyclophilin C-associated protein, alpha-2-SGP, alpha-2-seminoglycoprotein) (Kong et al, 2007)
¥¥ gas-6 (Growth arrest-specific gene-6, Growth-potentiating factor, GPF, AXLLG, axl receptor tyrosine kinase ligand, AXSF, axl stimulatory factor) receptors (Alciato et al, 2010)
¥ G-CSF (Granulocyte colony stimulating factor, CSF-3, colony stimulating factor-3, CSF-beta, colony stimulating factor-beta, G-CSA, granulocytic neutrophil colony stimulating activity, Pluripoietin-beta) (Brown et al, 1996; de Waal Malefyt et al, 1991; de Waal Malefyt et al, 1993; Hamilton et al, 1992; Hareng et al, 2003; Nioche et al, 1988; Oster et al, 1989; Sallerfors and Olofsson, 1992; Wieser et al, 1989; Dower et al, 2008)
¥¥ G-CSF (Granulocyte colony stimulating factor, CSF-3, colony stimulating factor-3, CSF-beta, colony stimulating factor-beta, G-CSA, granulocytic neutrophil colony stimulating activity, Pluripoietin-beta) receptors (CD114, CSF3R, AURA28, augmented in rheumatoid arthritis 28) (Boneberg et al, 2000; Cranny et al, 2002; Ancuta et al, 2009)
¥ GDF5 (growth/differentiation factor-5, BMP14, Bone morphogenetic protein-14, CDMP-1, Cartilage-derived morphogenetic protein-1, LAP4, Lipopolysaccharide-associated protein 4, LPS-associated protein 4) (Triantafilou et al, 2001)
¥¥ ghrelin (GHRL, GRLN, MTLRP, motilin-related peptide, GHSR ligand, growth hormone secretagogue receptor ligand, GGDT, ghrelin gene-derived transcript) receptors (GHSR, growth hormone secretagogue receptor, Growth hormone secretagogue receptor type 1, GHSR-1a, growth hormone secretagogue receptor 1a, GHSR-1b, growth hormone secretagogue receptor 1b, GRLNR, GH-releasing peptide receptor) (Dixit et al, 2004)
¥ glycodelin (PP14, placental protein 14, GdA, Glycodelin-A, GdS, Glycodelin-S, PAEP, progestagen-associated endometrial protein, pregnancy-associated endometrial alpha-2-globulin, progestagen-dependent endometrial protein) (Lang and Venkatraman, 2007)
¥¥ glycodelin (PP14, placental protein 14, GdA, Glycodelin-A, GdS, Glycodelin-S, PAEP, progestagen-associated endometrial protein, pregnancy-associated endometrial alpha-2-globulin, progestagen-dependent endometrial protein) receptors (Vigne et al, 2001; Tee et al, 2008)
¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) (Blanchard et al, 1991; Brown et al, 1996; de Waal Malefyt et al, 1991; de Waal Malefyt et al, 1993; Epling-Burnette et al, 1993; Ernst et al, 1989; Hamilton et al, 1992; Lenhoff et al, 1999; Sallerfors and Olofsson, 1992; Holmes et al, 2002; Song et al, 2009)
¥¥ GM-CSF (Granulocyte-macrophage colony stimulating factor, BPA, burst promoting activity, CSF-2, colony stimulating factor-2, GM-CSA, Granulocyte-macrophage colony stimulating activity, MGI-1GM, macrophage-granulocyte inducer, Pluripoietin-alpha) receptors (CSF2RA, CSF-2 receptor-A, Colony stimulating factor-2 receptor A, Colony stimulating factor-2 receptor-alpha, CSF2R, CSF-2 receptor, Colony stimulating factor-2 receptor, CSF2RY, GMCSFR, GM-CSF receptor, CDw116, CD116; common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Adib-Conquy and Cavaillon, 2002; Alderson et al, 1994; Alvaro-Gracia et al, 1989; Bach and Brashler, 1995; Cannistra et al, 1987; Cluitmans et al, 1994; Danis et al, 1995; Erickson-Miller et al, 1990; Essner et al, 1990; Finbloom et al, 1993; Finnin et al, 1999; Fischer et al, 1990; Gerrard et al, 1990; Hashimoto et al, 1997; Horiguchi et al, 1987; Inamura et al, 1990; Kruger et al, 1996; Oster et al, 1989; Prevost et al, 2002; Rosen et al, 1996; Suzuki et al, 2004; Sorg et al, 2001)
¥¥ gp130 (IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Bosco et al, 2006)
¥¥ GPR77 (G-protein-coupled receptor-77, C5L2, C5a receptor-like 2, complement 5a-like receptor 2) (Otto et al, 2004; Strey et al, 2009)
¥ Gr-1 (granulocyte differentiation antigen 1, Ly6G, lymphocyte antigen 6G) (Varga et al, 2008)
¥ granulin (GRN, Acrogranin, PCDGF, PC cell-derived growth factor, epithelins, GEP, granulin/epithelin precursor, PGRN, progranulin, GP88) (Ancuta et al, 2009)
¥ Gremlin (gremlin-1, GREM1, BMP antagonist 1, CKTSF1B1, DAND2, DAN domain family member 2, IHG-2, increased in high clucose-2, DRM, Downregulated by mos, PIG2, proliferation inducing gene-2, Cell proliferation-inducing gene 2 protein) (Lange et al, 2007)
¥¥ growth hormone (GH, Somatotropic hormone, Somatotropin, GH1, growth hormone 1, GHN, growth hormone normal) receptors (Haeffner et al, 1997; Warwick-Davies et al, 1995)

¥ HB-EGF (Heparin binding EGF-like factor, Heparin binding EGF-like growth factor, Hegfl, par-2, prostate apoptosis response protein 2, DTR, Diphtheria toxin receptor) (Mograbi et al, 1997; Nakano et al, 1994; Pan et al, 1995; Lange et al, 2007)
¥ HDGF (hepatoma-derived growth factor, HuHGF, HMG1L2, high mobility group protein 1-like-2; TDRM1 protein) (Boomgaarden et al, 2010)
¥ Hepcidin (HEPC, Hepc25, hepcidin-25, Hep-25, Hepc20, hepcidin-20, Hep-20, LEAP-1, liver-expressed antimicrobial peptide, liver-expressed antimicrobial peptide-1, HAMP, Hepcidin antimicrobial peptide, Hamp1, Hepcidin antimicrobial peptide-1, Hamp2, Hepcidin antimicrobial peptide-2, Hepc1, hepcidin-1, Hepc2, hepcidin-2 ) (Theurl et al, 2008; Zhang X and Rovin BH, 2010)
¥ heregulin (Mograbi et al, 1997)
¥ HGF (hepatocyte growth factor, HGF/SF, Hepatocyte growth factor-scatter factor, F-TCF, fibroblast tumor cytotoxic factor, HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic factor, Lung fibroblast-derived mitogen) (Galimi et al, 2001; Koyama et al, 2003)
¥¥ HGF (hepatocyte growth factor, HGF/SF, Hepatocyte growth factor-scatter factor, F-TCF, fibroblast tumor cytotoxic factor, HPTA, Hepatopoietin A, SF, scatter factor, TCF, tumor cytotoxic factor, Lung fibroblast-derived mitogen) receptors (met, HGFR, HGF receptor, hepatocyte growth factor receptor, scatter factor receptor) (Beilmann et al, 1997, 2000; Galimi et al, 2001; Jiang et al, 2001)
¥ HLA-G (Human leukocyte antigen G, HLA-6.0, HLA60, Qa) (Moreau et al, 1999; Wiendl et al, 2005)
¥¥ HMG-1 (high mobility group protein-1, HMGB1, high mobility group box-1, amphoterin, DEF, Differentiation enhancing factor, Neurite growth-promoting protein, SBP-1, Sulfoglucuronyl carbohydrate binding protein-1) receptors (Andersson et al, 2000; Park et al, 2004; Kalyan and Chow, 2008)
¥ HMGN2 (high mobility group nucleosomal binding protein 2, HMG17, high mobility group protein 17, HCP-1) (Feng et al, 2005)
¥ hsp70 (heat shock protein 70) (Housby et al, 1999; Vince et al, 2010)

¥¥ hsp70 (heat shock protein 70) receptors (Satoh et al, 2006)
¥ human neutrophil peptide-1 receptors (Chaly et al, 2000)
¥ HVEM (Herpesvirus entry mediator, HveA, Herpes simplex virus entry protein A, HveAt, TR2, TNF receptor-like-2, ATAR, another TRAF-associated receptor, TNFRSF14, TNF receptor superfamily member 14, LIGHTR, LIGHT receptor, CD270) (Dahl et al, 2008; Kwon et al, 1997; Heo et al, 2006, 2007, 2008; Jung et al, 2003; Otterdal et al, 2006; Kang et al, 2007)

¥ Ian-5 (immune-associated nucleotide-5, Iddm1, insulin-dependent diabetes mellitus 1, lyp, IROD, inhibitor of radiation- and okadaic acid-induced death) (Zenz et al, 2004)
¥ ICAM-2 (intercellular adhesion molecule 2, Ly60, CD102) (Prieto et al, 1994; Sorg et al, 2001; Varis et al, 2001; Ancuta et al, 2009)
¥ IFI16 (interferon-induced protein 16, interferon-gamma-inducible protein-16, IFNGIP1, interferon-gamma-inducible protein-1, PYHIN2) (Dawson and Trapani, 1995, 1995; Dawson et al, 1998; Wei W et al, 2003)
¥ IFITM2 (interferon-induced transmembrane protein 2, 1-8D, Interferon-inducible protein 1-8D, fragilis3) (Ancuta et al, 2009)
¥ IFN-alpha (interferon-alpha, Alpha-Interferon, aIFN, B-cell interferon, Leukocyte interferon, LeIFN, Lymphoblast interferon, LyIFN-alpha) (de Waal Malefyt et al, 1993)
¥¥ IFN-alpha (interferon-alpha, Alpha-Interferon, aIFN, B-cell interferon, Leukocyte interferon, LeIFN, Lymphoblast interferon, LyIFN-alpha) receptors (IFNAR1, IFN-alpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, IFN-alphaR1, IFRC, IFNAR, IFNAR2, IFN-alpha/beta receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-alphaR2, IFNABR) (Yamamoto et al, 2004)
¥¥ IFN-beta (Beta-Interferon, Interferon-beta, bIFN, Fibroblast interferon, Fi-IFN, F-IFN) receptors (IFNAR1, IFN-alpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, IFN-alphaR1, IFRC, IFNAR, IFNAR2, IFN-alpha/beta receptor 2, interferon (alpha, beta and omega) receptor 2, IFN-alphaR2, IFNABR) (Buelens et al, 2002; Fantuzzi et al, 2001; Marckmann et al, 2004)
¥ IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) (Barcova et al, 1998; Kim et al, 2005)
¥¥ IFN-gamma (IFNG, interferon-gamma, Gamma-Interferon, gIFN) receptors (IFNGR1, IFN-gamma receptor-1, IFN-gamma-R1, interferon-gamma receptor 1, immune interferon receptor 1, AVP type 2, antiviral protein type 2, CD119, IFNGR2, interferon-gamma receptor 2, IFN-gamma receptor 2, IFN-gamma-R2, IFGR2, IFNGT1, interferon-gamma transducer 1) (Adib-Conquy and Cavaillon, 2002; Alderson et al, 1993; Aman et al, 1996; Beigier-Bompadre et al, 2001; Bosco et al, 1994; Danis et al, 1995; Finbloom et al, 1993; Fischer et al, 1990; Fulton et al, 1998; Holter et al, 1986; Malaguarnera et al, 2005; Polentarutti et al, 1998; Schmittel et al, 1995; Ramos et al, 2010)
¥ IFN-kappa (Kappa-Interferon, interferon-kappa) (Nardelli et al, 2002)
¥ IGF-1 (Insulin-like growth factor-1, Erythropoietic factor, mechano growth factor, MGF, ILGF1, somatomedin C, NSILA, non-suppressible insulin-like activity, Somatomedin A, Somatomedin C, sulfation factor, Mecasermin) (Kirstein et al, 1992)
¥¥ IGF-1 (Insulin-like growth factor-1, Erythropoietic factor, mechano growth factor, MGF, ILGF1, somatomedin C, NSILA, non-suppressible insulin-like activity, Somatomedin A, Somatomedin C, sulfation factor, Mecasermin) receptors (IGF1R, CD221, JTK13) (Xu et al, 1995)
¥ IGFBP3 (Insulin-like growth factor binding protein-3, IGF binding protein-3, BP-53, Growth hormone dependent binding protein, Binding protein-29) (Wang et al, 2000)
¥¥ IGFBP10 (Insulin-like growth factor binding protein-10, IGF binding protein-10, cyr-61, Cysteine-rich angiogenic inducer 61, cysteine-rich 61, CCN1) receptors (Schober et al, 2002)
¥ IL1 (interleukin-1) (Chaitidis et al, 2005; Ferrari et al, 1993; Suzuki et al, 2000; Wang et al, 2000; Rich et al, 1993)
¥¥ IL1 (interleukin-1) receptors (IL1RA, IL1R-alpha, IL1 receptor-alpha; interleukin-1 receptor-alpha, IL1R1, IL1 receptor type 1, Interleukin-1 receptor 1, IL1 receptor R1, CD121a; IL1RB, IL1R-beta, IL1 receptor-beta; interleukin-1 receptor-beta, IL1R2, IL1 receptor type 2, Interleukin-1 receptor 2, IL1 receptor R2, CD121b, AURA31, augmented in rheumatoid arthritis 31) (Adib-Conquy and Cavaillon, 2002; Brown et al, 1996; Dalton et al, 1989; Ferrari et al, 1993; Granowitz et al, 1992; Gruber et al, 1994; Gyetko et al, 1993; Spriggs et al, 1992; Vouret-Craviari et al, 1997; Kim et al, 2005)
¥ IL1-alpha (IL1A, interleukin-1-alpha, IL1F1, Interleukin-1 family member 1, BAF, B-cell activating factor, BCAF, B-cell activating factor, EP, endogenous pyrogens, LAF, lymphocyte activating factor, LEM, leukocyte endogenous mediator, MCF, mononuclear cell factor, MNCF, mononuclear cell factor, MP, mitogenic protein, TRF-3, T-cell replacing factor-3, Tumor inhibitory factor-2) (Alderson et al, 1993; Andersson et al, 2000; Aotsuka et al, 1991; Asano et al, 1994; Caux et al, 1994; Dalton et al, 1989; Dalton et al, 1989; de Caestecker et al, 1992; de Waal Malefyt et al, 1991, 1993; Hurme and Serkkola, 1991; Okubo et al, 1989; Palkama et al, 1989; Hanriot et al, 2008; Barksby et al, 2009; StuhlmŸller et al, 2000)
¥ IL1-beta (IL1B, interleukin-1-beta, IL1F2, Interleukin-1 family member 2, Catabolin, H1, Hematopoietin-1, IFN-beta inducing factor, Interleukin-beta, OAF, osteoclast activating factor) (Alderson et al, 1993; Andersson et al, 2000; Andersson et al, 2004; Aotsuka et al, 1991; Asano et al, 1994; Baqui et al, 2000; Bisbocci et al, 1996; Boutten et al, 1992; Caux et al, 1994; Cluitmans et al, 1994; Conroy et al, 2009; Dalton et al, 1989; Dalton et al, 1989; Mathy et al, 2000; de Caestecker et al, 1992; de Waal Malefyt et al, 1991; de Waal Malefyt et al, 1993; DeLuca et al, 1999; Devaraj and Jialal, 1999; Dunlap and Tilden, 1991; Furse et al, 2002; Hurme and Serkkola, 1991; Lande et al, 2002; Liu PT et al, 2009; Palkama et al, 1989; Olsnes et al, 2007; Rubartelli et al, 1990; Holmes et al, 2002; Molnarfi et al, 2008; Moschen AR et al, 2007; Hanriot et al, 2008; Barksby et al, 2009; Salazar et al, 2009; Song et al, 2009; StuhlmŸller et al, 2000; Webb et al, 1990; Miossec C et al, 1996; Singer II et al, 1988; Perelman N et al, 2003; Selvaraj SK, et al, 2003)
¥ IL1-beta Convertase (ICE, IL1BC, IL1-beta converting enzyme, Caspase-1, CASP1) (Laliberte et al, 1999; Miossec C et al, 1996; Singer II et al, 1988; Barksby HE et al, 2009)
¥ IL1F6 (Interleukin-1 family member 6, FIL1-epsilon, FIL1E, Family of IL1-epsilon, IL1H1, IL1-epsilon; IL36-alpha, interleukin-36-alpha) (Barksby et al, 2009)
¥ IL1F9 (Interleukin-1 family member 9, IL1H1, IL1 homolog-1, IL1RP2, IL1-related protein-2; IL36-gamma, interleukin-36-gamma) (Barksby et al, 2009)
¥ IL1ra (IL1 receptor antagonist, IL1RN, IL1 inhibitor, IRAP, IL1 receptor antagonist protein, IL1 inhibitory activity, ILS, IL1F3, IL1 family member 3, DIRA, deficiency of the IL1 receptor antagonist) (Andersson et al, 2000, 2004; Chang, 1995; Malyak et al, 1998; Corradi et al, 1993; Danis et al, 1995; de Waal Malefyt et al, 1993; Gabay et al, 2001; Herbelin et al, 1994; Poutsiaka et al, 1993; Ruiz de Souza et al, 1995; Suzuki et al, 1995; Wolf et al, 1996; Wolf et al, 1996; Olsnes et al, 2007; Molnarfi et al, 2008; Lange et al, 2007: Burger et al, 2009)
¥ IL1Rrp2 [IL1 receptor-related protein-2, IL1RL2, IL1 receptor-like 2, interleukin-1 receptor-like 2, IL1R6, Interleukin-1 receptor 6, IL1 receptor R6] (Lange et al, 2007)
¥ IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) (Barcova et al, 1998; Simitsopoulou M et al, 2011)
¥¥ IL2 (Interleukin-2, BF, blastogenic factor, EDF, eosinophil differentiation factor, KHF, killer cell helper factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, MAF-C I, macrophage-activating factor for cytotoxicity I, PFC-EA, plaque forming cell enhancing factor, SCIF, secondary cytotoxic T-cell inducing factor, TCGF, T-cell growth factor, TCPA, T colony-promoting activity, TDF, thymocyte differentiation factor, T-LPF, T-lymphocyte promotor factor, TMF, thymocyte mitogenic factor, T-cell maturation factor, T-cell mitogenic factor, TRF-3, T-cell replacing factor-3, TSF, thymocyte stimulating factor) receptors (IL2RA, interleukin-2 receptor-alpha; IL2R-alpha; IL2 receptor-alpha, IL2R, interleukin-2 receptor, TAC antigen, TCGFR, T-cell growth factor receptor, IDDM10, insulin-dependent diabetes mellitus 10, CD25; Ly43, lymphocyte antigen 43, OX39, IL2RB, interleukin-2 receptor-beta; IL2R-beta; IL2 receptor-beta, CD122; IL2RG, IL2 receptor-gamma, interleukin-2 receptor-gamma, IL2R-gamma, common gamma, gammac, gamma common, common cytokine receptor-gamma; cytokine receptor common subunit gamma, CD132, SCIDX1, X-linked severe combined immunodeficiency-1) (Allen et al, 1990; Bosco et al, 1994; Cluitmans et al, 1994; Ennen et al, 1991; Epling-Burnette et al, 1993; Farina et al, 2004; Gyetko et al, 1993; Holter et al, 1986; Musso et al, 1995; Rambaldi et al, 1987; Scheibenbogen et al, 1992; Stankova et al, 1993)
¥ IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) (Ferrari et al, 1993; Simitsopoulou M et al, 2011)
¥¥ IL3 (Interleukin-3, 20-alpha-hydroxysteroid dehydrogenase inducing factor, BPA, burst promoting activity, CFU-S, colony-forming unit spleen, CSF-2-alpha, colony stimulating factor-2-alpha, CSF-2-beta, colony stimulating factor-2-beta, ECSF, erythroid colony stimulating factor, Eo-CSF, eosinophil colony stimulating factor, HCGF, Hematopoietic cell growth factor, HP2, Hematopoietin-2, HPGF, hematopoietic cell growth factor, MCGF, mast cell growth factor, MCSA, multi-colony stimulating activity, Meg-CSF, megakaryocyte colony stimulating factor, MGF, mast cell growth factor, Mixed colony stimulating factor, Multi-CSF, Multi-colony stimulating factor, multi-HGF, multilineage hemopoietic growth factor, Multipoietin, NC cell growth factor, natural cytotoxic cell growth factor, Neutrophil-granulocyte colony stimulating factor, PSF, progenitor stimulating factor, PSH, panspecific hemopoietin, SAF, stem cell activating factor, Thy1 inducing factor) receptors (IL3RA, interleukin-3 receptor-alpha, IL3R-alpha, common beta, beta c, betac, common cytokine receptor-beta, cytokine receptor common subunit beta, IL3RB, IL3 receptor subunit beta, IL3R-beta, IL3 receptor subunit beta; interleukin-3 receptor-beta, IL5RB, IL5 receptor subunit beta, IL5R-beta, GM-CSF receptor subunit beta, CSF2RB, colony stimulating factor-2 receptor-beta, CD131) (Alderson et al, 1993, 1994; Buelens et al, 2002; Chen and Clark, 1986; Cluitmans et al, 1994; Ebner et al, 2002; Ferrari et al, 1993; Hashimoto et al, 1997; Leveque et al, 1998; Oster et al, 1989; Suzuki et al, 2004; Thomassen et al, 1993; Sorg et al, 2001)
¥ IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) (Bonder et al, 2002; Danis et al, 1995)
¥¥ IL4 (Interleukin-4, BCDF-epsilon, B-cell differentiation factor-epsilon, BCDF-gamma, B-cell differentiation factor-gamma, BCGF-gamma, B-cell growth factor-gamma, BCGF-1, B-cell growth factor-1, Binetrakin, BSF-1, B-cell stimulating factor-1, BSF-p1, B-cell stimulating factor p1, EL4-BCGF, EL4 B-cell growth factor, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1-enhancing factor, IgG1-induction factor, LMW-BCGF, low molecular weight B-cell growth factor, MaGEF, Mast cell growth enhancing factor, MCGF-2, mast cell growth factor-2, MFF, macrophage fusion factor, Pitrakinra, TCGF-2, T-cell growth factor-2) receptors (IL4RA, IL4R-alpha, interleukin-4 receptor-alpha, IL4R, interleukin-4 receptor, CD124) (Alderson et al, 1994; Ameixa and Friedland, 2001; Andrew et al, 1998; Chaitidis et al, 2005; Cluitmans et al, 1994; Dickensheets et al, 1999; Ebner et al, 2002; Ernofsson et al, 1996; Gerrard et al, 1990; Gruber et al, 1994; Hamilton et al, 1992; Leveque et al, 1998; Musso et al, 1995; Paysant et al, 1998; Takahashi et al, 2005)
¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) (Aarden et al, 1991; Alderson et al, 1993; Alderson et al, 1993; Andersson et al, 2000; Andersson et al, 2004; Asano et al, 1994; Baqui et al, 2000; Bauer et al, 1988; Berger et al, 1996; Boutten et al, 1992; Brentano F et al, 2007; Breuninger et al, 1993; Buechler et al, 2003; Caux et al, 1994; Chaitidis et al, 2005; Cluitmans et al, 1994; Czeslick et al, 2003; Danis et al, 1995; de Waal Malefyt et al, 1991; de Waal Malefyt et al, 1993; Ferrari et al, 1993; Komorowski and Stepien, 1994, 1995; Lande et al, 2002; Moschen AR et al, 2007; Suzuki et al, 2000; Mathy et al, 2000; Wang et al, 2000; Wolf et al, 1996; Royaee et al, 2006; Olsnes et al, 2007; Rich et al, 1993; Holmes et al, 2002; Molnarfi et al, 2008; Hanriot et al, 2008; Kim et al, 2005; Ancuta et al, 2006; Barksby et al, 2009; Salazar et al, 2009; StuhlmŸller et al, 2000; Song et al, 2009; Conroy et al, 2009; Yoo SA, et al, 2009)
¥¥ IL6 (interleukin-6, 26 kDa protein, BSF-2, B-cell stimulating factor-2, CDF, CAT development factor, choline acetyltransferase development factor, Cytolytic differentiation factor for T-lymphocytes, FDGI, fibroblast-derived growth inhibitor, hybridoma growth factor, HPGF, hybridoma/plasmacytoma growth factor, HSF, hepatocyte stimulating factor, HSF-1, hepatocyte stimulating factor-1, ILHP1, Interleukin-hemopoietin-1, MGI-2A, Macrophage-granulocyte inducer-2A, Myeloma GF, myeloma growth factor, NKAF, natural killer cell activating factor, TAF, T-cell activating factor, Thymocyte growth factor, TSF, thymocyte stimulating factor) receptors (IL6RA, IL6R-alpha, IL6R, interleukin-6 receptor, interleukin-6 receptor-alpha, CD126, IL6ST, IL6 signal transducer, interleukin-6 signal transducer, IL6R-beta, interleukin-6 receptor-beta, IL6RB, CDw130, CD130) (Bauer et al, 1989; Ferrari et al, 1993)
¥¥ IL7 (Interleukin-7, B-cell precursor growth-promoting activity, Lpo-1, lymphopoietin-1, LP-1, PBGF, Pre-B-cell growth factor, serum factor from patients with ulcerative colitis, Thymocyte growth factor) receptors (IL7R, IL7RA, IL7R-alpha, interleukin-7 receptor, interleukin-7 receptor-alpha; CD127, CDw127) (Alderson et al, 1993; Musso et al, 1995)
¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) (Alderson et al, 1993; Ameixa and Friedland, 2001; Andersson et al, 2000; Asano et al, 1994; Badolato et al, 1997; Beaudeux et al, 2004; Bliss et al, 1998; Bosch et al, 2002; Browning et al, 2000; Caux et al, 1994; Chaitidis et al, 2005; Cluitmans et al, 1994; Comabella et al, 2002; de Waal Malefyt et al, 1991; de Waal Malefyt et al, 1993; Denault et al, 1997; Ember et al, 1994; Hashimoto et al, 1996; Kavelaars et al, 1997; Kownatzki et al, 1988; Monnier J et al, 2008; Musso et al, 1995; Ruiz de Souza et al, 1995; Schibler et al, 1993; Schnyder-Candrian and Walz, 1997; Suzuki et al, 2000; Hashimoto et al, 1996; Kienzle and von Kempis, 2000; Kessel et al, 1998; Wang et al, 2000; Pakala et al, 2002; Leali et al, 2003; Royaee et al, 2006; Holmes et al, 2002; Xie and Gu, 2008; Merck et al, 2006; Hanriot et al, 2008; Kim et al, 2005; Song et al, 2009; Wang L et al, 2010; Conroy et al, 2009; Dahl TB et al, 2007; Selvaraj SK, et al, 2003; Perelman N et al, 2003; Schraufstatter et al, 2012)
¥¥ IL8 (interleukin-8, SCYB8, 3-10C, 9E3, ANAP, anionic neutrophil-activating peptide, Chemotaxin, CEF-4, CT/IL8, CXCL8, CXC chemokine ligand 8, chemokine (C-X-C motif) ligand 8, EDNAP, endothelial-derived neutrophil-activating peptide, EMF-1, embryo fibroblast protein 1, Emoctakin, ENAP, Endothelial cell neutrophil-activating peptide, FDNAP, Fibroblast-derived neutrophil-activating peptide, FINAP, fibroblast-derived neutrophil-activating protein, GCF, granulocyte chemotactic factor, GCP, granulocyte chemotactic peptide, LAI, leukocyte adhesion inhibitor, LCF, lymphocyte chemotactic factors, LDNAP, leukocyte-derived neutrophil-activating peptide, leukocyte inhibitory factor, LUCT, lung carcinoma-derived chemotaxin, LYNAP, lymphocyte-derived neutrophil-activating peptide, MDNAP, monocyte-derived neutrophil-activating peptide, MDNCF, monocyte-derived neutrophil chemotactic factor, MOC, monocyte-derived chemotaxin, MONAP, monocyte-derived neutrophil-activating peptide, NAF, neutrophil-activating factor, NAP-1, neutrophil-activating protein-1, NCF, neutrophil chemotactic factor, NCP, neutrophil chemotactic protein, PLF, psoriatic leukotactic factor, TCF, T-cell chemotactic factor, TSG-1, Tumor necrosis factor-stimulated gene sequence-1) receptors (IL8RA, IL8R-alpha, interleukin-8 receptor-alpha; interleukin-8 receptor type A, IL8R1, IL8 receptor-1, interleukin-8 receptor type 1, CMKAR1, chemokine-alpha receptor 1, CXCR1, CD181, IL8RB, IL8R-beta, interleukin-8 receptor-beta; interleukin-8 receptor type B, IL8R2, IL8 receptor-2, interleukin-8 receptor type 2, CMKAR2, chemokine-alpha receptor 2, CXCR2, CD182) (Morohashi et al, 1995; Xie and Gu, 2008; Lei et al, 2002; Smith et al, 2006)
¥ IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) (Aiba et al, 2003; Aman et al, 1996; Badou et al, 2000; Barcova et al, 1998; Berger et al, 1996; Brown et al, 1996; Danis et al, 1995; de Waal Malefyt et al, 1991; de Waal Malefyt et al, 1993; Feng et al, 2002; Kienzle and von Kempis, 2000; Vancheri et al, 2001; Wolf et al, 1996; Lenhoff et al, 1999; Lande et al, 2002; Dobreva et al, 2009; Varga et al, 2008; Salazar et al, 2009; Song et al, 2009; Pilette et al, 2010; Conroy et al, 2009; Simitsopoulou M et al, 2011; Schraufstatter et al, 2012)
¥¥ IL10 (interleukin-10, B-TCGF, B-cell derived T-cell growth factor, CSIF, cytokine synthesis inhibitory factor, TGIF, T-cell growth inhibitory factor) receptors (IL10R, IL10R1, IL10RA, IL10 receptor-alpha, IL10R-alpha, interleukin-10 receptor-alpha; interleukin-10 receptor, CD210, CD210a, CDw210a; IL10R2, IL10RB, IL10R-beta, IL10 receptor-beta, interleukin-10 receptor-beta, CRF2-4, cytokine receptor family 2 member 4, CRFB4; CDw210b) (Ameixa and Friedland, 2001; Beigier-Bompadre et al, 2001; Bovolenta et al, 1998; Brandtzaeg et al, 1996; Calzada-Wack et al, 1996; Caux et al, 1994; de Waal Malefyt et al, 1991; Dickensheets et al, 1997; Ernofsson et al, 1996; Fulton et al, 1998; Gruber et al, 1994; Hashimoto et al, 1997; Houle et al, 1999; Leveque et al, 1998; Morinobu et al, 1996; Musso et al, 2005; Paysant et al, 1998; Spittler et al, 1995; Poitevin et al, 2007; Ramani et al, 1994; Sandanger et al, 2009; Lange et al, 2007; Yano et al, 2007; Wolk et al, 2002; Ramos et al, 2010; Chang GW et al, 2007; Zhong C et al, 2009)
¥ IL12 (IL12A, IL12-alpha IL12B, IL12-beta, IL12-p35, IL12-p40, IL12-p70, Interleukin-12, Interleukin-12A, Interleukin-12B, CLMF, cytotoxic lymphocyte maturation factor, NKSF, natural killer cell stimulatory factor, NKSF1, natural killer cell stimulatory factor-1, NKSF2, natural killer cell stimulatory factor-2, TcMF, CTL maturation factor, TSF, T-cell stimulating factor) (Aiba et al, 2003; Avice et al, 1998; Berger et al, 1997; Ebner et al, 2002; Fulton et al, 1996; Fulton et al, 1998; Lopez et al, 2001; Vancheri et al, 2001; Wittmann et al, 1999; Braun et al, 2001; Kim et al, 2005)
¥¥ IL12 (IL12A, IL12-alpha IL12B, IL12-beta, IL12-p35, IL12-p40, IL12-p70, Interleukin-12, Interleukin-12A, Interleukin-12B, CLMF, cytotoxic lymphocyte maturation factor, NKSF, natural killer cell stimulatory factor, NKSF1, natural killer cell stimulatory factor-1, NKSF2, natural killer cell stimulatory factor-2, TcMF, CTL maturation factor, TSF, T-cell stimulating factor) receptors (IL12RB1, IL12R-beta-1; interleukin-12 receptor-beta-1, IL12R, interleukin-12 receptor, IL12RB, IL12R-beta, interleukin-12 receptor-beta, CD212; IL12RB2, interleukin-12 receptor-beta-2; IL12R-beta-2) (Stuyt et al, 2003)
¥ IL12-p35 (IL12A, IL12-alpha, interleukin-12A) (de Waal Malefyt et al, 1993; Hayes et al, 1995)
¥ IL12-p40 (IL12B, IL12-beta, interleukin-12B, IL23-p40, Interleukin-23 p40) (de Waal Malefyt et al, 1993; Hayes et al, 1995; Olsnes et al, 2007)
¥¥ IL13 (Interleukin-13, NC30, P600) receptors (IL13RA1, interleukin-13 receptor-alpha-1, IL13R-alpha-1, IL13RA, NR4, CD213a1) (Andrew et al, 1998; Berkman et al, 1996; Berry et al, 2007; Chaitidis et al, 2005; Cosentino et al, 1995; de Waal Malefyt et al, 1993; Ernofsson et al, 1996; Graber et al, 1998; Leveque et al, 1998; Nassar et al, 1994; Paysant et al, 1998; Viale and Vercelli, 1995; Vouret-Craviari et al, 1997; Dubourdeau et al, 2008; Kim et al, 2005)
¥ IL15 (Interleukin-15, IL-T, Interleukin T) (Carson et al, 1995; Mathy et al, 2000; Mody et al, 1998; Musso et al, 1999; Neely et al, 2001; Kim et al, 2005)
¥¥ IL15 (Interleukin-15, IL-T, Interleukin T) receptors (IL15RA, IL15R-alpha, CD215) (Badolato et al, 1997; Vazquez et al, 1998)
¥ IL16 (Interleukin-16, Lymphocyte chemoattractant factor, LCF) (Elssner et al, 2004)
¥¥ IL16 (Interleukin-16, Lymphocyte chemoattractant factor, LCF) receptors (Mathy et al, 2000)
¥ IL17 (Interleukin-17, IL17A, interleukin-17A) (Wang et al, 2000)
¥ IL17F (interleukin-17F, ML-1) (Starnes et al, 2001)
¥¥ IL17 (Interleukin-17, IL17A, interleukin-17A) receptors (IL17RA, interleukin-17 receptor A, IL17 receptor A, CD217, CDw217) (Jovanovic et al, 2001; Matsumoto and Kanmatsuse, 2003)
¥¥ IL17B (interleukin-17B, Cytokine CX1, NIRF, neuronal interleukin-17-related factor, neuronal IL17-related factor, Zcyto7) receptors (IL17RB, interleukin-17 receptor B; IL17 receptor B, IL17BR, IL17B receptor; Interleukin-17B receptor, CRL4, Cytokine receptor-like 4, Evi27, ecotropic viral integration site 27, IL17Rh1, IL17 receptor homolog-1) (Li H et al, 2000)
¥¥ IL17C (interleukin-17C) receptors (Li H et al, 2000)
¥ IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) (Chaitidis et al, 2005; Takahashi et al, 2005; Salazar et al, 2009; Bellora F et al, 2012)
¥¥ IL18 (interleukin-18, IGIF, IFN-gamma inducing factor, IL1-gamma, IL1F4, IL1 family member 4, Iboctadekin) receptors (IL18R1, interleukin-18 receptor-1, IL18R-alpha, IL18RA, interleukin-18 receptor-alpha, IL1Rrp, IL1 receptor-related protein, IL1R5, Interleukin-1 receptor 5, IL1 receptor R5, CD218a, CDw218a) (Stuyt et al, 2003; Barksby et al, 2009)
¥¥ IL18RAP (IL18 receptor accessory protein, AcPL, accessory protein-like subunit, IL18RB, IL18R-beta, IL18RAcP, IL18 receptor accessory protein, IL1RAcPL, IL-1R accessory protein-like, IL1R7, Interleukin-1 receptor 7, CD218b, CDw218) (Barksby et al, 2009)
¥ IL19 (interleukin-19, IL10C, MDA1, ZMDA1, melanoma differentiation antigen-1, melanoma differentiation associated protein-like protein) (Gallagher et al, 2000; Hsing et al, 2006, 2007; Wolk et al, 2002; Kunz et al, 2006; AlanŠrŠ T et al, 2010; Jordan et al, 2005)
¥¥ IL19 (interleukin-19, IL10C, MDA1, ZMDA1, melanoma differentiation antigen-1, melanoma differentiation associated protein-like protein) receptors (Liao et al, 2002; Jordan et al, 2005)
¥ IL20 (interleukin-20, Zcyto10; IL10D, interleukin-10D) (AlanŠrŠ T et al, 2010; Chen WY and Chang MS, 2009; Chen WY et al, 2006; Hsing et al, 2006; Kunz et al, 2006; Wang F et al, 2006; Wolk et al, 2002; Simitsopoulou M et al, 2011)
¥¥ IL20 (interleukin-20, Zcyto10; IL10D, interleukin-10D) receptors (IL20RA, interleukin-20 receptor-alpha, IL20R-alpha, IL20R1, IL20 receptor-1, CRF2-8, cytokine receptor family 2 member 8, ZcytoR7; IL20RB, interleukin-20 receptor-beta, IL20R-beta, IL20R2, IL20 receptor-2, DIRS1) (Wei and Chang, 2008; Wolk et al, 2002)
¥¥ IL21 (interleukin-21) receptors (IL21R, IL21R-alpha, IL21RA, IL21 receptor-alpha, interleukin-21 receptor, interleukin-21 receptor-alpha, NILR, novel interleukin receptor, CD360) (Fuqua et al, 2008; Pelletier et al, 2004)
¥ IL22 (Interleukin-22, IL-TIF, IL10-related T-cell derived inducible factor) (Hsing et al, 2006; AlanŠrŠ T et al, 2010)
¥ IL22BP (IL22 binding protein, IL22RA2, interleukin-22 receptor-alpha-2, IL22R-alpha-2, CRF2-10, Cytokine receptor family 2 member 10, CRF2-s1, CRF2 soluble 1, cytokine receptor family type 2 soluble-1, CRF2X) (Xu W et al, 2001)
¥ IL23 (interleukin-23, IL12B, IL12-p40, IL23-p40, p19, IL23-p19, IL23A, SGRF, IL6 G-CSF related factor) (Begum et al, 2004; Bosco et al, 2003, 2006; Dower et al, 2008; He et al, 2006; Shime et al, 2008; Tchatalbachev S et al, 2010)
¥ IL24 (interleukin-24, ST16, suppression of tumorigenicity-16, MDA-7, melanoma differentiation-associated gene 7, mob-5, C49a, FISP, IL4 induced secreted protein) (Wolk et al, 2002; Garn et al, 2002; Kunz et al, 2006)
¥¥ IL24 (interleukin-24, ST16, suppression of tumorigenicity-16, MDA-7, melanoma differentiation-associated gene 7, mob-5, C49a, FISP, IL4 induced secreted protein) receptors (Mumm et al, 2006)
¥¥ IL27 (interleukin-27, EBI-3, EBV induced gene-3, IL27A, IL27-alpha, interleukin-27-alpha, IL27B; IL27-beta, interleukin-27-beta, p28, IL27p28, IL30, interleukin-30) receptors (IL27RA, IL27 receptor-alpha, interleukin-27 receptor-alpha, IL27R, IL27R-alpha, CRL1, Cytokine receptor-like 1, WSX-1, TCCR, T-cell cytokine receptor, ZCytoR1) (Feng XM et al, 2008)
¥ IL29 (IFN-lambda-1, interferon-lambda-1, IFNL1) (Wolk et al, 2008)
¥¥ IL29 (IFN-lambda-1, interferon-lambda-1, IFNL1) receptors (IL28RA, interleukin-28 receptor-alpha, IL28R-alpha, IL28R1, interleukin-28 receptor-1, IFN-lambda-R1, IFN-lambda receptor 1; interferon-lambda receptor-1, IFNLR1, IFNLR, interferon-lambda receptor, CRF2-12, Cytokine receptor family 2 member 12, LICR2, Likely Interleukin or Cytokine Receptor-2) (Jordan et al, 2007)
¥¥ IL31 (interleukin-31) receptors (IL31RA, interleukin-31 receptor A; IL31 receptor-alpha; IL31R-alpha, GLMR, gp130-like monocyte receptor, GPL, gp130-like receptor, CRL3, cytokine receptor-like 3; OSMR, oncostatin M receptor, OSMRB, Oncostatin-M receptor-beta; OSMR-beta; Oncostatin-M-specific receptor subunit beta, IL31R-beta, IL31RB, Interleukin-31 receptor-beta) (Dillon et al, 2004; Ghilardi et al, 2002; Diveu et al, 2003)
¥ IL32 (interleukin-32, IL32-alpha, IL32-beta, IL32-delta, IL32-epsilon, IL32-gamma, IL32-zeta, NK4, natural killer cell transcript 4, TAIF, tumor necrosis factor alpha-inducing factor, TAIFa, TAIF-alpha, TAIFb, TAIFc, TAIF-beta, TAIFd, TAIF-delta) (Netea et al, 2006; Shoda et al, 2006; Barksby et al, 2009)
¥¥ IL32 (interleukin-32, IL32-alpha, IL32-beta, IL32-delta, IL32-epsilon, IL32-gamma, IL32-zeta, NK4, natural killer cell transcript 4, TAIF, tumor necrosis factor alpha-inducing factor, TAIFa, TAIF-alpha, TAIFb, TAIFc, TAIF-beta, TAIFd, TAIF-delta) receptors (Joosten et al, 2006; Netea et al, 2008)
¥ IL33 (interleukin-33, NFHEV, nuclear factor from high endothelial venules, C9orf26, chromosome 9 open reading frame 26, DVS27) (Nile CJ et al, 2010)
¥¥ IL34 (interleukin-34, C16orf77, chromosome 16 open reading frame 77) receptors (CSF1R, fms, FIM2, CD115) (Lin H et al, 2008; in addition, presence inferred also from observation that IL34 binds to the M-CSF receptor, fms)
¥ IL37 (interleukin-37, IL1F7, IL1 family member 7, Interleukin-1 family member 7, IL1F7b, Interleukin-1 family member 7b, IL1H, IL1HLa, IL1HL, IL1HS, IL1H4, IL1 homolog-4, IL1-zeta, FIL1-zeta, Family of IL1-zeta, FIL1Z, IL1RP1, IL1-related protein-1) (Bufler et al, 2004; Barksby et al, 2009; Sharma S et al, 2008; cited as unpublished in Boraschi et al, 2011)
¥¥ insulin receptors (CD220, INSR) (Fantus et al, 1993; Grigorescu et al, 1986; Hj¿llund et al, 1983; Jehle et al, 1996; Lecavalier et al, 1987; McElduff et al, 1985; Mishra et al, 1992; Pedersen et al, 1982; Perurena and Festoff, 1989; Spanheimer et al, 1982; Stuart et al, 1991; Trischitta et al, 1989; Viardot et al, 2007; Whitson and Kaplan, 1983, 1985)
¥ IRAKM (IL1 receptor-associated kinase M, IRAK3, IL1 receptor-associated kinase-3) (del Fresno et al, 2005; Piao et al, 2009)

¥ JAM1 (Junctional adhesion molecule 1, JAM-A, Junctional adhesion molecule A, JCAM, Platelet F11 receptor, F11R, F11 receptor, platelet adhesion molecule 1, PAM-1, Ly106, lymphocyte antigen 106, CD321) (Ogasawara N et al, 2009)

¥
Klotho (KL, Alpha-Klotho, alpha-KL, a-KL) (Bacchetta et al, 2013)

¥
LBP (LPS binding protein, lipopolysaccharide-binding protein, BPIFD2, BPI fold containing family D member 2) (Tsutsumi-Ishii et al, 2000)
¥ LCRF (luminal CCK-releasing factor, luminal cholecystokinin releasing factor, diazepam binding inhibitor, DBI, endozepine, acyl-CoA-binding protein, ACBP, cholecystokinin releasing peptide, CCK-RP) (Klapper et al, 2006; Rocca et al, 1993)
¥ leptin (ob, ob/ob, obese protein, obesity factor, Metreleptin) receptors (OBR, CD295, db, db/db, fatty, fa, fa/fa) (Chatzantoni et al, 2004; Gabay et al, 2001; Zarkesh-Esfahani et al, 2001)
¥ Leu-Enkephalin receptors (Prieto et al, 1989)
¥ LIA (leukemia-associated inhibitory activity, acidic isoferritin, MDS-IA, myelodysplastic syndrome-associated inhibitory activity) (Broxmeyer et al, 1982)
¥ LIF (leukemia inhibitory factor; myeloid leukemia inhibitory factor, ABAE cell growth-inhibitory activity; CDF, cholinergic differentiation factor, CNDF, cholinergic neuronal differentiation factor, D-Factor, differentiation stimulating factor, DIA, differentiation inhibiting activity, DIF, differentiation inducing factor, DRF, Differentiation-retarding factor, ES cell growth factor, ESCGF, embryonic stem cell growth factor, GATS, growth stimulatory activity for TS1 cells, HILDA, human interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2, HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase inhibitor, M1 differentiation inducing activity, MCGEF, mast cell growth-enhancing factor, MLPLI, melanoma-derived lipoprotein lipase inhibitor, OAF, osteoclast activating factor) (Anegon et al, 1990, 1991; Grolleau et al, 1991; Vanderlocht et al, 2006; Kim et al, 2005; Barksby et al, 2009)
¥¥ LIF (leukemia inhibitory factor; myeloid leukemia inhibitory factor, ABAE cell growth-inhibitory activity; CDF, cholinergic differentiation factor, CNDF, cholinergic neuronal differentiation factor, D-Factor, differentiation stimulating factor, DIA, differentiation inhibiting activity, DIF, differentiation inducing factor, DRF, Differentiation-retarding factor, ES cell growth factor, ESCGF, embryonic stem cell growth factor, GATS, growth stimulatory activity for TS1 cells, HILDA, human interleukin for Da cells, HSF-2, hepatocyte stimulating factor-2, HSF-3, hepatocyte stimulating factor-3, Lipoprotein lipase inhibitor, M1 differentiation inducing activity, MCGEF, mast cell growth-enhancing factor, MLPLI, melanoma-derived lipoprotein lipase inhibitor, OAF, osteoclast activating factor) receptors (LIFR, leukemia inhibitory factor receptor, LIF receptor, LIFR-alpha, leukemia inhibitory factor receptor-alpha, LIF receptor-alpha, LIFR-beta, LIF receptor-beta; leukemia inhibitory factor receptor-beta, CD118, IL6ST, IL6 signal transducer, IL6R-beta, IL6RB, CDw130, CD130) (Musso et al, 1995)
¥ LIGHT (TNFSF14, TNF ligand superfamily member 14, HVEM ligand, HVEM-L, Herpesvirus entry mediator ligand, CD258) (Lee WH et al, 2001)
¥ LRRFIP1 (leucine rich repeat (in FLII) interacting protein 1; Leucine-rich repeat flightless-interacting protein 1; LRR FLII-interacting protein 1, FLAP-1, FLIIAP1, FLI LRR associated protein-1, GCF2, GC-binding factor 2, TRIP, TAR RNA-interacting protein, Transcription factor 9-like, HUFI-1) (Arakawa et al, 2010)
¥ LRRK2 (leucine-rich repeat kinase 2, Dardarin, PARK8, Parkinson disease-8; Autosomal Dominant Parkinson Disease-8, AURA17, augmented in rheumatoid arthritis 17, RIPK-7, receptor-interacting serine/threonine kinase 7) (Hakimi et al, 2011; ThŽvenet J et al, 2012)
¥ Luteinizing hormone receptors (Komorowski and Stepien, 1994)
¥ Ly6C (lymphocyte antigen 6C, Ly6C1, lymphocyte antigen 6C1) (Daley et al, 2008; Getts et al, 2008; Hatakeyama et al, 1994; Jutila et al, 1988, 1994; King et al, 2009; Lin SL et al, 2009; Masuya et al, 2011; Serbina and Pamer, 2006; Varga et al, 2008; Yanez et al, 2011)
¥ lymphotoxin-beta (LT-beta, LTB, TNFSF3, TNF ligand superfamily member 3, TNF C, tumor necrosis factor C) (Ancuta et al, 2009)
¥ Lysozyme (LYZ, EC3.2.1.17, 1,4-beta-N-acetylmuramidase C) (Miyauchi et al, 1985; StuhlmŸller et al, 2000; Ancuta et al, 2009)

¥ MARCO (macrophage receptor with collagenous structure, SCARA2, scavenger receptor class A member 2; Ly112, lymphocyte antigen 112) (HIN-2 receptor) (Bosco et al, 2006)
¥ MBL (Mannose-binding lectin; mannan-binding lectin, MBL2, mannose-binding lectin 2, MBP, mannose-binding protein; mannan-binding protein, MBP1, COLEC1, Collectin-1; L-MBP, liver-type MBP; liver-type mannan-binding protein, S-MBP, serum-type MBP, serum-type mannan-binding protein, MBP-C, mannan-binding protein C; Mannose-binding protein C, MBP-A, mannan-binding protein A; Mannose-binding protein A, MBL-C, mannan-binding lectin C, MBL-A, mannan-binding lectin A, RaRF p28A, Ra-reactive factor p28A, CSL, core-specific lectin) (Downing et al, 2003; Wagner et al, 2003)
¥ Mcl-1 (myeloid cell factor-1, myeloid cell leukemia sequence 1, BCL2L3) (Lange et al, 2007)
¥ M-CSF (macrophage colony stimulating factor, CSF-1, colony stimulating factor-1, CSF-HU, Urinary colony stimulating factor, MGF, macrophage growth factor, MGI-1M, macrophage-granulocyte inducer, op, osteopetrotic, toothless, tl, Lanimostim) receptors (fms, CD115) (Abordo et al, 1996; Brach et al, 1993; Gruber and Gerrard, 1992; Gruber et al, 1992, 1994; Hashimoto et al, 1996; Horiguchi et al, 1987; Wieser et al, 1989; Dower et al, 2008; Bellora F et al, 2012)
¥¥ M-CSF (macrophage colony stimulating factor, CSF-1, colony stimulating factor-1, CSF-HU, Urinary colony stimulating factor, MGF, macrophage growth factor, MGI-1M, macrophage-granulocyte inducer, op, osteopetrotic, toothless, tl, Lanimostim) receptors (fms, CSF1R, CSF-1 receptor, FIM2, CD115) (Andoh et al, 1993; Asakura et al, 1996; Bergamini et al, 1994; Erickson-Miller et al, 1990; Essner et al, 1990; Eubank et al, 2003; Finnin et al, 1999; Hamilton et al, 1993 1996, 1997; Katsura et al, 1992; Mufson, 1990; Nakamura et al, 1991; Sariban et al, 1989; Suzuki et al, 2004; Ancuta et al, 2009)
¥ MD-2 (Ly96, lymphocyte antigen 96, ESOP-1, ES-OP9 coculture clone 1) (Sandanger et al, 2009)
¥ mer (MERTK, eyk, East Lansing Tyrosine Kinase, nyk, NCAM-related tyrosine kinase, RP38, retinitis pigmentosa type 38, tyro12, tyrosine-protein kinase 12) (Graham et al, 1994; Mahajan and Earp, 2003)
¥¥ Met-Enkephalin (Met5-Enkephalin, MENK, OGF, opioid growth factor) receptors (Prieto et al, 1989)
¥ MIA3 (melanoma inhibitory activity 3, TANGO, TANGO1, Transport and Golgi organization protein 1, KIAA0268) (Arndt et al, 2007)
¥ MIF (MMIF, macrophage migration inhibitory factor, GIF, GLIF, glycosylation inhibiting factor, DER6, Delayed early response protein 6, phenylpyruvate tautomerase, PPT, EC5.3.2.1, phenylpyruvate keto-enol isomerase; phenylpyruvate tautomerase; phenylpyruvate keto-enol isomerase; EC5.3.2.1) (Schmidt-Supprian et al, 2000)
¥ MMP-1 (matrix metalloproteinase-1, collagenase, collagenase-1, CL-1, CLG1, fibroblast collagenase, fibroblast-type collagenase, interstitial collagenase, tissue collagenase, EC3.4.23.7) (Bar-Or et al, 2003; Chizzolini et al, 2000; Corcoran et al, 1992; Kouwenhoven et al, 2001; Gebbia et al, 2001; Lai et al, 2003; Lange et al, 2007; Jalian et al, 2008; Zhang and Wahl, 2006; Philp et al, 2006)
¥ MMP-2 (matrix metalloproteinase-2, EC3.4.24.24, 70 kDa gelatinase, 72 kDa gelatinase, 72 kDa metalloproteinase, collagenase type 4, collagenase type 4A, 72 kDa type IV collagenase, Gelatinase 72 kDa, Gelatinase A, Type IV collagenase, Type IVA collagenase, neutrophil gelatinase) (Bar-Or et al, 2003; Rodgers et al, 2003; Wahl et al, 1993; Wang L et al, 2010)
¥ MMP-3 (matrix metalloproteinase-3, stromelysin-1, STMY1, STR1, SL-1, transin, transin-1, collagenase activating protein, procollagenase activator, proteoglycanase) (Bar-Or et al, 2003)
¥ MMP-7 (matrix metalloproteinase-7, matrilysin, Matrilysin-1, PUMP, punctuated metalloproteinase, pump-1, putative metalloproteinase-1, matrin, EC3.4.24.23) (Kouwenhoven et al, 2001)
¥ MMP-9 (matrix metalloproteinase-9, EC3.4.24.35, gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase, or PMNL gelatinase, polymorphonuclear leukocyte gelatinase, gelatinase type IV-B, collagenase type 5, collagenase-5, CL-5) (Bar-Or et al, 2003; Rodgers et al, 2003; Chizzolini et al, 2000; Corcoran et al, 1992; Klier et al, 2001; Kumar et al, 1999; Locati et al, 2002; Vaday et al, 2001; Wahl et al, 1993; Gebbia et al, 2001; Lai et al, 2003; Marom et al, 2007; Poitevin et al, 2008; Jalian et al, 2008; Dreier et al, 2001; Ancuta et al, 2006; Chang et al, 2009; Philp et al, 2006; Wang L et al, 2010; Dahl TB et al, 2007)
¥ MMP-10 (matrix metalloproteinase-10, stromelysin-2, STMY2, SL-2, ST-2, transin-2, EC3.4.24.22) (Bar-Or et al, 2003)
¥ MMP-11 (matrix metalloproteinase-11, stromelysin-3, STMY3, SL-3, ST-3) (Royaee et al, 2006)
¥ MMP-14 (matrix metalloproteinase-14, MT1-MMP, Membrane-type matrix metalloproteinase-1, MT-MMP-1, MMP-X1) (Bar-Or et al, 2003)
¥ MMP-17 (matrix metalloproteinase-17, MT4-MMP, Membrane-type matrix metalloproteinase-4, MT-MMP-4) (Bar-Or et al, 2003)
¥ MMP-19 (matrix metalloproteinase-19, RASI-1, rheumatoid arthritis synovium inflamed-1) (Bar-Or et al, 2003; Locati et al, 2002)
¥ MMP-25 (matrix metalloproteinase-25, Membrane-type matrix metalloproteinase-6, MT6-MMP, MT-MMP-6, leukolysin, MMPL1, matrix metalloproteinase-like 1, matrix metallopeptidase-like 1) (Bar-Or et al, 2003)
¥ MyD88 (Adib-Conquy et al, 2006)
¥ myeloperoxidase (MPO, AURA60, augmented in rheumatoid arthritis 60) (Nichols and Bainton, 1973)

¥ NALP1 (NACHT-LRR-PYD-containing protein-1, DEFCAP, death effector filament-forming CED4-like apoptosis protein, CARD7, caspase recruitment domain-containing protein-7, KIAA0926, NAC, nucleotide-binding domain and CARD containing protein, NLRP1, NLR family, pyrin-domain containing 1, CLR17.1) (Kummer et al, 2007; Genel et al, 2012; Deo et al, 2011; anz et al, 2004)
¥ NELL-2 (NEL-like 2, neural epidermal growth factor-like 2, NEL-like protein 2, NRP2, Nel-related protein 2) (Luce and Burrows, 1999)
¥ neuromodulin (Wang et al, 2000)
¥ neurokinin A receptors (Lotz et al, 1988)
¥ neurturin (NTN, NRTN) (Vargas-Leal et al, 2005)
¥¥ neurturin (NTN, NRTN) receptors (Vargas-Leal et al, 2005)
¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) (Caroleo et al, 2001, 2004)
¥¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) receptors (NGFR, p75NTR, p75 neurotrophin receptor, p75LNGFR, p75NGFR, LNGFR, p75 low affinity NGF receptor, TNFRSF16, TNF receptor superfamily member 16, CD271) (Caroleo et al, 2001)
¥¥ NGF (nerve growth factor, 7S NGF, 7S nerve growth factor, NGF-alpha, Nerve growth factor-alpha, kallikrein Klk1b4, Klk1b4, NGF-beta, NGFB, Nerve growth factor-beta, NGFG, NGF-gamma, Nerve growth factor-gamma, kallikrein Klk1b3, Klk1b3) receptors (trkA) (la Sala et al, 2000)
¥ NKEF-B (Natural killer enhancing factor B, Peroxiredoxin-2, PRDX2, PRX2, TDPX1, thioredoxin-dependent peroxide reductase-1, Calpromotin, PRP, protector protein, Torin, TSA, thiol-specific antioxidant protein) (Wang et al, 2000)
¥ NLRC4 (NLR family, CARD domain containing 4, IPAF, ICE protease-activating factor, CARD12, caspase recruitment domain-containing protein-12, CLAN, CARD LRR and NACHT domain-containing protein) (Abdelaziz et al, 2011; Gutierrez et al, 2004; Damiano et al, 2004)
¥ NLRC5 (NLR family, CARD domain containing 5, NOD27, caspase recruitment domain-containing protein-27, CLR16.1) (Davis et al, 2011)
¥ NLRP6 (NLR family, pyrin-domain containing 6, PYPAF5, Pyrin-containing APAF-1-like protein 5, NALP6, NACHT-LRR-PYD-containing protein-6, PAN3, PAAD and NACHT-containing protein 3, CLR11.4) (Meixenberger et al, 2010)
¥ NLRP10 (NLR family, pyrin-domain containing 10, PYNOD, pyrin domain and nucleotide-binding oligomerization domain containing protein, NALP10, NACHT-LRR-PYD-containing protein-10, NOD8, Nucleotide-binding oligomerization domain protein 8, PAN5, PAAD and NACHT-containing protein 5, CLR11.1) (Wang Y et al, 2004)
¥¥ nociceptin (PNOC, PPNOC, Orphanin FQ, Nociceptin/Orphanin FQ, N/OFQ, Orphanin FQ/Nociceptin, OFQ/N) receptors (LC132, NOCIR, OPRL1, ORL1, opioid receptor-like 1, opiate receptor-like 1, OP4, opioid receptor 4, NOP, non-classical opioid receptor) (Kaminsky and Rogers, 2008; Serhan et al, 2001; KrŸger C et al, 2006; Peluso et al, 1998)
¥ NOD1 (Nucleotide-binding oligomerization domain protein 1, CARD4, caspase recruitment domain-containing protein-4, NLRC1, NLR family, CARD domain containing 1) (Uehara et al, 2007; House et al, 2008; Paul-Clark et al, 2008; Fritz et al, 2005; Adib-Conquy et al, 2006)
¥ NOD2 (Nucleotide-binding oligomerization domain protein 2, CARD15, caspase recruitment domain-containing protein-15, NLRC2, NLR family, CARD domain containing 2, IBD1, inflammatory bowel disease 1, BLAU, CLR16.3) (Damiano et al, 2004; Uehara et al, 2007; Beynon et al, 2008; Gutierrez et al, 2002; Lala et al, 2003; Ogura et al, 2001; House et al, 2008; Paul-Clark et al, 2008; Fritz et al, 2005; Adib-Conquy et al, 2006; Wang TT et al, 2010; Poole et al, 2011; GLubb et al, 2011)
¥ Notch-1 (Notch, Motch, Motch A, TAN-1, translocation-associated notch homolog-1) (Ohishi et al, 2000; Lange et al, 2007)
¥¥ NPR3 (natriuretic peptide receptor 3, NPR-C, natriuretic peptide receptor-C, ANPRC, atrial natriuretic peptide clearance receptor C, C5ORF23, chromosome 5 open reading frame 23, osteocrin receptor, musclin receptor, longjohn, Lgj, longjohn-2J, lgj(2J), strigosus, stri) (Baldini et al, 2003)

¥ Oncostatin M (OSM, OM, Onco M, OnM) (Repovic and Benveniste, 2002)
¥ OSCAR (osteoclast-associated receptor, osteoclast-associated immunoglobulin-like receptor) (Hermann et al, 2008)
¥ Osteoactivin [HGFIN, hematopoietic growth factor inducible neurokinin-1 type, GPNMB, Glycoprotein non-metastatic melanoma protein B, nmb, DC-HIL, dendritic cell-associated heparan sulfate proteoglycan-integrin ligand] (Chung et al, 2009)
¥ osteopontin (OPN, OP, Osp, 2ar, 44 kDa bone phosphoprotein, 66 kDa bone phosphoprotein, bone sialoprotein, bone sialoprotein-1, BSP, BSP1, BSPI, Calcium oxalate crystal growth inhibitor protein, Eta-1, early T-lymphocyte activation protein 1, Nephropontin, Spp-1, Secreted Phosphoprotein-1, transformation-related phosphoprotein, tumor-secreted phosphoprotein, urinary stone protein, Uropontin) (Iwata et al, 2004; Lange et al, 2007)
¥¥ osteopontin (OPN, OP, Osp, 2ar, 44 kDa bone phosphoprotein, 66 kDa bone phosphoprotein, bone sialoprotein, bone sialoprotein-1, BSP, BSP1, BSPI, Calcium oxalate crystal growth inhibitor protein, Eta-1, early T-lymphocyte activation protein 1, Nephropontin, Spp-1, Secreted Phosphoprotein-1, transformation-related phosphoprotein, tumor-secreted phosphoprotein, urinary stone protein, Uropontin) receptors (Leali et al, 2003)
¥¥ Oxytocin (OT, OXT) receptors (Szeto et al, 2008)

¥ PAI-1 (Plasminogen activator inhibitor-1, PAI, plasminogen activator inhibitor, endothelial plasminogen activator inhibitor, Serpin E1, MSF, monocyte suppressor factor, EIP-1, EGF-inducible protein 1, mesosecrin) (Buechler et al, 2001; Hamilton et al, 1993)
¥ PAI-2 (Plasminogen activator inhibitor-2, placental plasminogen activator inhibitor, epidermal plasminogen activator inhibitor, monocyte-derived plasminogen activator inhibitor, Monocyte Arg-serpin, PLANH2, urokinase inhibitor, PP10, placental protein 10, Serpin B2) (Hamilton et al, 1992, 1993; Mahoney et al, 1998; Antalis et al, 1996; Gyetko et al, 1993; Ritchie et al, 1995, 1997; Ritchie and Booth, 1998; Wada et al, 1994; Pepe et al, 1997; Dougherty et al, 1999; Humphries et al, 2002; Suzuki et al, 2000; Buechler et al, 2001)
¥ par-4 (prostate apoptosis response protein 4, WT1-interacting protein, PAWR, PRKC apoptosis WT1 regulator protein) (Ohki et al, 2002)
¥ PD-ECGF (platelet-derived endothelial cell growth factor, ECGF-1, endothelial cell growth factor-1, GLS, GLS/TP, Gliostatin, platelet-derived endothelial cell mitogen, EC2.4.2.4, thymidine phosphorylase, dThdPase, TYMP, Pyrimidine phosphorylase) (Hotchkiss et al, 2003)
¥ PDGF (platelet-derived growth factor, PDGF-1, PDGF-2, PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast-derived growth factor, GDGF, glioma-derived growth factor-1, GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid-suppressible mitogenic activity, MDF, mesangial cell proliferating factor, MDGF, monocyte-derived growth factor, OBIF, osteoblastogenesis inhibitory factor, ODGF, osteosarcoma-derived growth factor, T47D factor) (Dill et al, 1993; Kotecha et al, 1994; Nagaoka et al, 1991; Sariban and Kufe, 1988; Schraufstatter et al, 2012)
¥¥ PDGF (platelet-derived growth factor, PDGF-1, PDGF-2, PDGF-A, PDGF-AA, PDGF-B, PDGF-BB, FDGF, fibroblast-derived growth factor, GDGF, glioma-derived growth factor-1, GDGF-2, glioma-derived growth factor-2, GSM, Glucocorticoid-suppressible mitogenic activity, MDF, mesangial cell proliferating factor, MDGF, monocyte-derived growth factor, OBIF, osteoblastogenesis inhibitory factor, ODGF, osteosarcoma-derived growth factor, T47D factor) receptors (PDGFR, PDGFR1, PDGFR2, PDGFRA, PDGFR-alpha, PDGFRB, PDGFR-beta, PDGF receptor, PDGF receptor-1, PDGF receptor-2, PDGF receptor-alpha, PDGF receptor-beta; patch; CD140a, CD140b, JTK12) (Ernofsson and Siegbahn, 1996; Shure et al, 1992)
¥ PDL2 (programmed death-1 ligand 2, PDCD1L2, PDCD1LG2, PDCD1 Ligand 2, B7-DC, Butyrophilin B7-DC, CD273) (Semnani et al, 2011)
¥ Pentraxin-3 (Pentaxin-3, PTX3, TNFAIP5, tumor necrosis factor-alpha-induced protein 5, pentraxin-related gene rapidly induced by IL1-beta, TSG-14, tumor necrosis factor-stimulated gene sequence-14) (Vouret-Craviari et al, 1997; Alles et al, 1994; Imamura et al, 2007; Polentarutti et al, 1998; Maina et al, 2009)
¥¥ Pentraxin-3 (Pentaxin-3, PTX3, TNFAIP5, tumor necrosis factor-alpha-induced protein 5, pentraxin-related gene rapidly induced by IL1-beta, TSG-14, tumor necrosis factor-stimulated gene sequence-14) receptors (Napoleone et al, 2004)
¥ PI9 (proteinase inhibitor-9, Serpin B9, CAP3, cytoplasmic antiproteinase 3, serine protease inhibitor-6, SPI-6) (Classen et al, 2006; Boomgaarden et al, 2010)
¥ Pim-2 (Proviral Integration of Moloney virus 2) (Jiang H et al, 2004)
¥ pleiotrophin (PTN, HARP, heparin affin regulatory peptide, HBBM, heparin binding brain mitogen, HB-GAF, heparin binding growth-associated factor, HB-GAM, heparin binding growth-associated molecule, HBGF-8, heparin binding growth factor-8, HBNF, heparin binding neurotrophic factor, NEGF-1, neurite growth-promoting factor-1, OSF-1, osteoblast-specific factor-1) (Wang et al, 2000)
¥ Plexin-B1 (PLXNB1, Plexin-5, SEP, Semaphorin 4D receptor, CD100 receptor, KIAA0407) (Semaphorin 4D receptor) (Chabbert-de Ponnat et al, 2005)
¥ plexin-C1 (PLXNC1, VESPR, virus-encoded semaphorin protein receptor, CD232) (Chabbert-de Ponnat et al, 2005)
¥¥ PlGF (placenta growth factor, Placental growth factor, PGF, PlGF-1, placenta growth factor-1, PlGF-2, placenta growth factor-2) receptors (Barleon B et al, 1996; Selvaraj SK, et al, 2003; Yoo SA, et al, 2009; Clauss M et al, 2006; Perelman N et al, 2003; Tchaikovski V et al, 2008)
¥ prokineticin-2 (PROK2, PK2, Bv8 homolog) (LeCouter J et al, 2004; Zhong C et al, 2009)
¥¥ prolactin (PRL, lactogenic hormone, lactotropin, lactotropic hormone, mammotropin, mammotropic hormone, luteotropic hormone, LTH, luteotropin) receptors (PRLR) (Malaguarnera et al, 2005)
¥¥ PSG23 (Pregnancy-specific glycoprotein 23, CEA11, carcinoembryonic antigen 11) receptors (Wu et al, 2008)
¥¥ prothymosin-alpha (PTMA) receptors (Garbin et al, 1997)
¥ PYPAF1 (Pyrin-containing APAF-1-like protein 1, NLRP3, NLR family, pyrin-domain containing 3, NALP3, NACHT-LRR-PYD-containing protein-3, CIS1, CIAS1, cold-induced auto-inflammatory syndrome, Cryopyrin, CLR1.1) (Dowds et al, 2004; Guarda et al, 2011; Kummer et al, 2007; Nour et al, 2011; O'Connor et al, 2003; Sa•d-Sadier N et al, 2010)
¥ PYPAF7 (Pyrin-containing APAF-1-like protein 7, Monarch-1, RNO, regulated by nitric oxide, RNO-2, regulated by nitric oxide-2, NALP12, NACHT-LRR-PYD-containing protein-12, PAN6, PAAD and NACHT-containing protein 6, CLR19.3, NLRP12, NLR family, pyrin-domain containing 12) (Arthur et al, 2007; Fahy et al, 2008; Lich et al, 2007; Lord et al, 2009; Reilly et al, 2011; Wang L et al, 2002; Williams et al, 2003)
¥ pyrin (MEFV, FMF protein, Familial Mediterranenan fever protein, Marenostrin, TRIM20, tripartite motif-containing protein 20) (Seshadri et al, 2007)

¥ RAGE (receptor for advanced glycosylation end products, AGER, advanced glycosylation end product-specific receptor) (Ichikawa et al, 1998; Khechai et al, 1997; Kirstein et al, 1992; Xanthis et al, 2010)
¥ RANK (receptor activator of NF-kappa-B, TNF receptor superfamily member 11A, TNFRSF11A, ODAR, osteoclast differentiation and activation receptor, ODFR, Osteoclast differentiation factor receptor, TRANCER, PDB2, CD265) (Breuil et al, 2003)
¥ RANKL (RANK ligand, receptor activator of NF-kappa-B ligand, ODF, Osteoclast differentiation factor, OPGL, Osteoprotegerin ligand, SOFA, Stromal osteoclast-forming activity, TRANCE, tumor necrosis factor-related activation induced cytokine, TNFSF11, TNF ligand superfamily member 11) (Seta et al, 2008)
¥¥ Relaxin (RLN, RLX, RLN1, relaxin 1, relaxin H1, H1 relaxin, RLXH1, RXN1, RLN2, relaxin 2, relaxin H2, H2 relaxin, RLXH2, RXN2, relaxin 1/2) receptors (Figueiredo et al, 2009)
¥ resistin (RSTN, RETN, RETN1, ADSF, adipose tissue-specific secretory factor, FIZZ-3, found in inflammatory zone-3, XCP4, ten-cysteine protein 4) (Hu et al, 2007; Laudes et al, 2010)
¥¥ resistin (RSTN, RETN, RETN1, ADSF, adipose tissue-specific secretory factor, FIZZ-3, found in inflammatory zone-3, XCP4, ten-cysteine protein 4) receptors (Cho Y et al, 2011)
¥ RGMa (Repulsive guidance molecule A; RGM domain family member A) (Mirakaj et al, 2011)
¥ Rhesus Theta-Defensin-1 (Tang et al, 1999)
¥ ribosomal protein S19 (RPS19, S19 ribosomal protein) (Wang et al, 2000)

¥¥ S1PR1 (sphingosine-1-phosphate receptor 1, S1P receptor 1, S1P1, Endothelial differentiation G-protein coupled receptor 1, EDG1, endothelial differentiation gene 1, CD363) (Fueller et al, 2003)
¥ S100A4 (S100 calcium binding protein A4, CAPL, calcium placental protein, Calvasculin, metastasin, metastasin-1, mts-1, 18A2, 42A, P9Ka, pEL98, fibroblast-specific protein 1, fibroblast secretory protein-1, FSP-1) (Takenaga et al, 1994)
¥ S100A8 (S100 calcium binding protein A8, MRP-8, migration inhibition factor-related protein-8, myeloid-related protein-8, CP-10, chemotactic protein 10, CAGA, Calgranulin A, CGLA, CFAG, cystic fibrosis antigen, CF antigen) (Bouma et al, 2005; Wang et al, 2000; Royaee et al, 2006; Bhardwaj et al, 1992; Hessian et al, 1993; Ancuta et al, 2009; Poduri et al, 2012)
¥ S100A9 (S100 calcium binding protein A9, MRP-14, migration inhibition factor-related protein-14, myeloid-related protein-14, Calgranulin B, CAGB, CGLB, Calprotectin, CFAG, cystic fibrosis antigen, CF antigen) (Bouma et al, 2005; Wang et al, 2000; Royaee et al, 2006; Bhardwaj et al, 1992; Hessian et al, 1993; Kido et al, 2005; Ancuta et al, 2009; Nomura et al, 2005)
¥ S100A12 (S100 calcium binding protein A12, p6, CGRP, calgranulin-related protein, Calgranulin C, CAAF-1, calcium-binding protein in amniotic fluid-1, ENRAGE, extracellular newly identified RAGE-binding protein, CO-Ag) (Ancuta et al, 2009)
¥¥ S100A15 (S100 calcium binding protein A15, Koebnerisin) receptors (Wolf et al, 2008)
¥ S100P (S100-E) (Parkkila et al, 2008)
¥ Salusin-beta (TOR2A, torsin family 2 member A, torsin 2A, TORP1, torsin-related protein-1) (Sato et al, 2010)
¥ SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) (Ferrari et al, 1993)
¥¥ SCF (stem cell factor, HLGF-1, hemolymphopoietic growth factor-1), kit ligand, KITL, KITLG, Mast/stem cell growth factor, MGF, mast cell growth factor, SLF, steel factor) receptors (kit, SCFR, CD117) (Ferrari et al, 1993)
¥ Secretogranin-5 (SCG5, 7B2, SGNE1, secretory granule neuroendocrine protein 1, P7B2, pituitary polypeptide 7B2) (Lange et al, 2007)
¥¥ Secretoneurin (SN, Chromogranin C, CHGC, SCG2, SgII, Secretogranin-2, gonadotrope polypeptide, GP-87, TSP86/84, tyrosine-sulfated protein 86/84 kDa) receptors (Kong et al, 1998)
¥¥ Semaphorin 4D (SEMA4D, Semaphorin J, SEMAJ, CD100, M-sema G, collapsin-4, coll-4, BB18, A8, GR3, C9orf164, chromosome 9 open reading frame 164) receptors (Chabbert-de Ponnat I et al, 2005)
¥ Semaphorin 7A (SEMA7A, Semaphorin L, SEMAL, H-Sema-L, H-Sema K1, Semaphorin K1, CD108, CDw108, JMH human blood group antigen) (Holmes et al, 2002)
¥¥ Semaphorin 7A (SEMA7A, Semaphorin L, SEMAL, H-Sema-L, H-Sema K1, Semaphorin K1, CD108, CDw108, JMH human blood group antigen) receptors (Holmes et al, 2002; Suzuki et al, 2007)
¥ serglycin (SRGN, PRG1, PRG, PPG, platelet proteoglycan protein core) (Stellrecht et al, 1991; Toyama-Sorimachi et al, 1997; Kolset et al, 2008)
¥ Serpin B1 (LEI, Leukocyte elastase inhibitor, MNEI, monocyte neutrophil elastase inhibitor, ELANH2, Monocyte/neutrophil elastase inhibitor-2, EI, elastase inhibitor, L-DNase II, LEI-derived DNase II) (Remold-O'Donnell, 1985; Remold-O'Donnell et al, 1989, 1992)
¥¥ serum amyloid A (serum amyloid A, SAA, SAA1, serum amyloid A1, SAA2, serum amyloid A2, SAAL, A-SAA, acute phase serum amyloid A) receptors (Song et al, 2009)
¥ SIGIRR (single immunoglobulin domain-containing IL1R-related protein, TIR8, TOLL/IL1R8, TOLL/interleukin-1 receptor 8) (Adib-Conquy et al, 2006)
¥ SIGLEC-1 (sialic acid binding immunoglobulin-like lectin 1, SLG, SIGLEC-like gene, sialoadhesin, SER, sheep erythrocyte receptor, CD169, MOMA-1, C19orf75, chromosome 19 open reading frame 75) (Jaroenpool et al, 2007; Rempel et al, 2008; Xiong et al, 2012; Xiong et al, 2009; York et al, 2007)
¥ SIGLEC-5 (sialic acid binding immunoglobulin-like lectin 5, SIGLEC-F, CD33L2, CD33-like-2, OBBP2, Ob binding protein 2, CD170) (Jaroenpool et al, 2007)
¥ SIGLEC-7 (sialic acid binding immunoglobulin-like lectin 7, AIRM1, adhesion inhibitory receptor molecule 1, p75/AIRM1, QA79 membrane protein, D-SIGLEC, CDw328, CD328) (Avril et al, 2004; Jaroenpool et al, 2007; Ito et al, 2001)
¥ SIGLEC-9 (sialic acid binding immunoglobulin-like lectin 9, OBBP-like, Ob binding protein-like, CDw329, CD329, FOAP-9, SIGLEC-E) (Angata and Varki et al, 2002; Avril et al, 2004; Zhang et al, 2000; Jaroenpool et al, 2007)
¥ SIGLEC-10 (sialic acid binding immunoglobulin-like lectin 10, CD330, SLG2, SIGLEC-like gene 2) (Munday et al, 2001; Ancuta et al, 2009)
¥ sirtuin-1 (SIRT1, SIR2L1, Sir2-like 1, SIR2-alpha) (de Kreutzenberg SV et al, 2010)
¥ SOCS1 (Suppressor of cytokine signaling-1, SSI1, STAT induced STAT inhibitor-1, JAB, JAK binding protein, TIP3, TEC-interacting protein 3, CISH1, Cytokine inducible SH2-containing protein-1) (Dickensheets et al, 1999; Adib-Conquy et al, 2006; Piao et al, 2009)
¥ SOCS3 (Suppressor of cytokine signaling-3, CIS3, Cytokine inducible SH2-containing protein-3, SSI3, STAT induced STAT inhibitor-3) (Kim et al, 2005)
¥ SOD1 (superoxide dismutase-1, SOD, superoxide dismutase) (Ancuta et al, 2009)
¥¥ somatostatin (SST, Somatotropin release inhibiting hormone, SIH, Somatotropin release inhibiting factor, SRIF, growth hormone-inhibiting hormone, GIH, growth hormone release inhibitory hormone, GH-RIH) receptors (Dalm et al, 2003; Komorowski and Stepien, 1995; Lichtenauer-Kaligis et al, 2004; Peluso et al, 1996)
¥ sprouty-2 (Spry-2) (Lange et al, 2007)
¥ STAT3 (signal transducer and activator of transcription-3, APRF, acute phase response factor, STAT3-alpha, STAT3-beta, STAT3-gamma, STAT3-delta) (Kremlev et al, 2008)
¥¥ substance P (Neurokinin-1, NK1, NKA, Neurokinin A, Tac1, tachykinin-1) receptors (Ho et al, 1996; Kavelaars et al, 1994; Laurenzi et al, 1990; Lotz et al, 1988; Amoruso et al, 2008; Chernova et al, 2009)
¥ suppressin (SPN) (Ban and LeBoeuf, 1994)
¥¥ surfactant protein A (SP-A, SFTPA1, surfactant protein A1, collectin-4, SFTP1, surfactant-associated protein, pulmonary 1) receptors (Rosseau et al, 1999)
¥ Syndecan-1 (syndecan, syndecan proteoglycan 1, SDC1, Synd1, SD-1, 104-9 antigen, 1D4 antigen, B-B2 antigen, B-B4 antigen, Mi15, CD138) (Mosheimer et al, 2005)
¥ Syndecan-4 (SDC4, SYND4, amphiglycan, ryudocan) (Kaneider et al, 2003)

¥ TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor, TNFRSF13B, TNF receptor superfamily member 13B, CD267) (Chang SK et al, 2006)
¥ TDAG51 (T-cell death-associated gene 51, TSSC3, tumor-suppressing subchromosomal transferable fragment cDNA 3, IPL, imprinted in placenta and liver, PQR, PHLDA1, pleckstrin-homology-like domain family A member1) (Lange et al, 2007)
¥ TFPI-2 (tissue factor pathway inhibitor-2, MSPI, matrix-associated serine protease inhibitor, REF-1, RPE cell factor, retinal pigment epithelial cell factor-1, PP5, placental protein 5) (Lange et al, 2007)
¥ TGF-alpha (transforming growth factor-alpha, TGFA, TGF-A, MDGF-2, milk-derived growth factor-2, TCGF, transformed cell growth factor, wa-1, waved-1) (Calafat et al, 1997)
¥ TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) (Aung et al, 2002; Cunningham et al, 1992; Danis et al, 1995; Grotendorst et al, 1989; Porreca et al, 1997; Rodgers et al, 2003; Schalch et al, 1991; Szabo et al, 1992; Kim et al, 2005)
¥¥ TGF-beta (transforming growth factor-beta, TGFB, B-TGF, Aqueous humor lymphocyte inhibitory activity, DIF, differentiation-inhibiting factor, EGI, epithelial cell-specific growth inhibitor; epithelial growth inhibitor, EIF, Epstein-Barr virus inducing factor, Epithelial cell growth inhibiting factor, G-TsF, glioma-derived T-cell suppressor factor, MDGF, milk-derived growth factor, MGF, milk growth factor, Polyergin, Simian BSC-1 cell growth inhibitor, SP factor, TCGF, transformed cell growth factor, TGI, tissue-derived growth inhibitor, TIF-1, tumor inducing factor-1) receptors (TGFBR1, TbetaRI, TbetaR1, transforming growth factor-beta receptor 1, TGF-beta receptor 1; TGF-beta receptor type 1, type 1 TGF-beta receptors, ALK5, Activin receptor-like kinase 5, activin A receptor type 2-like kinase, ACVRLK4, activin receptor-like kinase 4 ; TGFBR2, TbetaRII, TbetaR2, transforming growth factor-beta receptor 2, TGF-beta receptor 2, TGF-beta receptor type 2, type 1 TGF-beta receptors, MFS2, Marfan syndrome type 2) (Drouin et al, 1998; Ernofsson et al, 1996; Fulton et al, 1998; Hogasen et al, 1995; Kruger et al, 1996; Leveque et al, 1998; McCartney-Francis et al, 1990; Reterink et al, 1996; Wiseman et al, 1988; Bradford L et al, 2010)
¥ Thimet oligopeptidase (THOP1, Thimet oligopeptidase 1, EC3.4.24.15, Endopeptidase 24.15, EP24.15, MP24.15, metalloendopeptidase 24.15, TOP, thiol-activated metallo-oligopeptidase, BIE, bradykinin inactivating endopeptidase, MP78, Pz-peptidase, endo-oligopeptidase A)
(Casale et al, 1994)
¥¥ thioredoxin (TRX, TRX1, thioredoxin-1, TRX80, BSF-MP6, B-cell stimulating factor MP6, ADF, adult T-cell leukemia-derived factor) receptors (Pekkari et al, 2001)
¥¥ Thrombin receptor (TR, CF2R, coagulation factor 2 receptor, F2R, PAR-1, Proteinase-activated receptor 1) (Chang CJ et al, 2009; Colognato et al, 2003; L—pez-Pedrera C et al, 2010; Naldini et al, 2000; Popovic et al, 2008; Roche et al, 2003)
¥ Thrombospondin-1 (Thrombospondin, TSP1, TSP, THBS1) (StuhlmŸller et al, 2000)
¥¥ thymosin-alpha-1 (Prothymosin-alpha, PTMA, Thymalfasin, Zadaxin) receptors (Cordero et al, 1990; Malinda et al, 1998; Hu et al, 1989; Vordero et al, 1990)
¥ thymosin-beta-4 (TMSB4, TMSB4X, Tb4, Tbeta-4, 6-26, Fx, PTMB4, THYB4) (Suzuki et al, 2000; Young et al, 1999; StuhlmŸller et al, 2000)
¥¥ thymosin-beta-4 (TMSB4, 6-26, Fx) receptors (Philp et al, 2006)
¥ Thymosin-beta-10 (TMSB10, Tbeta-10, Tb10, PTMB10, THYB10) (Suzuki et al, 2000; Wang et al, 2000)
¥ Tim-3 (T-cell immunoglobulin and mucin domain-containing protein 3; T-cell membrane protein 3, T-cell immunoglobulin mucin 3, T-cell Ig mucin 3, Timd3, HAVCR2, hepatitis A virus cellular receptor 2) (Dorfman et al, 2010; Mengshol et al, 2010; Nakayama et al, 2009; Sui L et al, 2006; Zhang Y et al, 2011, 2012; Zhao J et al, 2009)
¥ TIMP-1 (tissue inhibitor of metalloproteinases-1, TIMP metallopeptidase inhibitor 1, TIMP, tissue inhibitor of metalloproteinases, HCI, human collagenase inhibitor, CLGI, 3/10, 16C8, Fibroblast elongation factor, fibroblast collagenase inhibitor, B1 anticollagenase, Beta-1 anticollagenase, EPA, erythroid promoting activity, embryogenin-1, TPA-S1, TPA-induced protein S1) (Bar-Or et al, 2003; Jovanovic et al, 2001; Kouwenhoven et al, 2001; Royaee et al, 2006; Jalian et al, 2008)
¥ TIMP-2 (tissue inhibitor of metalloproteinases-2, TIMP metallopeptidase inhibitor 2, CSC-21K, MI, CHIAMP, Chondrocyte-derived inhibitor of angiogenesis and metalloproteinase activity) (Bar-Or et al, 2003; Rodgers et al, 2003)
¥ TIMP-3 (tissue inhibitor of metalloproteinases-3, TIMP metallopeptidase inhibitor 3, mitogen-inducible gene 5, mig-5; SFD, Sorsby fundus dystrophy) (Bar-Or et al, 2003; Chaitidis et al, 2005)
¥ TIMP-4 (tissue inhibitor of metalloproteinases-4, TIMP metallopeptidase inhibitor 4) (Bar-Or et al, 2003; Koskivirta et al, 2006)
¥ Tissue factor (TF, TFA, thromboplastin, tissue thromboplastin, CD142, factor III, factor 3, F3, FIII, coagulation factor III) (Akahane et al, 2001; Bohgaki et al, 2004; Brand et al, 1994; Broussas et al, 2002; Cermak et al, 1993; Corseaux et al, 2000; Ernofsson and Siegbahn, 1996; Ernofsson et al, 1996; Mackman et al, 1990; Osterud, 2000; Ramani et al, 1994; Wada et al, 1994; Pepe et al, 1997; Poitevin et al, 2007, 2008; Gerrits et al, 2009; Su and Yeh, 1996; Semeraro et al, 2009; Clauss M et al, 2006)
¥ TLR-1 (Toll-like receptor-1, rsc786, randomly sequenced cDNA 786, TIL, Toll-interleukin-1 receptor-like, CD281) (Muzio et al, 2000; Saccani et al, 1998; Lange et al, 2007; House et al, 2008; Paul-Clark et al, 2008; Liu PT et al, 2009)
¥ TLR-2 (Toll-like receptor-2, TIL-4, Toll-interleukin-1 receptor-like-4, Ly105, lymphocyte antigen 105, CD282) (Begum et al, 2004; Farina et al, 2004; Frasnelli et al, 2005; Galdiero et al, 2004; Iwahashi et al, 2004; Jung et al, 2006; Lin and Rikihisa, 2004; Mita et al, 2001; Ogawa et al, 2002; Park et al, 2004; Skinner et al, 2005; Orihara et al, 2007; Dasu et al, 2008; Ichiki et al, 2008; Uehara et al, 2007; House et al, 2008; Paul-Clark et al, 2008; Adib-Conquy et al, 2006; Bonfim et al, 2009; Salazar et al, 2009; Shen et al, 2009; Kuwahata et al, 2009; Niebuhr et al, 2010; Juarez et al, 2010; Nile CJ et al, 2010; Devaraj S et al, 2011; Kuwahata S et al, 2010; Liu PT et al, 2009)
¥ TLR-3 (Toll-like receptor-3, CD283) (Uehara et al, 2007; Semnani et al, 2011)
¥ TLR-4 (Toll-like receptor-4, human Toll, TOLL, Ly87, Rasl2-8, CD284) (Begum et al, 2004; del Fresno et al, 2005; Farina et al, 2004; Frasnelli et al, 2005; Jung et al, 2006; Lin and Rikihisa, 2004; Methe et al, 2005; Mita et al, 2001; Mita et al, 2002; Moreno et al, 2004; Park et al, 2004; Raymond and Wilkie, 2005; Skinner et al, 2005; Tamandl et al, 2003; Viemann et al, 2005; Dasu et al, 2008; Lange et al, 2007; Uehara et al, 2007; House et al, 2008; Paul-Clark et al, 2008; Satoh et al, 2006; Fritz et al, 2005; Bonfim et al, 2009; Shen et al, 2009; Juarez et al, 2010; Nile CJ et al, 2010; Devaraj S et al, 2011)
¥ TLR-5 [Toll-like receptor-5, TIL-3, Toll-interleukin-1 receptor-like-3) (Farina et al, 2004; Raymond and Wilkie, 2005; Semnani et al, 2011)
¥ TLR-6 (toll-like receptor-6, CD286) (Nakao et al, 2005; House et al, 2008; Paul-Clark et al, 2008)
¥ TLR-7 (Toll-like receptor-7) (Bosco et al, 2006; Uehara et al, 2007; Semnani et al, 2011)
¥ TLR-8 (Toll-like receptor-8, CD288) (Uehara et al, 2007)
¥ TLR-9 (Toll-like receptor-9, A6RP, A6-related protein, CD289) (Raymond and Wilkie, 2005; Uehara et al, 2007; House et al, 2008; Juarez et al, 2010)
¥ TLR-10 (Toll-like receptor-10, CD290) (Hornung et al, 2002)
¥ TNFAIP2 (tumor necrosis factor-alpha-induced protein 2, TNF-alpha-induced protein 2, B94) (Lange et al, 2007)
¥ TNFAIP8L2 (TNFAIP8-like protein-2; TNFAIP8-like-2, tumor necrosis factor-alpha-induced protein 8-like-2; TNF-alpha-induced protein 8-like-2, TIPE2, Inflammation factor protein 20, Oxi-c, Oxidative stress regulated gene-c) (Zhang G et al, 2010)
¥ TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) (Abrahams et al, 2000; Adams and Czuprynski, 1990; Alderson et al, 1993; Alderson et al, 1993; Andersson et al, 2000; Aosasa et al, 2001; Asano et al, 1994; Averill et al, 1995; Baqui et al, 2000; Barksby et al, 2009; Baur et al, 1998; Belge et al, 2002; Berry et al, 2005; Boutten et al, 1992; Brentano F et al, 2007; Burke et al, 2008; Cannistra et al, 1987; Caux et al, 1994; Chaitidis et al, 2005; Cluitmans et al, 1994; Conroy et al, 2009; Cosentino et al, 1995; Czeslick et al, 2003; Dahl TB et al, 2007; de Caestecker et al, 1992; de Waal Malefyt et al, 1991; de Waal Malefyt et al, 1993; DeLuca et al, 1999; Devaraj and Jialal, 2005; Essner et al, 1990; Holmes et al, 2002; Kienzle and von Kempis, 2000; Kim et al, 2005; Leali et al, 2003; Mathy et al, 2000; Misuno et al, 1990; Molnarfi et al, 2008; Moschen AR et al, 2007; Olsnes et al, 2007; Rich et al, 1993; Salazar et al, 2009; Selvaraj SK, et al, 2003; Song et al, 2009; StuhlmŸller et al, 2000; Suzuki et al, 2000; Wang et al, 2000; Webb et al, 1990; Wolf et al, 1996; Xie and Gu, 2008; Yoo SA, et al, 2009; Schwartzkopff F et al, 2012)
¥¥ TNF-alpha (tumor necrosis factor-alpha, TNFSF2, TNF ligand superfamily member 2, Cachectin, CF, cytotoxic factor, CTX, cytotoxin, DIF, differentiation inducing factor, EP, endogenous pyrogens, Hemorrhagic factor, Macrophage-derived cytotoxic factor, J774-derived cytotoxic factor, MCF, macrophage cytotoxic factor, MCT, macrophage cytotoxin, MD-FGF, monocyte-derived fibroblast growth factor, PCF, peritoneal cytotoxic factor, RCF, Released cytotoxic factor) receptors (CD120a, TNFRSF1A, TNF receptor superfamily member 1A, FPF, TNFAR, TNFR, TNFR1, TNFR55, TNFR60, TNFR-alpha, TNF receptor 1; CD120b, TNFRSF1B, TNF receptor superfamily member 1B, p75TNFR, TNFR2, TNFR75, TNFR80, TNFR-beta) (Andersson et al, 2002; Baur et al, 1998; Dickensheets et al, 1997; Fulton et al, 1998; Imamura et al, 1987; Joyce and Steer, 1995; Wang et al, 2000; Royaee et al, 2006; Malaguarnera et al, 2005; Galve-de Rochemonteix et al, 1996; Mytar et al, 2002)
¥ TOLLIP (Toll-interacting protein) (Adib-Conquy et al, 2006; Ohnuma et al, 2005; Piao et al, 2009)
¥ TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) (Yamamoto et al, 2004)
¥¥ TRAIL (TNF-related apoptosis inducing ligand, APO-2 ligand, APO-2L, TL2, TNF-like-2, TNF ligand superfamily member 10, TNFSF10, Ly81, CD253) receptor-4 (TRAIL receptor-4, TRAIL-R4, DcR-2, Decoy receptor-2, TRUNDD, TRAIL receptor with a truncated death domain, TNFRSF10D, TNF receptor superfamily member 10D, CD264) (Lange et al, 2007)
¥¥ transferrin (TRF, DF-77, GPBP, granulocyte/pollen-binding protein, Lung-derived growth factor) receptors (CD71, TFR, TFR1, TRFR, TFRC, OKT9, T9, OX26) (Spittler et al, 1997; Walsh et al, 2005; Kim et al, 2005)
¥ TREM1 (triggering receptor expressed on myeloid cells 1, CD354) (Begum et al, 2004; Bouchon et al, 2001; Ferat-Osorio et al, 2008; del Fresno et al, 2008; Dower et al, 2008; G—mez-Pi–a et al, 2007; Plachouras D et al, 2006; Wong-Baeza et al, 2006; Gibot et al, 2005; Ferat Osorio et al, 2009; Zanzinger et al, 2009; Ancuta et al, 2009)
¥ TREM2 (triggering receptor expressed on myeloid cells 2, TREM2a, TREM2b) (Begum et al, 2004; Gingras et al, 2002)
¥ TREML2 (Trem-like transcript 2 protein; triggering receptor expressed on myeloid cells-like 2; TREM-like protein 2, TLT-2, C6orf76, chromosome 6 open reading frame 76) (Allcock et al, 2003)
¥ TRIM5 (tripartite motif-containing protein 5, TRIM5-alpha, tripartite motif-containing protein 5-alpha, RNF88, RING finger protein 88, Lv1, lentivirus susceptibility factor 1; Ref1, restriction factor 1) (Mous et al, 2011)
¥ trkA (tropomyosin-related kinase A, NTRK1, neurotrophic tyrosine kinase receptor 1) (El Zein N et al, 2010)
¥ TSG-6 (tumor necrosis factor-stimulated gene sequence-6, TNFAIP6, tumor necrosis factor-alpha-induced protein 6, TNFIP6, tumor necrosis factor-induced protein 6, PS4) (Maina et al, 2009; Robinson et al, 2010; Nomura et al, 2005)
¥¥ TSLP (thymic stromal derived lymphopoietin, Thymic stromal lymphopoietin) receptors (CRLF-2, cytokine receptor-like factor-2, Ly114, CRL2) (Zhang et al, 2001)
¥ TWEAK (TNF-like weak inducer of apoptosis, APO-3L, APO-3 ligand, DR3LG, DR3 ligand, TNF ligand superfamily member 12, TNFSF12) (Kang et al, 2005; Desplat-Jego et al, 2009)
¥ TWE-PRIL (Pradet-Balade et al, 2002)

¥¥ Uromodulin (URO, UMOD, Uromucoid, THP, THGP, Tamm-Horsfall glycoprotein) receptors (Su et al, 1997)
¥¥ urotensin-2 (UTS-2, UTN-2, U2) receptors (Segain et al, 2007)

¥ VEGF-A (Vascular endothelial growth factor A; VEGF-1, vascular endothelial growth factor-1, VEGF, vascular endothelial growth factor; vasculo-endothelial growth factor, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor; VPF, vascular permeability factor, Mouse sarcoma 180-derived growth factor; FSdGF, Folliculo stellate cell-derived growth factor) (Pakala et al, 2002; Panutsopulos et al, 2003; Eubank et al, 2003; Griga et al, 1999; Hojo et al, 2000; Melillo et al, 1999; Melter et al, 2000; Royaee et al, 2006; Clark et al, 2007; Malaguarnera et al, 2005; Perelman N et al, 2003; Subimerb et al, 2010)
¥¥ VEGF-A (Vascular endothelial growth factor A; VEGF-1, vascular endothelial growth factor-1, VEGF, vascular endothelial growth factor; vasculo-endothelial growth factor, VEG/PF, vascular endothelial growth factor/vascular permeability factor, GD-VEGF, glioma-derived vascular endothelial growth factor, VAS, Vasculotropin, Vascular endothelial cell proliferation factor; VPF, vascular permeability factor, Mouse sarcoma 180-derived growth factor; FSdGF, Folliculo stellate cell-derived growth factor) receptors (Barleon et al, 2001; Sawano et al, 2001; Tezono et al, 2001; Zhao et al, 2002; Barleon B et al, 1996; Clauss M et al, 2006; Tchaikovski V et al, 2008)
¥ VEGF-C (vascular endothelial growth factor C, VEGF-2, Vascular endothelial growth factor-2, flt-4 ligand, flt-4L) (Schmeisser A et al, 2006)
¥ VEGF-D (vascular endothelial growth factor D, FIGF, fos induced growth factor) (Schmeisser A et al, 2006)
¥ VEGFR1 (VEGF receptor-1, flt, fms-like tyrosine kinase, flt-1, fms-like tyrosine kinase-1; FRT, fms-related tyrosine kinase) (Conroy et al, 2009; Tchaikovski V et al, 2008; Yoo SA, et al, 2009; Barleon B et al, 1996; Clauss M et al, 1996)
¥ VEGFR3 (VEGF receptor-3, flt-4, fms-like tyrosine kinase-4) (Schmeisser A et al, 2006)
¥ VEGI (vascular endothelial growth inhibitor, VEGI-174, TNFSF15, TNF ligand superfamily member 15, TL1, TL1A, TNF-like-1) (Lange et al, 2007)
¥ Visfatin (VF, PBEF, pre B-cell colony enhancing factor, PBEF1, pre B-cell colony enhancing factor-1, EC2.4.2.12, Nicotinamide phosphoribosyltransferase, NMN diphosphorylase, NMN pyrophosphorylase, NAmPRTase, Nampt, AURA94, augmented in rheumatoid arthritis 94) (Turpaev et al, 2005; Laudes et al, 2010)
¥¥ Visfatin (VF, PBEF, pre B-cell colony enhancing factor, PBEF1, pre B-cell colony enhancing factor-1, EC2.4.2.12, Nicotinamide phosphoribosyltransferase, NMN diphosphorylase, NMN pyrophosphorylase, NAmPRTase, Nampt, AURA94, augmented in rheumatoid arthritis 94) receptors (Moschen AR et al, 2007; Dahl TB et al, 2007; Brentano F et al, 2007)
¥ vitronectin (VN, VTN, Epibolin, Serum spreading factor, SF, Membrane attack complex inhibitor, S protein, Protein X, Complement S protein, PAIBP, Plasminogen activator inhibitor-1 binding protein, Somatomedin B) (Guc et al, 1993)

¥ XCL1 (chemokine C motif ligand-1, CL1, lymphotactin, Ltn, Lptn, SCM-1-alpha, Single C motif-1-alpha, ATAC, activation induced T-cell derived and chemokine related, SCYC1) (Kim et al, 2004)
For related information of interest see also: Cell types, Cell lines in Cytokine Research, Cell culture.

For other entries pertaining to hematopoiesis see also the Hematology Dictionary section of this encyclopedia.


Copyright © 2012 by H IBELGAUFTS. All rights reserved.
ENTRY LAST MODIFIED: December 2012



 

See REFERENCES for entry monocytes.

Click BACKLINKS to see which COPE entries contain the term monocytes .




COPE Homepage Top of Page


 
 
SUPPORT COPE | Santa Claus | Intro | Subdictionaries | New Entries | Contribute data | COPE Credentials
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Please inquire. COPE is looking for long-term support from a company appreciating and committed to communication biology

              Created, developed, and maintained by Prof Dr H Ibelgaufts              
About the author of COPE
  |    Contact COPE   |    postcard and stampware   |    Terms & Conditions


Access to COPE is free only for academic institutions and non-profit organizations.
OTHER USERS: must contact COPE and pay a site licence fee.

U L T R A   P O S S E   N E M O   O B L I G A T U R